

YORK AGAINST CANCER

England & Wales · Charity number 1130835

Details

Status	Registered
Legal form	Charitable company
Company number	06884476
Registered	2009-07-29
Register	View on the Charity Commission register

Contact

Address	York Against Cancer York Community Stadium Kathryn Avenue Huntington York YO32 9AF
Phone	01904764466
Email	heather.atkinson@yorkagainstcancer.org.uk
Website	www.yorkagainstcancer.org.uk

Activities

Objects: TO INSTITUTE FOSTER AND PROMOTE JOINT RESEARCH BETWEEN CLINICIANS AND RESEARCH SCIENTISTS IN YORK AND DISTRICT AND MORE EFFECTIVE EXCHANGE OF IDEAS AND INFORMATION BETWEEN THEM IN ORDER TO ADVANCE THE CURE AND THE ALLEVIATION OF CANCER PARTICULARLY IN RESIDENTS OF THE YORK AREA AND TO DISSEMINATE TO THE PUBLIC THE RESULTS OF SUCH RESEARCH AND EXCHANGE OF INFORMATION

Activities: To raise funds to support cancer patients and advance the alleviation and cure of cancer.

Classification

- **How:** Provides Services, Sponsors Or Undertakes Research
- **What:** Education/training, The Advancement Of Health Or Saving Of Lives
- **Who:** People With Disabilities, The General Public/mankind

Geography

- **Area of benefit:** YORK AREA
- City Of York
- North Yorkshire

Finances

Period end	Income	Expenditure	Assets	Employees
2024-12-31	£1,460,424	£1,136,857	£4,466,498	10
2023-12-31	£763,604	£1,093,420	£4,060,891	10
2022-12-31	£1,468,175	£1,819,580	£4,397,069	8
2021-12-31	£647,704	£537,850	£4,778,060	8
2020-12-31	£389,859	£536,646	-	-

Trustees

Name	Role	Appointed
IAN YEOWART	Chair	2012-12-11
Andrew James Proctor		2018-08-08
DR Angela Jayne Darby		2016-07-12
Michael Anthony Sweet		2020-07-07
PROFESSOR STEPHEN LEVESON		
Robert Paul Onyett		2020-07-07
Sarah Barbara Wearing		2018-08-08
Tarnia Jane Hudson		2018-08-08

YORK AGAINST CANCER

England & Wales - Charity number 1130835

Accounts

Company Number 06884476



YORK AGAINST CANCER
A company limited by guarantee
and
A registered charity number 1130835

REPORT AND ACCOUNTS
For the year ended
31 December 2024

HPH
Chartered Accountants
54 Bootham
York
YO30 7XZ

YORK AGAINST CANCER

CONTENTS

	Page
Chairman’s Report	1
Trustees’ Report	2 - 22
Auditor’s Report	23 – 26
Statement of Financial Activities	27
Balance Sheet	28
Cash Flow Statement	29
Notes to the Financial Statements	30 - 40

YORK AGAINST CANCER

CHAIRMAN'S REPORT 2024

2024 was again a busy year for the Charity and the success of the Leveson Centre has certainly given York Against Cancer a further boost in visibility, meaning more people are now aware of what we do and can take advantage of the many services on offer. The feedback from users is extremely positive, and we thank the staff and volunteers who deliver this service in such a professional manner. Our local MPs helped to celebrate our opening and first year anniversary, and this was followed by an unexpected, but welcome, visit from the Prime Minister [Rishi Sunak] who took time out to speak to everyone and send his best wishes.

As the Charity has continued to grow, it is important that our processes can keep pace, so we are able to continue to do the things that make the Charity unique. Strategically we have acknowledged the need for more focus in certain areas with the appointment of an External Relations Manager and Community Fundraiser. Their role is to ensure we can harness the undoubted goodwill of the people and businesses of York and North Yorkshire to keep awareness in the forefront at a time of significant challenge for charities. We are fortunate that the work we do, alongside our solid reputation, means we maintain a high level of support from users and others, with legacies continuing to provide a vitally important income to support the many services that are offered.

The Charity has, for many years, supported research at York University for the Jack Birch Unit, a world-renowned centre investigating bladder cancer. The Unit has been led since 1999 by Professor Jenny Southgate, who will be retiring in 2025. We are pleased to announce that Will Brackenbury will be Jenny's successor, and we wish Jenny a long and happy retirement.

After many years as a Trustee, Mike Stower has stepped down from the Board of Trustees, although he continues to volunteer at events and in the Leveson Centre. We are all grateful for his past and continuation contribution to the work of the Charity.

Many of our volunteers work within the retail arm of the Charity, manning the shops at both the Community Stadium and the Hospital. Sales have continued to grow at both locations, due in no small part to their efforts and the excellent range of goods made available by the astute buying of our retail management team.

Our small office team are usually the first point of contact for the Charity, and along with our mini-bus drivers continue to work hard throughout the year. To them, our volunteers, and Board colleagues I would, once again, like to pass on my grateful thanks for your continuing support and promotion of the Charity.

Once again, we sadly lost a number of our volunteers and supporters throughout the year, and our thoughts go out to their families and friends. Each one of them supported the work of the Charity, and helped it continue to provide the important services and funding for research that we are recognised for.

Ian Yeowart

Chair York Against Cancer

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

The Directors (who are also the Trustees of the Charity and are listed below) are pleased to present their report of the Charitable Company for the year ended 31 December 2024.

Objectives and activities

The objects of the Charity are to raise funds to:

1. Foster and promote joint research between clinicians and research scientists in York and wider area and, by encouraging a more effective exchange of ideas and information, to advance the alleviation and cure of cancer.
2. Support treatment of cancer patients at York Hospital and the local area.
3. Fund education and information about cancer for patients and their families and the wider public.

The Trustees believe they have complied with the duty in section 4 of the 2006 Charities Act to have due regard to guidance published by the Charity Commission in respect of public benefit.

Aims and strategies

The Charity aims to provide support to cancer patients and the community through the: -

- funding and the provision of services and resources for patients and their families
- funding of research programmes
- funding of education initiatives

The Team

The team is made up of a small group of dedicated people who, together, cover the main office, retail, the Leveson Centre and the minibus service. Each member of the team has their own responsibilities but the flexibility and ability to cover each other's roles should not be underestimated.

The team has annual appraisals where individuals are given the opportunity to discuss the previous year's targets, to celebrate achievements and discuss any concerns. The team are encouraged to discuss any training requirements they consider relevant to their role, which may be useful for their personal development.

The team are required to undertake training to enable them to do their roles safely and to meet minimum criteria ensuring general compliance. This includes health & safety, manual handling, safeguarding (relevant staff only) and G.D.P.R.

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

CARE GROUP – SERVICES AND SUPPORT 2024

During 2024 Mike Stower, stood down from his role as Care Group Chairman after 5 years in the role, and as a Board member. He, however, remains heavily involved with the Charity as a volunteer at The Leveson Centre. The Care Group and the Board of Trustees wish to thank Mike for his hard work and leadership throughout his tenure.

With this change we have taken the opportunity to update the Group's Terms of Reference and the process for applying for, and subsequent assessment of, the funding for new projects. We have also undertaken a skills audit of the Group's membership to identify skills gaps and invited clinical experts to join the Group.

New applications / requests for project funding are always welcome and will be progressed if they pass the Group's agreed assessment process. To be successful a project must show clear evidence that it represents value for patients, has longevity and fulfils the over-arching aims of the charity in providing benefits to those affected by cancer be they patients, family members or carers.

During 2024 York Against Cancer funded many services and projects including:

- The provision of the following services at the Leveson Centre
 - Complementary Therapy
 - Welfare Benefits Advice through the local Citizens Advice offices at York and Selby
 - Adult & Teenage Psychology Support

And also:

- A regular minibus service to the Leeds Cancer Centre
- Transport to enable patients to fulfil appointments where rapid / short notice diagnosis was required
- Respite breaks at properties in Filey and Yapham
- Exercise classes at the Better York Leisure centre at the York Community Stadium
- Provision of cancer prehabilitation classes at York and Selby

Most of these projects are for a fixed term contract, (usually 2 or 3 years), and are reassessed before being renewed or otherwise. With all care project funding real-time and ongoing assessments are essential to ensure that the charity is getting value. Recommendations can be made to the Board part-way through a fixed contract for either an increased budget or time extension if the Group considers this to be appropriate. However, such adjustments are only proposed if there is good evidence that the service is proving to be popular (as measured by uptake) and is considered to be effective.

As a charity we continue to support the running costs of the Mobile Chemotherapy Unit (MCU) that provides "local" chemotherapy services away from York Hospital. Initially, in 2017, YAC funded the construction and project management of the MCU before handing its management to York Hospital. However, we remain committed to the maintenance and operation of the unit. In 2024 the MCU provided Chemotherapy treatments 'closer to home' for cancer patients in Selby, Malton and Bridlington.

YORK AGAINST CANCER


DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

Our working relationship with the York & Scarborough Hospital trust and the local health community remains very strong. This is made possible by having clinicians - consultants, nurses - and administrators from the hospital together with representatives from the local health community as members of the Care Group. This is supplemented by YAC attending meetings of the hospital Cancer Board where issues and concerns can be approached collaboratively.

Below is a selection of information on some of the services we provide:

Minibus

Our minibus service which provides free transport for patients attending St James Hospital in Leeds for radiotherapy treatments continues to be popular and much appreciated. During 2024 we provided 86 individual patients with transport to Leeds – radiotherapy is given daily (Mon-Fri) and length of treatments can range from 3 to 7 weeks. If the demand is high, we use the minibus and our volunteer drivers, but if demand is low, we use the YAC car, thereby making the service more efficient.



Feedback from minibus service users.

‘I have been so grateful for the service I have received.’

To put this service on every day for people like myself who would normally struggle to get to Leeds is brilliant.’

YORK AGAINST CANCER


DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

Transport to Rapid Diagnostic appointments.

We have supported patients under the care of the Rapid Diagnostic Centre at York & Scarborough Hospitals helping to provide transport for those who need to attend a diagnostic appointment, most commonly not at their local hospital (for example transport to Castle Hill Hospital, Hull) and at short notice, when other transport options are not available.

We have provided transport to these types of appointments since 2021 and during 2024 we have helped 43 patients from York, Malton and Scarborough at a cost of £4054 p.a.

Respite break figures – quarter 4 - 2024



We are currently able to offer free self-catering respite breaks in Filey and Yapham

Number of guests per stay

Guest numbers	1 to 2	3 to 4	5 to 6	7 to 8
Sept	1	3	2	3
Oct	0	2	3	1
Nov	1	2	3	1

Filey is very popular because it is by the sea and has more space (4 double bedrooms) and is therefore suitable for families / groups of friends. Yapham, on the other hand, having only 1 bedroom, is ideal for couples looking the peace and quiet of a few days in the country.

Feedback from guests at Filey

‘The Bay respite house was truly a lovely break for our young family. A beautiful space to relax & spend quality time together.’

‘A fabulous, cosy place which we absolutely loved – thank you so much!’

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

Feedback from guests at Yapham

'The cottage was so relaxing & it was great to spend time away from all the medical appointments & treatments & to be able to fully unwind.'

'Such a beautiful & comfortable holiday house, we sat outside & ate our breakfast watching the Alpacas and sheep So relaxing.'

We encourage feedback from service users to ensure we get to know of any issues and to maintain high standards. If any improvements need addressing, we act on these quickly. Above is some of the feedback we have received.

Cancer Benefits Advice Service – Scarborough – in collaboration with Citizens Advice North Yorkshire

The charity continues to fund a cancer benefits advice service providing holistic financial advice for cancer patients in the Scarborough area, ensuring they receive the financial help to which they are entitled.

The main issues faced by clients by proportion are shown as follows:

ISSUE – Patients Concerns	2023-24	2022-23
· Benefits	78%	97%
· Charitable applications	12%	28.5%
· Health & Community Care	4%	5%
· Debt	1%	2%
· Financial services	3.5%	3.5%
· Employment	1.2%	1.5%
· Housing	1%	2%
· Travel & Transport	5.6%	5%

As demonstrated by these figures, the issue of Benefits remains highest. However, the increased complexity of clients' situations has resulted in addressing a broader range of issues including referrals to food banks, to the Household Support Fund for fuel vouchers and to local charitable support for essential household items.

We obtained a total of £542,926, of confirmed monetary benefit for clients in the last 12 months, with the expected outcomes to reach even greater sums. 320 clients were supported with new awards or increases in existing benefits, reaching income gains of £527,320. Clients and their families have acknowledged they would have struggled to achieve any of this without our help.

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

Cancer Benefits Advice Service - York

We have had a strong year of collaboration to help people affected by cancer in York.

This financial year we have seen 276 clients and helped them with 1,029 issues.

Most of these issues we helped with were working out benefits entitlements and helping people to claim the benefits which were due to them. We helped people to claim £928,919 of benefits. Most of these benefits were in the form of Personal Independence Payments and Attendance Allowance.

However, we provide fully holistic advice, and we also advise on charitable support, hate crime, housing, relationships and family, travel and transport and utilities.

We helped people aged between 30 and 94 and this was evenly split between women and men. We have noticed a trend of younger people using the service year on year. 87% of people using this service said that it improved their mental health and 89% of people would recommend the service to others.

Citizens Advice York are pleased to be working with York Against Cancer to provide a valuable service to people when they most need it.

Adult Psychology

The Clinical Psychology service for adults is offered from the Leveson Centre by Dr Joanne McVey (Jo). This service commenced in 2023 and during 2024 we have seen consolidation of the service, we are now seeing its real value for patients and their families.

During 2024, Jo saw 17 individual referrals for a total of 64 sessions, at a cost of £8,782. These are on Tuesday afternoons, mainly face to face. This input has been much appreciated by people living with cancer who were able to access psychological input quickly and easily in a venue that was familiar to them.

Jo has also trained to become a HOPE (Help Overcoming Problems Effectively) facilitator and has co-facilitated a HOPE course during November/ December with Debbie Smith the Leveson Centre Manager, there are more planned for 2025. Between 4 and 6 participants attended the course and results were very positive, with group attendees remaining in touch with each other for peer support. Subsequent courses are already being signed up for and both Jo and Debbie are working closely with York Hospital to spread the word and promote the courses.

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

Young People's Psychology service

The York against Cancer Teenage and Young Adult Psychology Service continues to offer Clinical Psychology support to young people aged 12 to 25 coping with cancer in their family alongside all the usual demands of adolescents into adulthood. The service continues to grow and evolve, with demand in 2024 being the highest since the service began in 2018. The service is entirely provided by Dr Becky Donaldson, Child/ Adolescent Clinical Psychologist, at present. Becky's therapy dog, Luna (fully registered with Pets as Therapy charity) is an almost constant fixture in her therapeutic work and the young people love her being part of the sessions at the Leveson Centre.

Families can bring their teenage/ young adult family members for appointments at the Leveson Centre, with a small minority choosing Becky's Selby clinic which may be a more convenient location or because a different day/ time is preferred. The service also offers online appointments, which are popular with young adults juggling cancer in their family with being away at university, or students fitting the support around their GCSE or higher education revision and exams.

In 2024, the service completed 207 teen/ young adult sessions. It also provided psychological consultation/ advice/ recommendations to school and parents in support of young people on occasions. Where safeguarding concerns are identified, these are also key points of essential liaison and contribution. In addition, the Leveson Centre has also accessed Becky's clinical child psychology advice when needed, such as for signposting to support for Under 12s (which is largely web-based resources due to severe lack of provision for this cohort). The service has also provided the Leveson Centre with written resources / signposting for issues that may arise in general conversation with visitors to the centre (e.g. how to talk to a child about cancer/ illness/ end of life; resources for young people who are self-harming).

In December 2024, Dr Simon Baker, York University invited Becky to contribute to a school's project he is running to develop materials to support Science teachers as they teach cancer/ illness themes at Key stage 3&4. This project will evolve in 2025. The Teen service can also contribute to any child/adolescent projects provided by York against Cancer, such as the Primary school book bag project, designing an emotionally supportive fact sheet for parents/carers on ways to talk to their child about cancer – a common worry for families navigating cancer diagnosis and beyond.

Dr Becky Donaldson, Chartered Clinical Psychologist



Becky's therapy dog, Luna

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

The Leveson Centre: Providing Cancer Support Services

As we reflect on 2024, The Leveson Centre has continued to grow as a vital support hub for individuals affected by cancer. Between January to December 2024, the centre recorded 9,896 points of contact — including visits, phone calls, and emails.

In early January 2024, Debbie (Centre Manager) and Victoria (Assistant Manager) took time to reflect on the successes of 2023 and plan for the year ahead. Looking back, 2024 has seen significant growth in our services, thanks to valuable feedback from those who use the centre.

Our Core Services

The Leveson Centre offers comprehensive support to both patients and their families throughout diagnosis, treatment, and beyond. Through peer support and one-on-one services, we provide a range of well-being focused activities, including:

- Complementary Therapy
- Art Workshops
- Weekly Coffee Morning
- Nicola Jane (bra fitting service and advice)
- Wellbeing Choir
- Look Good Feel Better (make up and skincare workshop)
- Pilates
- Welfare and Benefits Service

New Services Introduced in 2024

To meet growing demand and offer continuing support, we have expanded our services to include:

- Holistic Needs Assessments hosted by Cancer Nurse Specialists
- Hosting New Support Groups including those for colorectal and prostate cancer patients led by NHS specialist nurses and doctors
- "Healthy Living with and Beyond Cancer" Talk by Prof. Robert Thomas
- Increased Complementary Therapy Appointments to accommodate rising demand
- HOPE Course a six-week course for people who have finished treatment and are struggling with life after cancer
- Yoga
- Women's Wellbeing Workshops

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

Driving Growth and Building Connections

This expansion has been driven by positive feedback and word-of-mouth recommendations from service users, which has made Health Care providers more confident to recommend our services to patients. Also, as a result of this we are seeing a considerable uplift in the numbers of people who just drop in for a chat and a drink.

The Leveson Centre remains committed to providing a welcoming and supportive environment for everyone navigating their cancer diagnosis.

Paul "The Leveson Centre has been a god send. It's like family and its helping with my treatment, but it's not a hospital. When you're in a hospital, immediately it's clinical; it's sterile. Here, it's just so relaxing and there's so much on offer."

John "To anyone thinking of coming to The Leveson Centre, I would encourage them to come. It's not clinical, but it can help regardless of whatever type of cancer you've got. There's all sorts of exercise classes, therapies and everything that can help, and the staff are really friendly."

Pauline Family member " (the Leveson Centre) has lifted us. We have dark days but we know the Leveson centre's here"

Mobile Chemotherapy Unit



The Mobile Chemotherapy Unit (MCU) takes chemotherapy services to the wider areas of the York & Scarborough Hospital Trust, in Malton, Selby, Scarborough and Bridlington, this has enabled the charity to widen its reach. The MCU has helped thousands of patients avoid the time-consuming and tiring journeys to the hospital in York. During 2024 we continued to fund the cost of servicing and repairs to keep the MCU on the road.


YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

RESEARCH ACTIVITIES

Jack Birch Unit (University of York) – Molecular Carcinogenesis

The Jack Birch Unit has continued to expand with recruitment of Dr Vicki Jennings in December 2024 to a five-year research fellowship supported by York Against Cancer. Vicki is a cancer immunologist by training and will be studying the development and use of immunotherapies for epithelial cancers, including bladder cancer. Vicki joins Dr Simon Baker and Dr Andrew Mason as the third independent group leader working in the Jack Birch Unit. This is likely to be one of the last major changes to the JBU instigated under the current directorship of Professor Jenny Southgate, who is planning retirement in summer 2025 after 25 years at the helm! In preparation of this, a scientific review of the last five-year programme was submitted for external scientific review, securing the way for future funding of the JBU under a new Director.



Dr Vicki Jennings at her desk in the JBU

Simon has made progress studying how a common virus, ("BK virus"), may cause bladder cancer. This work has been gaining recognition, with Simon invited to give talks around the UK and internationally, in Germany, Italy and Switzerland. Simon was awarded funding from The Urology Foundation for a study using samples from the "Malmö Diet and Cancer Study" biobank in Sweden to study whether BK virus infections relate to future development of bladder cancer. Diane Lee entered Simon's group as a PhD student funded by Kidney Research UK, joining York Against Cancer's PhD student George Hatton, now in his 2nd year.

Andrew's cancer informatics group has expanded, with several postgraduate students joining to study different aspects of cancer informatics. Richard Gawne left to take up a place on the NHS bioinformatics training programme and was replaced, in September, by Marcello Beltrami. Andrew has also been busy delivering talks, including bladder cancer results from analysis of Genomics England's 100,000 genomes project, where Andrew has a leading role.

Debora Morgante, Vlad Ungureneanu and Ryan Ellison all submitted their PhD theses and passed their viva examinations subject to minor corrections. Debora has returned to her job as a Consultant Paediatric surgeon, Ryan has taken up a job in medical writing and Vlad has returned to Romania where he is applying for postdoctoral positions.

Internationally, the JBU received major recognition at the International Bladder Cancer Network meeting in Bern Switzerland. Jenny was invited to deliver The 2024 IBCN lecture and during the conference was awarded Honorary Membership as a lifetime achievement award for her contribution to bladder cancer research. At the same meeting, Andrew and Simon both gave research talks – with Simon's selected as the best research talk.



Andrew, Jenny & Simon taking in the scenery at the IBCN conference in Bern

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

In my final report as JBU Director, I would like to give a very personal thank you to everyone at York Against Cancer for the fantastic support given to the JBU over the years. I further thank my colleagues and our scientific and clinical collaborators for their major contribution to the quality and output of our research.

**Professor Jenny Southgate, Director, Jack Birch Unit of Molecular Carcinogenesis,
University of York**


<https://www.york.ac.uk/biology/jack-birch-unit/>

Clinical Trials Research Nurse and Assistant posts at York Hospital

As of July 2024, York & Scarborough Teaching Hospital NHS Foundation Trust had over 30 Cancer Research studies:



These include.

- 2309 enrolled participants – Since April 2019
- 11 studies open to recruitment and a further 23 in follow-up.
- Cancer research follow-ups often follow the participant until death, which often incurs a large work burden for the Team.



YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2024



As you can see from this snapshot, the Cancer Research portfolio is active and thriving, a testament to the support and funding received from York Against Cancer.

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

EDUCATION ACTIVITIES

The Cancer Awareness and Prevention group continues to work to spread information about cancer across as wide a range of the public as possible with an emphasis on young people.

York Against Cancer Awareness and Education Committee Report 2024

The Communications & Awareness Working Group was created as a sub-committee of The Board of Directors of York Against Cancer in 2024. As Communications & Awareness will be a strategic pillar in the new strategy, to be launched in 2025, it was agreed that the Education & Awareness Working Group and the Communications Working Group should combine to form the Communications & Awareness Working Group, to best support the strategic goals of the Charity. The Terms of Reference of the Group were updated and agreed by the committee in September 2024. The purpose of the group will now be to:

- Provide strategic advice and leadership to the Board as to all matters concerning the communications of the Charity both internal and external, and all matters concerning the development and support of education and awareness.
- Conduct rolling and exhaustive reviews of stakeholders with whom the Charity needs to communicate, identifying the differentials of those messages. The messages must always be aligned with the vision and values of the Charity.
- To review and advise as to the best use of communication channels in the delivery of the communications of the Charity.
- To provide a forum for discussion and debate regarding the educational and awareness activities of the charity in their widest context.
- To advise the Board as to the provision of costed, clear, consistent, timely, accurate and compelling communications and educational and awareness activities to the stakeholders to which they must be directed.
- To review communication plans and educational and awareness activities being delivered by the Charity to ensure they are meeting strategic objectives.

The Enthuse Partnership, which was delivered primarily as teacher training/professional development to train teachers to be more confident in teaching cancer related topics and included events for schools and students to teach young people about cancer research, came to end in the Spring Term of 2024. The next phase for the Enthuse Partnership was approved by the Board of Trustees in October 2024. Building on the success of Phase 1, Phase 2 will be led by Huntington Research School and will focus on PHSE, the curriculum for which changed for 24/25 to include more need for discussion on cancer related topics. In Phase 2, a series of interactive teaching resources for PHSE around cancer will be piloted by Huntington Research School and then delivered regionally by the NSLC.

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

This will include topics such as:

- Teacher training on difficult conversations with children around cancer
- Cervical Cancer and HPV Vaccination
- UV, Sunbeds and Skin Cancer
- Smoking/Vaping and Lung Cancer

Interviews for the lead teacher for Phase 2 were conducted in December.

In Spring 2021, York Against Cancer offered a range of free books to schools in the local area, helping teachers and families to have open conversations about cancer with young people and enabling them to better understand what cancer is, what treatment might involve, and the feelings they may experience around it. These books have been invaluable in supporting teachers and families to have conversations about cancer. It was agreed that this project should be repeated and expanded upon in 2025, with packs of books delivered to 188 primary schools in the region.

York Against Cancer's annual Awareness Day was held in October in the centre of York. This provided a valuable opportunity to engage with the public about the work of the charity, the research being conducted by the Jack Birch Unit, and raise funds.

A new Social Media Strategy was created to grow our supporter base to raise awareness of the charity and its services and increase opportunities for income generation. It was agreed that the charity would cease posting on the platform X, as its values do not align with York Against Cancer. Accounts were created on Bluesky and Threads and will continue to be monitored to see if our audience engage with these platforms. To support the development of our social media channels, videos and photos will be commissioned in 2025 to provide more authentic and engaging content.

A key focus for 2025 will be expanding the brand to reach a wider audience across North and East Yorkshire.

Thank you to the York Against Cancer team and the Communications and Awareness Working Group Members.

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

FUNDRAISING REPORT 2024

2024 saw another wonderful year of support from our volunteers, local businesses, organisations and groups alike. With fundraising growing, we have increased the team, to include an External Relations Manager and a Community Fundraiser.

We were lucky enough to have been supported by several businesses during 2024 with some fantastic fundraising results. Every penny raised help us to continue providing services, which we could not do without this level of support:

COMPANY	RAISED
Barratt Development	£5,000.00
Arosa Caravan & Camping Park	£4,155.00
Hugs Ltd	£3,267.85
Hilton York Hotel	£3,098.00
William Birch & Sons Ltd	£2,995.70
Portakabin Limited	£2,500.00
Ged Bell Butchers	£2,205.10
Benevity	£2,102.20
Ardent Uk	£1,700.00
Darley Funeral Directors	£1,508.41

Local Organisations are also key to our fundraising results, with some incredible efforts and support from the local community:

Organisation Name	Raised
Dunnington Cancer Support Group	£20,000.00
Stamford Bridge Community Choir	£6,214.78
The Blue Light Theatre Company	£1,500.00
Chamber of Commerce	£1,232.15
Archbishop Holgate School	£1,165.22
St Michaels Church	£1,068.55

Here a few of our events and the fantastic amounts raised:

Events	Raised
Annual Golf Day	£12,639.80
Jane Tomlinson 10k Run	£6,755.06
Weighton Wolds Rotary Club- Classic Car Show	£5,525.00
EBOR Model Railway	£1,073.24
Dragon Boat Race	£5,165.80
AVIVA Cycle Ride	£11,583.99
Christmas Lunch	£1,288.40
Light a Light Carol Service	£4,515.26

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

Without the support and passion from our volunteers, supporters and team, fundraising would not be possible, so a huge THANK YOU to each and everyone who has helped York Against Cancer during 2024. We look forward to working with you and making 2025 fundraising just as successful.

When we are talking to prospective fundraisers, we like to tell them how the money they raise will be spent. The following graphic is used for this purpose.

York Against Cancer is committed to maintaining high standards of fundraising and retail activity. The Charity is registered with the Fundraising Regulator. The Charity has recognised and begun to put in place a comprehensive policy for fundraising. The Charity does not use any third parties to act on its behalf in relation to fundraising. No complaints were received by the charity during 2024 in relation to its fundraising activities.



FUTURE PLANNING

The Board have continued their consistently adopted policy of only making commitments when the finance for these is already in place. The Board are mindful of the responsibility of ensuring that the generous donations received are used in the most effective manner possible to meet with the aims of the charity.

With a sudden increase in legacies over the last few years the board established a Finance Sub-group to consider the most effective way to manage the funds for the future of the charity.

The Board has agreed with the recommendations of the sub-group that a significant proportion of funds should be invested to provide for both future security of the charity and to ensure that the capital is used most effectively and to be available when future projects are considered and to ensure that the long-term plans and services the charity provides can be continued into the foreseeable future.

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

Structure, Governance and Management

The charity was incorporated on 22 April 2009 and its governing document is the memorandum and articles of association. The charity is a company limited by guarantee.

The charity is governed by a Board of Directors, supported by working groups as required. The Board members are all Trustees and include Officers of the Charity.

The Board meets four times a year and the various working groups meet as required during the year.

The members of the Board are volunteers. New Board members are elected by the existing members up to a maximum of twelve in total.

Trustee Induction and Training

New Trustees are briefed on their legal obligations under charity law, the committee and decision-making processes, the business plan and recent financial performance of the Charity. During their induction they meet key employees and other trustees. Trustees are encouraged to attend appropriate external training events where these will facilitate the undertaking of their role. At the end of each three year tenure the trustees are required to update their trustee training.

Organisational Structure

The Board delegates the day-to-day management of the affairs of the Charity to Chief Executive Officer with assistance from a Board member, Tarnia Hudson, who serves as the Honorary Administrator.

Board membership

In March 2013 the Board adopted, by unanimous agreement, a protocol to introduce a three-year rule from that date. Board members continue to actively seek new trustees, taking into consideration a good mix of professional skills including business, education and medical. A term of office for a director is 3 years, after which time he/she may be re-elected for a further 3-year term (details of current terms of office available on request).

Remuneration of key personnel

All members of staff employed by the charity have an annual appraisal in January following which salaries are set for the following 12 months. The appraisals are carried out by the Chief Executive Officer.

No Board member received any income or expenses for their work for the charity.

Related parties

The Charity owns the whole of the issued ordinary share capital of York Against Cancer Trading Company Limited, a company registered in England and Wales. The subsidiary is used for the raising of funds for the Charity through the sale of bought in goods through the Charity's two shops.

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

Risk management

The Trustees have assessed the major risks to which the charity is exposed, in particular those related to the operations and finances of the Charity and continues to take measures to reduce those risks to an acceptable minimum. The policy of only making new commitments when the funds are in hand is a very practical way of eliminating unnecessary financial risks. By its very nature a charity relies on fundraising, donations and legacies which can vary a great deal. Ongoing commitments are to our staff and to a range of time limited research and care projects.

The Board is proactive in identifying projects on which to spend its reserves, ensuring to find effective ways in which to fulfil the aims of York Against Cancer, whilst at the same time investing some funds to provide for future security.

Financial review and policies

The Charity's funds in 2024 increased by £405,607 (2023 - decreased by £336,178). Prior to any adjustment for investments, the Charity made a surplus of £323,567 (2023 – deficit of £329,816). The largest new commitment in the year was £120,000 for the renewal of the clinical trial nurse posts for another 2 years.

The detail of funding of services and care activities can be found in note 6.

The principal funding sources are fund-raising, the trading shops, donations, and legacies. Gross income in 2024 amounted to £1,460,424 (2023 £763,604). These funds support the key objectives of the Charity, namely, to fund clinical research, to support people with cancer and to fund education about the disease.

The charity has continued to benefit from legacies during the year, and we are immensely grateful to the generous donors. Legacy income is unpredictable and is another reason why the charity must husband its resources in the most effective way to enable the services we provide to both continue and develop.

Investment powers and policy

The Trustees have a general power of investment and so have the discretion to invest in such investment assets as they see fit. The Trustees have set a policy that sufficient of the 'free reserves' should be invested to retain a reasonable liquidity to meet grant commitments.

Our policy is a medium low risk approach for the growth of the portfolio of investments. The investment managers have discretion about how the investments are managed within the policy parameters set by the Trustees.

The Investment Group oversees the investment management of the Charity's funds. The services of HSBC Private Bank and Ruffer were retained as investment managers during 2024. Funds not invested are held on deposit to earn interest.

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

The total return on the investment portfolio managed by HSBC for the year ended 31 December 2024, before fees, was 9.86% (2023 8.33%). The total return on investment portfolio managed by Ruffer for the year ended 31 December 2024, before fees, was -1.9% (2023 -6.6%).

Reserves Policy

The reserves policy is to ensure the charity holds sufficient funds for the continuation of our support services, whilst maintaining the ability to commitment to future projects. When the Leveson Centre was being planned the trustees understood that this would change the funding model needed for the Charity. The Leveson Centre will increase the operating costs of the charity as we bare all the costs for running the centre.

Cash reserves are accumulated before making a binding commitment to fund set term projects. The total funds held as at 31 December 2024 are £4,466,498 (2023 £4,060,891).

The Board is very mindful that the charity is wholly reliant on donated income and therefore has designated funds for future projects which are under consideration. This ensures its undesignated funds reflect the true level of reserves we hold for future operating commitments.

Undesignated Fund

These are reserves retained to provide working capital and funds for future projects. At the end of the financial year, the unrestricted undesignated reserves were £1,521,157 (2023 £1,093,281). The level of free reserves is £1,113,248 (after excluding lease commitments which we expect to be covered from future annual income). This is the equivalent of 12 months of our budgeted undesignated operating costs. It is the charity's policy to hold 12 months of our operating costs as the charity is largely reliant on donated and legacy income.

Excess reserves will be available for additional fixed term projects or grants not already under consideration.

Designated Funds

Designated funds are part of the unrestricted funds which trustees have earmarked for assets held for the use in the charity and specific projects. At the year end, The Charity had consolidated designated funds of £2,713,980 (2023 £2,852,276) details of which are given in Note 16 of the financial statements.

Restricted Funds

Restricted funds represent monies raised by the Charity from public appeals for specific projects. At the year end, the Charity had restricted funds of £231,361 (2023 £115,334) details of which are given in Note 17 to the financial statements.

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

Reference and administrative details

Registered Charity	number 1130835	Company	number 06884476
		Limited by	
		Guarantee	
Principal Office and Trading Address		East Stand	
		York Community Stadium	
		Kathryn Avenue	
		Huntington	
		York	
		YO32 9AF	
Company Secretary	Julie Pamela Russell		
Directors and Trustees	Andrew Proctor	Sarah Wearing	
	Angela Darby	Michael Sweet	
	Rachel Goddard	Robert Onyett	
	Ian Yeowart	Tarnia Hudson	
	Prof Stephen Leveson	Michael John Stower (resigned 31 December 2024)	
	Trustee's protocol available on request		
Accountants	HPH	Auditors	Henton & Co LLP
	Chartered Accountants		Chartered Accountants
	54 Bootham		124 Acomb Road
	York		Holgate
	YO30 7XZ		York
			YO24 4EY
Bankers	National Bank	Solicitors	Harrowells
	Westminster		
	1 Market Street		Moorgate House
	York		Clifton Moorgate
	YO1 8SR		York
			YO30 4WY
Investment Advisors	HSBC Global Asset Management		Ruffer LLP
	78 St James's Street		80 Victoria Street
	London		London
	SW1A 1EJ		SW1E 5JL

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

Directors and Trustees Responsibilities

The purpose of this statement is to distinguish the Directors' and Trustees' responsibilities for the financial statements from those of the auditors as stated in their report.

Company and charity law require the Directors and Trustees to prepare financial statements which give a true and fair view of the Charitable Company's state of affairs at the end of its financial activities for that year. In preparing those financial statements the Trustees are required to:

- Select suitable accounting policies and then apply them consistently
- Make judgements and estimates that are reasonable and prudent;
- State whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements.
- Prepare the financial statements on the going concern basis unless it is inappropriate to assume that the Charitable Company will continue in operation.

The Directors and Trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the Charitable Company and enables them to ensure that the financial statements comply with the Companies Act 2006 and applicable charity law. They are also responsible for safeguarding the assets of the Charitable Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the Directors and Trustees are aware:

- There is no relevant information of which the Charitable Company's auditor is unaware; and
- The Directors and Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.

Approved by the Board on 3 June 2025 and signed on its behalf by:

Ian Yeowart
Director and Trustee

YORK AGAINST CANCER

INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER YEAR ENDED 31 DECEMBER 2024

Opinion

We have audited the financial statements of York Against Cancer (the 'parent charitable company') and its subsidiary (the 'group') for the year ended 31 December 2024 which comprise the group statement of financial activities, the group balance sheet, the charitable company balance sheet, the group statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the state of the group's and the parent charitable company's affairs as at 31 December 2024 and of the groups incoming resources and application of resources, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the group and parent charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and parent charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

YORK AGAINST CANCER

INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER YEAR ENDED 31 DECEMBER 2024

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the trustees' report (incorporating the strategic report and the directors' report) for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the trustees' report have been prepared in accordance with applicable legal requirements.

Matter on which we are required to report by exception

In the light of the knowledge and understanding of the group and parent charitable company and their environment obtained in the course of the audit, we have not identified material misstatements in the trustees' report.

We have nothing to report in respect of the following matters where the Companies Act 2006 required us to report to you if, in our opinion:

- adequate accounting records have not been kept by the parent charitable company, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of Board of Trustees's remuneration specified by law are not made; or
- we have not obtained all the information and explanations necessary for the purposes of our audit.

Responsibilities of the trustees

As explained more fully in the trustees' responsibilities statement, the trustees, who are also the directors of the charity for the purpose of company law, are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the parent charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

YORK AGAINST CANCER

INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER YEAR ENDED 31 DECEMBER 2024

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

- We have obtained an understanding of the legal and regulatory framework applicable to the group and parent charitable company through discussions with senior management and review of the regulatory framework of any professional or membership bodies that the charitable company is a part of. The charitable company uses third parties to ensure that it remains up to date with changes and to review compliance with all its legal and regulatory requirements. In making our assessment of detecting irregularities, including fraud, we have discussed the issue with management who have advised that, other than changes to the work place to ensure that they are Covid-19 compliant, there have been no changes and the company remains compliant with its legal and regulatory requirement. Nothing has been brought to light in completing our audit work that contradicts this.
- The following laws and regulations have been identified as being of significance in the context of the group and charitable company; Companies Act 2006, Charities Act 2011, fundraising regulations, health and safety legislation, employment laws, data protection, and relevant tax laws.
- In making our assessment of the susceptibility of the group's and charitable company's financial statements to material misstatement, we have also considered how fraud might occur. No instances of material misstatement or fraud have been noted in the audit of the accounts for the year ended 31 December 2024.
- All matters regarding non-compliance with laws and regulations and fraud have been communicated to all members of the audit engagement team. The engagement partner has assessed that the engagement team has the appropriate competence and capabilities to identify or recognise non-compliance with laws and regulations, affected by the inherent difficulty in detecting irregularities, the effectiveness of the group's and charitable company's controls, and the nature, timing and extend of the audit procedures performed.

As part of an audit in accordance with ISAs (UK), we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the internal control.

YORK AGAINST CANCER

**INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER
YEAR ENDED 31 DECEMBER 2024**

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the trustees.
- Conclude on the appropriateness of the trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the group's and charitable company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Use of our report

This report is made solely to the Charity's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Charity's members those matters we are required to state to them in an auditors report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Charity's members as a body, for our audit work, for this report, or for the opinions we have formed.

.....
Brett Davis (Senior Statutory Auditor)

For and on behalf of Henton & Co LLP

**Chartered Accountants
Statutory Auditor**
124 Acomb Road
York
YO24 4EY

Date:

YORK AGAINST CANCER
CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES
AND INCOME AND EXPENDITURE ACCOUNT
FOR THE YEAR ENDED 31 DECEMBER 2024

	Note	Unrestricted General Fund £	Designated Funds £	Restricted Funds £	Year ended 31 Dec 2024 £	Year ended 31 Dec 2023 £
Income and endowments from:						
Donations and legacies	2	916,327	-	135,070	1,051,397	430,282
Other trading activities	3	372,040	-	-	372,040	287,169
Investments	4	36,987	-	-	36,987	46,153
Total		1,325,354	-	135,070	1,460,424	763,604
Expenditure on:						
Raising funds	5	343,685	-	-	343,685	321,182
Charitable activities	6	555,955	218,174	19,043	793,172	772,238
Total		899,640	218,174	19,043	1,136,857	1,093,420
Net income/(expenditure) before gains on investments		425,714	(218,174)	116,027	323,567	(329,816)
Net (losses)/gains on investments	11	82,040	-	-	82,040	(6,362)
Net income/(expenditure)		507,754	(218,174)	116,027	405,607	(336,178)
Transfers between funds	16	(79,878)	79,878	-	-	-
Net movement in funds		427,876	(138,296)	116,027	405,607	(336,178)
Reconciliation of funds:						
Total funds brought forward		1,093,281	2,852,276	115,334	4,060,891	4,397,069
Total funds carried forward		£ 1,521,157	£ 2,713,980	£ 231,361	£ 4,466,498	£ 4,060,891

The notes on pages 30 to 40 form part of these financial statements.

YORK AGAINST CANCER
(Registration number: 06884476)

BALANCE SHEET
AS AT 31 DECEMBER 2024

	Note	Charity 2024 £	Consolidated 2024 £	Charity 2023 £	Consolidated 2023 £
FIXED ASSETS					
Tangible Fixed Assets	12	914,103	943,730	998,691	1,033,276
Investments	11	2,980,639	2,980,638	2,987,058	2,987,057
		<u>3,894,742</u>	<u>3,924,368</u>	<u>3,985,749</u>	<u>4,020,333</u>
CURRENT ASSETS					
Stock		-	82,186	-	65,919
Debtors	13	989,056	845,035	726,455	583,982
Cash at Bank and in Hand		313,129	364,669	487,179	548,880
		<u>1,302,185</u>	<u>1,291,890</u>	<u>1,213,634</u>	<u>1,198,781</u>
CREDITORS: amounts falling due within one year	14	425,599	499,779	1,014,539	1,078,223
		<u>425,599</u>	<u>499,779</u>	<u>1,014,539</u>	<u>1,078,223</u>
NET CURRENT ASSETS		876,586	792,111	199,095	120,558
TOTAL ASSETS LESS CURRENT LIABILITIES		4,771,328	4,716,479	4,184,844	4,140,891
CREDITORS: amounts falling due after one year	15	249,981	249,981	80,000	80,000
		<u>249,981</u>	<u>249,981</u>	<u>80,000</u>	<u>80,000</u>
NET ASSETS		<u>£ 4,521,347</u>	<u>£ 4,466,498</u>	<u>£ 4,104,844</u>	<u>£ 4,060,891</u>
THE FUNDS OF THE CHARITY					
Unrestricted					
Undesignated	18	1,605,633	1,521,157	1,171,819	1,093,281
Designated	16,18	2,684,353	2,713,980	2,817,691	2,852,276
Restricted	17,18	231,361	231,361	115,334	115,334
		<u>231,361</u>	<u>231,361</u>	<u>115,334</u>	<u>115,334</u>
TOTAL CHARITY FUNDS		<u>£ 4,521,347</u>	<u>£ 4,466,498</u>	<u>£ 4,104,844</u>	<u>£ 4,060,891</u>

Approved by the Trustees on 3 June 2025 and signed on its behalf by:

Sarah Wearing

S B Wearing
Director and Trustee

The notes on pages 30 to 40 form part of these financial statements.

**YORK AGAINST CANCER
CONSOLIDATED CASHFLOW STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2024**

	Note	2024 £	2023 £
Cash flows from operating activities:			
Net cash used in operating activities	21	(302,978)	(484,244)
Cash flows from investing activities:			
Dividends, interest and rents from investments		36,987	46,153
Purchase of property, plant and equipment		(6,679)	(405,743)
Proceeds from sale of property		-	5,987
Proceeds from sales of investments		813,121	1,383,378
Purchase of investments		(724,662)	(860,300)
Net cash provided by investing activities		<u>118,767</u>	<u>169,475</u>
Change in cash and cash equivalents in the reporting period		(184,211)	(314,769)
Cash and cash equivalents at the beginning of the reporting period		<u>548,880</u>	<u>863,649</u>
Cash and cash equivalents at the end of the reporting period		<u><u>£ 364,669</u></u>	<u><u>£ 548,880</u></u>

The notes on pages 30 to 40 form part of these financial statements.

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

1. ACCOUNTING POLICIES

Legal entity

York Against Cancer is regulated by the Charities Commission (1130835), limited by guarantee and is registered in England and Wales. The address of the registered office and principal place of business is York Community Stadium, Kathryn Avenue, Huntington, York, England, YO32 9AF.

Basis of preparation

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The consolidated accounts include the results of the Charitable Company and its subsidiary undertaking. The results of the subsidiary are consolidated on a line by line basis.

No separate SOFA has been presented for the Charitable Company alone as permitted by the SORP.

The Charitable Company constitutes a public benefit entity as defined by FRS 102.

The accounts are presented in UK Sterling pounds (£).

Going Concern

The Charitable Company has cash resources and has no requirement for external funding. The Directors and Trustees have a reasonable expectation that the Charitable Company has adequate resources to continue in operational existence for the foreseeable future. They continue to believe the going concern basis of accounting appropriate in preparing the annual financial statements.

Income

Donations and legacies

Credit is taken for donations and subscriptions when they are received. Credit is taken for legacies when received or if, before receipt, there is sufficient evidence to provide the necessary certainty that the legacy will be received and the value of the incoming resources can be measured with sufficient reliability.

Other trading activities

Fundraising income - represents gross income from events.

Subsidiary's non-charitable trading turnover - represents gross income from York Against Cancer Trading Company Limited, the Charitable Company's trading subsidiary.

Investments

Investment income has been accounted for on an accruals basis.

Expenditure

Raising funds

Fundraising costs - represents the total costs of fundraising events and activities held during the year.

Non charitable trading expenditure - comprises of the direct costs and administrative costs of the Charitable Company's trading subsidiary, York Against Cancer Trading Company Limited.

Charitable activities

Direct costs - comprises of expenditure on various projects the Charitable Company is supporting and is accounted for in full when the Charitable Company commits to provide the funding.

Support costs - comprises of the salaries and office expenses of the Charitable Company.

Governance costs - comprises the costs associated directly with the management by the Directors/Trustees of the Charitable Company's activities, including audit fees and costs of meetings.

All costs are apportioned on an actual cost basis.

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

1. ACCOUNTING POLICIES (continued)

Pension costs

The Charitable Company operates a defined contribution money purchase pension scheme for specific employees. The assets of the scheme are invested and managed independently of the finances of the Charitable Company. The charge for pension costs represents the contributions payable in the year.

Fixed Assets

Individual fixed assets costing £200 or more are capitalised and included in the accounts at cost.

Tangible fixed assets are depreciated over their expected useful lives at the following annual rates:

Freehold/Leasehold property	at straight line over 50 years or life of lease
Equipment	
- Shop and office equipment	at straight line over 10 years
- Computer equipment	at straight line over 3 years
- Respite home equipment	at straight line over 4 years
- Motor vehicles	at 25% reducing balance

Stock

Stock is valued at the lower of cost and net realisable value. Cost is computed on a first in first out basis. Net realisable value is based on estimated selling price less the estimated cost of disposal.

Funds Structure

Unrestricted Funds are funds which are available for use or retention at the discretion of the Directors/Trustees, in accordance with the Charity's objects. Designated Funds represent unrestricted funds earmarked by the Directors/Trustees for particular purposes. Restricted Funds are subjected to restrictions on their expenditure imposed by the donor or through the terms of an appeal. Details of Designated and Restricted Funds are contained in Notes 16 and 17, respectively.

Investments

The investment portfolios have been valued at market value at 31 December 2024. The SOFA includes the net gains and losses on investments arising on revaluation at the year end and on disposals throughout the year. Realised gains and losses on sales of investments are calculated as the difference between the sale proceeds and opening market value. Unrealised gains and losses represent the movement between market values.

Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

Cash at bank and in hand

Cash at bank and cash in hand includes cash and any short term deposit accounts with a maturity of three months or less from the date of opening.

Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

Financial instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

Operating leases

Rentals paid under operating leases are charged in the SOFA on a straight line basis over the lease term.

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

2. DONATIONS AND LEGACIES	Unrestricted £	Restricted £	2024 £	2023 £
Donations and grants	147,636	10,070	157,706	185,542
In Memoriam	26,193	-	26,193	22,360
Legacies	737,498	125,000	862,498	217,380
Intangible income	5,000	-	5,000	5,000
	<u>£ 916,327</u>	<u>£ 135,070</u>	<u>£ 1,051,397</u>	<u>£ 430,282</u>

During the year the charity was notified of a potential further legacy income from various estates. The timing and amounts still remain uncertain and therefore have not been provided for.

Intangible income comprises accounting services, a proportion of which is provided free of charge for the preparation of the Charitable Company and Subsidiary statutory accounts. A corresponding amount is included within governance costs.

3. OTHER TRADING ACTIVITIES	2024 £	2023 £
Fundraising income	182,132	129,554
Subsidiary's non-charitable trading turnover	189,908	157,615
	<u>£ 372,040</u>	<u>£ 287,169</u>

4. INVESTMENTS	2024 £	2023 £
Interest received	50	5,571
Dividends received	36,937	40,582
	<u>£ 36,987</u>	<u>£ 46,153</u>

5. ANALYSIS OF RAISING FUNDS	Unrestricted £	Restricted £	2024 £	2023 £
Advertising	8,918	-	8,918	7,097
Fundraising costs	122,344	-	122,344	109,013
Non charitable trading - other costs	151,083	-	151,083	140,780
Non charitable trading - staff costs	44,266	-	44,266	43,677
Non charitable trading - depreciation	5,455	-	5,455	5,404
Investment fees	11,619	-	11,619	15,211
	<u>£ 343,685</u>	<u>£ -</u>	<u>£ 343,685</u>	<u>£ 321,182</u>

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

6. ANALYSIS OF CHARITABLE ACTIVITIES

<i>Direct project costs:</i>	Unrestricted £	Restricted £	2024 £	2023 £
Research				
Jack Birch Unit	18,240	2,070	20,310	-
Clinical Trial Nurses	120,000	-	120,000	5,144
Support and Care				
Leveson Centre - direct	118,611	8,000	126,611	111,384
Leveson Centre - staff	68,399	-	68,399	53,049
Leveson Centre - depreciation	67,866	-	67,866	56,287
Psychology services	30,697	-	30,697	16,855
Complementary therapy	30,502	-	30,502	16,212
Respite property expenses	33,582	-	33,582	29,970
Minibus running costs - direct	11,752	-	11,752	10,411
Minibus running costs - staff costs	23,841	-	23,841	22,602
Mobile Chemotherapy Unit	400	8,973	9,373	20,069
Transport - Rapid diagnostics	3,945	-	3,945	4,948
Cancer benefit advice service	-	-	-	160,000
One off costs	5,045	-	5,045	320
	532,880	19,043	551,923	507,251
Support costs:				
Staff costs	130,721	-	130,721	146,138
Staff training and travel	3,940	-	3,940	4,118
Rent, service charge and rates	23,726	-	23,726	35,885
Heat and light	3,887	-	3,887	4,465
Repairs and maintenance	-	-	-	132
Insurances	4,427	-	4,427	5,565
Printing, stationery and postage	5,797	-	5,797	4,271
Computer expenses	16,722	-	16,722	11,342
Telephone	1,519	-	1,519	816
Sundry expenses	10,664	-	10,664	8,680
Gains and losses on fixed assets	-	-	-	(3,332)
Depreciation	22,904	-	22,904	25,061
	224,307	-	224,307	243,141
Governance costs:				
Audit fees	7,440	-	7,440	7,440
Accountancy fees	7,743	-	7,743	7,760
Legal and professional fees	-	-	-	5,670
Bank charges	1,759	-	1,759	976
	16,942	-	16,942	21,846
Total charitable activities	£ 774,129	£ 19,043	£ 793,172	£ 772,238

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

7. NET INCOMING RESOURCES FOR THE YEAR

	2024 £	2023 £
This is stated after charging:		
Depreciation	96,225	86,752
Auditor's remuneration for audit services - charity	7,440	7,440

8. REMUNERATION AND EXPENSES OF TRUSTEES

None of the Trustees received any remuneration or benefits by virtue of being a Trustee of the Charity and no Trustees were reimbursed any expenses incurred for services provided to the Charity.

9. STAFF COSTS

	2024 £	2023 £
Wages and salaries	286,686	237,607
Social security costs	20,618	15,396
Pension costs	11,070	8,550
Recruitment costs	1,819	930
Medical Insurance	4,533	2,517
Sub-contractor costs	-	6,424
	<u>£ 324,726</u>	<u>£ 271,424</u>

The average monthly head count was 10 staff (2023 10) and the average monthly number of full-time equivalent employees (including casual and part-time staff) during the year were as follows:

Projects	3	2
Trading	2	2
Management and administration	5	6

No employee received emoluments in excess of £60,000.

The key management personnel of the Charitable Company, comprise the directors and trustees, the CEO and Deputy CEO following the restructure. The total employee benefits of the key management personnel of the Charitable Company were £97,772 (2023 - £93,271).

10. SUBSIDIARY COMPANY

The Charitable Company owns the whole of the issued ordinary share capital of York Against Cancer Trading Company Limited. This company is registered in England and Wales (reg. no. 3405708) and its registered office is York Community Stadium, Kathryn Avenue, Huntington, York, England, YO32 9AF. The subsidiary is used for the raising of funds for the Charitable Company through the sale of bought in goods through the Charitable Company's shop and stalls. All activities have been consolidated on a line by line basis in the There is a loan account between the Charitable Company and the subsidiary. The balance on the loan account outstanding at the year end was £144,631 (2023 £149,404). Interest of £nil (2023 £nil) was charged during the year in respect of this loan.

A summary of the results of the subsidiary is shown below:

	2024 £	2023 £
Turnover	189,908	160,310
Cost of sales	<u>(98,153)</u>	<u>(82,637)</u>
Gross profit	91,755	77,673
Administrative expenses	<u>(102,652)</u>	<u>(107,224)</u>
Operating profit	(10,897)	(29,551)
Profit on ordinary activities before taxation	(10,897)	(29,551)
Taxation	<u>-</u>	<u>-</u>
Profit on ordinary activities after taxation	(10,897)	(29,551)
Amount gifted to York Against Cancer	<u>-</u>	<u>-</u>
Retained (withdrawn from)/within Subsidiary	<u>£ (10,897)</u>	<u>£ (29,551)</u>
Net Assets	<u>£ (54,847)</u>	<u>£ (43,950)</u>

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

11. INVESTMENTS

Consolidated	2024	2023
	£	£
Market value at 1 January 2024	2,987,057	3,516,497
Additions at cost	724,662	860,300
Disposals	(813,121)	(1,383,378)
Revaluations	82,040	(6,362)
Market value at 31 December 2024	<u>£ 2,980,638</u>	<u>£ 2,987,057</u>
Analysis of investments by class:		
Listed investments	<u>£ 2,980,638</u>	<u>£ 2,987,057</u>
The historical cost of the above investments amounts to:	<u>£ 2,744,421</u>	<u>£ 2,710,556</u>

The following material investments are over 5% by value of the investments held

	2024	2023
	Market value	Market value
	£	£
Ruffer Charity Assets Trust Account	1,482,817	1,611,882
	<u>£ 1,482,817</u>	<u>£ 1,611,882</u>

The Charitable Company holds all of the issued shares of its subsidiary undertaking York Against Cancer Trading Company Limited, at cost of £1, in addition to the above investments.

12. TANGIBLE FIXED ASSETS

	Property	Motor	Equipment	Charity	Subsidiary -	Consolidated
	£	Vehicles	£	Total	Shop	Total
		£		£	Equipment	£
					£	
<i>Cost</i>						
At 1 January 2024	1,046,364	61,936	53,862	1,162,162	54,048	1,216,210
Additions in year	-	-	6,182	6,182	497	6,679
At 31 December 2024	<u>1,046,364</u>	<u>61,936</u>	<u>60,044</u>	<u>1,168,344</u>	<u>54,545</u>	<u>1,222,889</u>
<i>Depreciation</i>						
At 1 January 2024	107,766	29,880	25,825	163,471	19,463	182,934
Charge for year	75,220	8,014	7,536	90,770	5,455	96,225
At 31 December 2024	<u>182,986</u>	<u>37,894</u>	<u>33,361</u>	<u>254,241</u>	<u>24,918</u>	<u>279,159</u>
<i>Net book value</i>						
At 31 December 2024	<u>£ 863,378</u>	<u>£ 24,042</u>	<u>£ 26,683</u>	<u>£ 914,103</u>	<u>£ 29,627</u>	<u>£ 943,730</u>
At 31 December 2023	<u>£ 938,598</u>	<u>£ 32,056</u>	<u>£ 28,037</u>	<u>£ 998,691</u>	<u>£ 34,585</u>	<u>£ 1,033,276</u>

All fixed assets are held for direct charitable purposes in Designated Funds.

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

13. DEBTORS	Charity 2024 £	Consolidated 2024 £	Charity 2023 £	Consolidated 2023 £
Amounts owed by subsidiary	144,631	-	149,404	-
Trade debtors	-	480	-	-
Prepayments	38,850	38,980	34,138	41,069
Accrued income	805,575	805,575	542,913	542,913
	£ 989,056	£ 845,035	£ 726,455	£ 583,982

14. CREDITORS: amounts falling due
within one year

Trade creditors	69,469	71,803	14,785	24,562
Project creditors	278,613	278,613	891,796	891,796
Taxation and social security	7,532	18,087	6,484	16,656
Accruals	67,946	129,237	98,459	142,194
Other creditors	2,039	2,039	3,015	3,015
	£ 425,599	£ 499,779	£ 1,014,539	£ 1,078,223

15. CREDITORS: amounts falling due
after one year

Project creditors	£ 249,981	£ 249,981	£ 80,000	£ 80,000
-------------------	-----------	-----------	----------	----------

16. DESIGNATED FUNDS (consolidated)

Designated Funds - 2024	Balance 01/01/2024 £	Income £	Expenditure £	Transfers £	Balance 31/12/2024 £
Leveson Centre	243,000	-	(60,750)	-	182,250
On demand services	66,000	-	(61,199)	73,199	78,000
Education Project	10,000	-	-	-	10,000
Jack Birch Unit	1,500,000	-	-	-	1,500,000
Fixed Assets Fund	1,033,276	-	(96,225)	6,679	943,730
Total	£ 2,852,276	£ -	£ (218,174)	£ 79,878	£ 2,713,980

Designated Funds - 2023	Balance 01/01/2023 £	Income £	Expenditure £	Transfers £	Balance 31/12/2023 £
Leveson Centre	553,750	-	(60,750)	(250,000)	243,000
On demand services	66,000	-	(36,780)	36,780	66,000
Education Project	10,000	-	-	-	10,000
Health Welfare	114,000	-	(114,000)	-	-
Jack Birch Unit	1,500,000	-	-	-	1,500,000
Fixed Assets Fund	866,230	-	(83,419)	250,465	1,033,276
Total	£ 3,109,980	£ -	£ (294,949)	£ 37,245	£ 2,852,276

Leveson Centre

The charity has set aside 5 years of lease costs of which 3 are remaining.

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

16. DESIGNATED FUNDS (consolidated continued)

On demand services

The Trustees have set aside monies to fund the following on demand services each year - patient travel for rapid diagnostics, complementary therapy and teenage psychology services. These services levels are set budgets at the beginning of each year based on current demand.

Education Project

The Board agreed to fund the annual budgeted costs of the Education Project which is aimed at raising the awareness of cancer to the public.

Jack Birch Unit

The Jack Birch Unit grant is up for renewal in July 2025 and the Trustees wish to continue this support the on-going research. Investments of £1.5m has been designated to ensure the charity can fund the continued support in 2025.

Fixed Asset Fund

This fund represents funds invested in tangible fixed assets.

Health Welfare

The board funded an additional health welfare post for 3 years in 2023 for the York area and ring fenced £114,000.

17. RESTRICTED FUNDS (consolidated)

Restricted Funds - 2024	Balance 01/01/2024	Income	Expenditure	Transfers	Balance 31/12/2024
	£	£	£	£	£
Mobile Chemotherapy Unit	113,657	-	(8,973)	-	104,684
Jack Birch Unit	-	8,000	(8,000)	-	-
Leveson Centre	-	2,070	(2,070)	-	-
Health Welfare	-	125,000	-	-	125,000
Mouth Cancer	1,677	-	-	-	1,677
Total 2024	£ 115,334	£ 135,070	£ (19,043)	£ -	£ 231,361

Restricted Funds - 2023	Balance 01/01/2023	Income	Expenditure	Transfers	Balance 31/12/2023
	£	£	£	£	£
Mobile Chemotherapy Unit	133,726	-	(20,069)	-	113,657
Minibus Appeal	-	100	(100)	-	-
Mouth Cancer	1,677	-	-	-	1,677
Total 2023	£ 135,403	£ 100	£ (20,169)	£ -	£ 115,334

Mobile Chemotherapy Unit

The Mobile Chemotherapy Unit Appeal relates to funds raised for the specific purpose of running the service.

Jack Birch Unit

Money from restricted donations for the Jack Birch Unit were used to fund the additional monies needed for a fellowship.

Leveson Centre

Restricted donations for the Leveson Centre were used to fund the running costs of the centre.

Health Welfare

A legacy for £125,000 was received in the year for our Health Welfare Service. Our next renewal for this service will be in 2025 and these funds will go to support the continuation of this service.

Mouth Cancer

Monies raised for the Head and Neck cancer department.

Minibus Appeal

Monies were received for the running costs of the minibus in 2023 and the purchase of the new minibus which was in 2022.

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

18. ANALYSIS OF GROUP NET ASSETS BETWEEN FUNDS

	General Funds £	Designated Funds £	Restricted Funds £	Total 2024 £
Fund balances at 31 December 2024 are represented by:				
Tangible fixed assets	-	943,730	-	943,730
Investments	1,480,638	1,500,000	-	2,980,638
Current assets	790,279	270,250	231,361	1,291,890
Current liabilities	(499,779)	-	-	(499,779)
Long term liabilities	(249,981)	-	-	(249,981)
	£ 1,521,157	£ 2,713,980	£ 231,361	£ 4,466,498
	General Funds £	Designated Funds £	Restricted Funds £	Total 2023 £
Fund balances at 31 December 2023 are represented by:				
Tangible fixed assets	-	1,033,276	-	1,033,276
Investments	1,487,057	1,500,000	-	2,987,057
Current assets	764,447	319,000	115,334	1,198,781
Current liabilities	(1,078,223)	-	-	(1,078,223)
Long term liabilities	(80,000)	-	-	(80,000)
	£ 1,093,281	£ 2,852,276	£ 115,334	£ 4,060,891

19. OPERATING LEASE COMMITMENTS

As at 31 December 2024 the group had the total minimum lease payments under operating leases at the end of the reporting period, for each of the following period:

	At 31 December 2024 Land and buildings £	Office equipment £	At 31 December 2023 Land and buildings £	Office equipment £
Total operating leases payable:				
Within one year	120,187	-	120,187	-
Between two and five years	309,269	-	336,887	-
After five years	160,312	-	227,812	-

20. RELATED PARTIES

During the year the Charitable Company paid £3,094 (2023 £3,182) to HPH Chartered Accountants for accountancy services and software costs, a firm in which the Charitable Company's Treasurer, Sarah Wearing, is a partner. At the year end there was £nil (2023 £nil) owing to HPH Chartered Accountants.

During 2024 Trustees and related parties donated £5,654 (2023 - £6,100) to the charity.

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

21. CASH FLOW NOTES

RECONCILIATION OF NET MOVEMENT IN FUNDS TO NET CASH FLOW FROM OPERATING ACTIVITIES	2024 £	2023 £
Net income/(expenditure) for the reporting period	405,607	(336,178)
Adjustments for:		
Depreciation charges	96,225	86,752
Gains on sale of fixed assets	-	(3,332)
(Gains)/Losses on investments	(82,040)	6,362
Dividends, interest and rents from investments	(36,987)	(46,153)
(Increase)/Decrease in stocks	(16,267)	(5,398)
(Increase)/Decrease in debtors	(261,053)	328,695
Increase/(Decrease) in creditors	(408,463)	(514,992)
Net cash used in operating activities	£ (302,978)	£ (484,244)
ANALYSIS OF CASH AND CASH EQUIVALENTS		
Cash at bank and in hand	364,669	548,880
Total cash and cash equivalents	£ 364,669	£ 548,880

ANALYSIS OF CHANGES IN NET DEBT

	At 01/01/2024 £	Cash-flows £	At 31/12/2024 £
Cash	548,880	(184,211)	364,669

22. VOLUNTEERS

The Charity is fortunate to be supported by over 100 volunteers. Their activities include working in our shops, attending events, supporting the office, collections and baking. Without them the Charity could not achieve what it does; their support is a massive asset in both workforce and financial terms. Whilst going about their work they are also ambassadors for the Charity which encourages more people to volunteer and support.

With varied knowledge, skills and experience the volunteers make an invaluable group. Our thanks goes to them all – together we really do make a difference to cancer patients and their families.

YORK AGAINST CANCER
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

23. COMPARATIVE INFORMATION

	Unrestricted			Year ended
	General	Designated	Restricted	31 Dec
	Fund	Funds	Funds	2023
	£	£	£	£
Income and endowments from:				
Donations and legacies	430,182	-	100	430,282
Other trading activities	287,169	-	-	287,169
Investments	46,153	-	-	46,153
Total	763,504	-	100	763,604
Expenditure on:				
Raising funds	321,182	-	-	321,182
Charitable activities	457,120	294,949	20,169	772,238
Total	778,302	294,949	20,169	1,093,420
Net expenditure before losses on investments	(14,798)	(294,949)	(20,069)	(329,816)
Net gains on investments	(6,362)	-	-	(6,362)
Net income/(expenditure)	(21,160)	(294,949)	(20,069)	(336,178)
Transfers between funds	(37,245)	37,245	-	-
Net movement in funds	(58,405)	(257,704)	(20,069)	(336,178)
Reconciliation of funds:				
Total funds brought forward	1,151,686	3,109,980	135,403	4,397,069
Total funds carried forward	£ 1,093,281	£ 2,852,276	£ 115,334	£ 4,060,891

YORK AGAINST CANCER

England & Wales - Charity number 1130835

Accounts



YORK AGAINST CANCER

**A company limited by guarantee
and
A registered charity number 1130835**

REPORT AND ACCOUNTS

For the year ended

31 December 2023

**HPH
Chartered Accountants
54 Bootham
York
YO30 7XZ**

YORK AGAINST CANCER

CONTENTS

	Page
Chairman's Report	1
Trustees' Report	2 - 18
Auditor's Report	19 – 22
Statement of Financial Activities	23
Balance Sheet	24
Cash Flow Statement	25
Notes to the Financial Statements	26 - 36

YORK AGAINST CANCER

CHAIRMAN'S REPORT 2023

2023 saw the Charity continue to provide the vital and valuable support that makes it so unique. A number of projects progressed and the important £680,000 donation to the York and Scarborough Hospitals NHS Foundation Trust to enable it to acquire a new robotic surgical system, has proven to be an important investment in helping not only local cancer patients, but also helping the Hospital Trust ensure that more cancer expertise can be retained closer to home.

The cancer support centre, The Leveson Centre - named after one of the Charity's founders Professor Steve Leveson - was completed and has quickly become a very important part of what the Charity strives to provide. It is now our most visible location and delivers a wide range of services for those affected by cancer.

The mini-bus continues to offer a vital service to many who need to travel to Leeds for radiotherapy treatment, while the respite home at Filey remains a haven for those able to use it. The Filey property has recently been supplemented by a smaller property at Yapham which is just outside Pocklington and we would like to thank Phil and Hazel Arnold for their very generous support which allows more people to benefit from that important 'time away'. The Jack Birch Unit at York University continues to provide internationally recognised research into cancers, research which remains an important part of what York Against Cancer is all about.

Once again, we sadly lost a number of our volunteers and supporters throughout the year, and our thoughts go out to their families and friends. Each of them supported the work of the Charity, and helped it continue to provide the important services and funding for research that we are recognised for.

Our small office and retail team, our mini-bus drivers, the Leveson Centre team and our army of volunteers continue their hard work week to week, and to them, and Board colleagues, I would like to pass on my grateful thanks for your continuing support and promotion of the Charity.

With the completion of the Leveson Centre our longer-term commitments are now significant, and the need to look forward and plan for our current and future funding requirements goes on to ensure we remain focused and able to fund the important services for people impacted by cancer.

It is now 36 years since York Against Cancer was created. Its longevity is very much down to the vision of those who established the Charity all those years ago, but it is also a testament to the work undertaken by everybody who is or has been involved over the years.

Ian Yeowart
Chair York Against Cancer

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

The Directors (who are also the Trustees of the Charity and are listed below) are pleased to present their report of the Charitable Company for the year ended 31 December 2023.

Objectives and activities

The objects of the Charity are to raise funds to:

1. Foster and promote joint research between clinicians and research scientists in York and wider area and, by encouraging a more effective exchange of ideas and information, to advance the alleviation and cure of cancer.
2. Support treatment of cancer patients at York Hospital and the local area.
3. Fund education and information about cancer for patients and their families and the wider public.

The Trustees believe they have complied with the duty in section 4 of the 2006 Charities Act to have due regard to guidance published by the Charity Commission in respect of public benefit.

Aims and strategies

The Charity aims to provide support to cancer patients and the community through the: -

- funding and the provision of services and resources for patients and their families
- funding of research programmes
- funding of education initiatives

Achievements and performance

The Office Team

The office team have settled into their new working environment within York Stadium and are building business relationships with other key stakeholders. They continue to deal with the complex operational challenges that arise, and they do this with great resolve and in a positive manner. Each member of the team has their own responsibilities; however, they support each other with day-to-day tasks, ensuring the smooth operation of the charity and everyone receives the support they need. They respond quickly to any requests and challenges they are faced with, and this is recognised as a key strength of the team.

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2023


Care group report 2023

The purpose of the Care group is to consider applications both external and internal for “care” projects to be funded by York Against Cancer and to make recommendations to the Board of Trustees for ratification.

The group comprises of YAC Trustees and representatives from different areas of the charity, who have the expertise to make judgements on the value of the proposed projects.

There is a stringent application process which is adhered to; a standard application form is used and the following pathway.

Pathway for applications for funding or new ventures from YAC.



19/08/2019

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

Not all applications are successful but the ones that are, must show clear evidence that the project is of value to patients, has longevity and fulfils the over-arching aims of the charity.

Please see below a list of successful projects funded in 2023.

- The Leveson Centre
- Transport to Rapid Diagnostic Appointments
- Adult & Teenage Psychology Support
- Cancer Prehabilitation project, Selby
- Da Vinci Surgical Robot
- Cancer Benefits Advice Service – Scarborough (continuation) **
- Cancer Benefits Advice Service – York (new) **

** Some projects have a fixed term contract, (usually 2 or 3 years) these are be reassessed before being renewed or otherwise.

This robust approach for the consideration of funding care projects shows due diligence given to the spending of money which has been donated or fundraised for by the general public.

I would like to thank my colleagues who sit on the Care group for their time and hard work during 2023.

Mike Stower

Chair of the Care group

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

SUPPORT AND CARE SERVICE ACTIVITIES

Services and posts supported by York Against Cancer

In addition to the team directly employed by the charity there are other support workers whose salary costs are paid by York Against Cancer. These posts are as follows, which illustrates the range of activities supported by the Board:

- **Cancer Benefits Advice Service – Scarborough (in collaboration with Citizens Advice North Yorkshire)**

The charity continues to fund a cancer benefits advice service providing holistic financial advice for cancer patients in the Scarborough area: ensuring they receive the financial help to which they are entitled.

The main issues faced by clients by proportion are shown as follows: -

ISSUE – Patients Concerns	2022-23	2021-2022
· Benefits	97%	97%
· Charitable applications	28.5%	15%
· Health & Community Care	5%	5%
· Debt	2%	2%
· Financial services	3.5%	4%
· Employment	1.5%	2%
· Housing	2%	5%
· Travel & Transport	5%	6%

As demonstrated by these figures the issue of Benefits remains at the top of the agenda, affecting 97% of clients.

During 2023 the majority (77%) of clients were aged between 55 and 84 years old; although, 14% of our clients were under 55 and 9% aged 85 or over.

Pressures of the escalating cost of living directly impact cancer patients as they fall into the most vulnerable of categories and as a result there was a substantial increase in the need for charitable support and food banks. The number of clients requiring this type of assistance for the previous year was 70, this year the number has more than doubled to 160.

- **Cancer Benefits Advice Service – York (in collaboration with Citizens Advice North Yorkshire)**

An agreement was signed in October 2023 for the York service and a full report will be available for the 2024 annual report.

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

- **Teenage Psychology Support**

YAC funds Dr Rebecca Donaldson, a Teenage Psychologist who supports young people when they or someone they know is affected by cancer. This service is funded on a need basis, during 2023 the charity spent £16k on this service. Referrals are received from Clinical Nurse Specialists, Oncologists, G.P's and the Leveson Centre. Dr Donaldson (Becky) is often accompanied by her Therapy dog, Luna.



- **Adult Psychology**

Dr Jo McVey, Adult Psychologist started seeing patients in October 2023 in the Leveson Centre, a full report will be available for the 2024 annual report.

Mobile Chemotherapy Unit



The Mobile Chemotherapy Unit (MCU) takes chemotherapy services to the wider areas of the York & Scarborough Hospital Trust, in Malton, Selby, Scarborough and Bridlington, this has enabled the charity to widen its reach. The MCU has helped thousands of patients avoid the time-consuming and tiring journeys to the hospital in York. During 2023 we continued to fund the cost of servicing and repairs to keep the MCU on the road.

Minibus

Our minibus service continues to be popular; we provide free transport for patients going to St James hospital in Leeds for radiotherapy treatments. During 2023 we provided 73 individual patients with transport to Leeds – radiotherapy is given daily (Mon-Fri) and length of treatments can range from 3 to 7 weeks. If the demand is high we use volunteer drivers and if demand is low, we use the YAC car, making the service more efficient.



DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

'Just to say thank you. The bus to Leeds was a God send. It was good fun with the people on the bus.'

'Thank you for your kindness and help getting to St James hospital.'

The provision of patient transport to Rapid Diagnostic appointments.

We work closely with the Rapid Diagnostic department offering transport to patients who need to get to their diagnostic appointments which are not always at their nearest hospital.

We have provided transport to these types of appointments since 2021 and in the last 12 months have helped 29 patients from York, Malton and Scarborough at a cost of £2900 p.a.

Respite Properties

Our Filey house provides valuable respite breaks for cancer patients; during 2023 156 patients visited the property along with family or friends.

In April, local couple Hazel and Phil Arnold completed a full renovation of one of their farm buildings, situated in Yapham, which is 4 miles from Pocklington. They have offered us full use of their property as a second respite offering. The cottage sleeps 2 people and is a valuable addition to the Filey house.

We encourage feedback from service users to ensure we get to know of any issues and so we can keep the standards high. If any improvements need addressing, we act on these quickly. On booking a break we ask for a deposit; visitors can request this be returned but many users donate it to us as a way of a thank you.



Thank you so much, our stay in Filey was wonderful and beyond our expectations.



Thank you for all you do for cancer patients. We had an amazing break and will treasure all the memories.

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

The Leveson Centre – providing cancer support services

On 6th February 2023 the doors of the Leveson Centre opened providing cancer patients, their friends and family somewhere to access support, care and information whilst going through cancer. The 'look and feel' of the Centre was intentionally non-clinical, the space is welcoming, friendly, calming, and inclusive.

The footfall during 2023 went from 173 visitors in its first month to over 600 per month by the end of the year. We record how many patients, family members, friends and hospital professionals visit each day and record whether the visit is a planned appointment or a walk-in. This information provides the data to ensure we have our staffing and volunteer numbers correct.

A range of activities are on offer in the Centre, this has grown gradually during 2023. We listen to visitors' feedback and have grown our activity accordingly.

- Complementary Therapy
- Arts and Crafts workshop
- Weekly coffee mornings
- Nicola Jane, bra fitting & advice
- Family and friends support groups
- Head covering design project
- Relaxation classes
- Well-being Choir
- Look good feel better
- Pilates
- Welfare Benefits Service

Also, Psychology appointments are available at the Leveson Centre as detailed on page 3 of this report.

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

RESEARCH ACTIVITIES

Clinical Research Nurse and Assistant posts at York Hospital

During 2023 funding support to clinical trials has enabled four new studies, including Haematology, Colorectal, Breast and early cancer detection. There were eleven cancer studies open, seven of these hit the target number of recruits which would not have been achieved without the YAC funding.

The funding was also instrumental in the continuation of the PINPOINT Study. This study is a simple blood test, which seeks to become another tool in primary care to triage those who are being considered for the two-week wait cancer pathway. This study works in collaboration with GPs and the Rapid Diagnostic Centre, it uses biomarkers in the blood to provide a 'Pinpoint score'. The study recruited 664 participants (as of 9/11/23) of which 41 were found to have cancer.

Our funding continues to provide essential support to many of the long-standing studies, many of which continue above and beyond 10+ years.

Jack Birch Unit (University of York)

The Charity is committed to another 9 months supporting the work of the Jack Birch Unit. The roles supported by York Against Cancer are: -

Director of the Jack Birch Unit

Assistant Director

Laboratory technician

Administrative assistant

Research Fellow in Informatics at the Jack Birch Unit is also being supported from 2019 to 2024.

Jack Birch Unit of Molecular Carcinogenesis – Annual Report 2023

York Against Cancer provides funds in the form of a generous five-year programme grant to support research in the Jack Birch Unit, where we have built unique expertise in urothelial (bladder) cancer research. Although one of the top 10 common cancers of ageing, bladder cancer typically receives less research funding than other cancers. This means that York Against Cancer's funding is able to make particular research impact.

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

One important aspect of our work in the JBU is the training of the next generation of scientists and it has been a timely year to mark the significant progress being made by two of JBU's outstanding researchers, Dr Simon Baker and Dr Andrew Mason, as they nurture their own research groups within the JBU. A reorganisation of the [JBU website](#)* was carried out to reflect their changing status as group leaders. Simon holds a fellowship from Kidney Research UK and is studying a common virus as a possible cause of bladder cancer. Andrew, who was originally appointed to the YAC 30th Anniversary Fellowship, now holds a lectureship and studies data collected from urothelial cancers in the UK and worldwide. Indeed, Andrew is himself now involved in training the next generation of students in cancer informatics, with two of his group receiving prizes at one of the scientific meetings attended. Under other staff news, Dr Jenny Baker (née Hinley) who had studied her PhD in the JBU, rejoined after a stint away and Denise Alaniz Barraza from Mexico joined the group for 12 weeks' research experience after completing her Master's degree in the Department of Biology. Our YAC-funded PhD student, Ryan Ellison left towards the end of the year to write up his thesis and was replaced by George Hatton, who prior to becoming the new YAC PhD student, completed his final year project in the JBU as part of his Integrated Master's degree.



Tea Party for YAC supporters in the Guildhall.

One of the year's highlights occurred in March, when Ian Yeowart and Julie Russell visited the University to meet the Vice Chancellor. Professor Charlie Jeffrey thanked York Against Cancer for their ongoing support of the Jack Birch Unit and discussed future opportunities for partnership with the University under the 2030 vision of a "University for Public Good". This was followed by a series of research presentations in the JBU. Later, in April, a tea party was held at the Guildhall in York to celebrate YAC's induction into the University's College of Benefactors and to thank YAC supporters and fundraisers for the fantastic job they do.

Finally, as JBU Director, I would like to thank York Against Cancer Trustees, fundraisers and supporters for the research support we receive. I further thank all our scientific and clinical collaborators for the important contribution they make to the quality and output of our research.

**Professor Jenny Southgate, Director,
Jack Birch Unit of Molecular Carcinogenesis, University of York**

* <https://www.york.ac.uk/biology/jack-birch-unit/>

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

EDUCATION ACTIVITIES

The Cancer Awareness and Prevention group continues to work to spread information about cancer across as wide a range of the public as possible with an emphasis on young people.

York Against Cancer Awareness and Education Committee Report 2023

Our committed team has continued to meet regularly, either face to face or via zoom.

Dr Simon Baker, Research Scientist at the Jack Birch Unit, has taken the lead with the Enthuse partnership project, working with the National STEM Learning Centre (NSLC) and 6 local secondary schools (spreading out from the city to include Selby and Malton). The partnership aims to train teachers to be more confident in teaching cancer-related topics and a cancer-focussed programme of continuing professional development has been delivered by the NSLC over the last two years. The partnership has engaged Amazelab who develop engaging, creative teaching resources relating to DNA and cell biology which have received very positive reviews from the schools.

Another key feature of the project is to teach young people about cancer research using practical experiments with scientists from the Jack Birch Unit in the state-of-the-art University of York teaching laboratories. We have taken students from three schools through a DNA mutation practical in the labs followed by bioinformatics work package created by Dr Andrew Mason. Again, the new practical designed around a specific cancer-causing mutation in the p53 gene was very well received.

We are now looking to cherry-pick the best bits of our Enthuse partnership and develop an ambitious new phase of this project aiming to reach more schools for even more impact. Every teacher we reach can influence hundreds of students and their families.

We have distributed 1300 sun hats to 37 primary schools in the York and surrounding area. Our committed volunteers helped with the delivery to the participating schools.

Before Covid we provided Primary schools with books about how to talk to children about cancer, they were popular and after seeking feedback from the schools, the A & E group plan to repeat this project but with new and up to date books.

We held an awareness day in York City Centre in October, this gave us the opportunity to talk to people about cancer awareness and about the work of the charity.

As always, the priority of the group is to ensure making the biggest difference with our limited resource. Our focus has been to look at local cancer screening uptakes and to compare with the national statistics. This year we looked specifically at bowel cancer screening as it was deemed this screening could be improved upon in Yorkshire. A drinks mat was designed and handed out at events which included the awareness day.

The group is also looking at the local geography and underrepresented groups comparing cancer statistics looking for areas which need our focus. We have contacts within the clinical commissioning group from whom we can get the detailed data on which we can act on in the future.

We are looking at widening our reach across the whole of York and North and East of Yorkshire in collaboration with the communications committee.

Thank you to the YAC team and the Awareness and Education group members.

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

FUNDRAISING

The retail outlets, at Huntington and the Hospital have continued to be an invaluable source of income and the hospital shop provides a very useful 'shop front' for the charity. The sterling work done by our volunteers; and our staff in the office has yet again given up many hours in the evening and at weekends to spread the message about York Against Cancer. The links with the local business community have again proved a great benefit to the charity. With all these efforts from our employed staff and volunteers the charity is able to provide more much-needed support to many in the local community.

York Against Cancer is committed to maintaining high standards of fundraising and retail activity. The Charity is registered with the Fundraising Regulator. The Charity has recognised and begun to put in place a comprehensive policy for fundraising. The Charity does not use any third parties to act on its behalf in relation to fundraising. No complaints were received by the charity during 2023 in relation to its fundraising activities.

Fundraising report 2023

We have again been very lucky with the fundraising support we have received from individuals, businesses, organisations, and groups in the last 12 months.

As well as holding our own events at which we have been supported brilliantly by our volunteers, there are events that are organised on our behalf. On many occasions the first we know about an event is when we see an amount of money come into the bank account or we are handed a cheque. Every pound received helps us to continue with services we already provide and to plan what we may do more to help, support and care for cancer patients. We really cannot do what we do without the support of fundraising.

Here are a few of our events and the fantastic amounts raised.

- The Three Bears Charity – Three Peak Challenge - £16,000
- YDL – Twelve Peak Challenge – £1,500
- Stamford Bridge Community Choir – £11,000
- York Rocks Christmas Against Cancer – £16,000
- Annual Golf Day - £16,500
- Jane Tomlinson 10k Run – £5,000
- Weighton Wolds Rotary Club – Classic Car show - £4,500
- Christmas Lunch – £1,500
- Charity of the Year – Hiscox Insurance - £3,300
- Charity of the Year – Deans Garden Centre - £10,000

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

When we are talking to prospective fundraisers, we like to tell them how the money they raise will be spent. The following graphic is used for this purpose.



FUTURE PLANNING

The Board have continued their consistently adopted policy of only making commitments when the finance for these is already in place. The Board are mindful of the responsibility of ensuring that the generous donations received are used in the most effective manner possible to meet with the aims of the charity. With a sudden increase in legacies over the last few years the board established a Finance Sub-group to consider the most effective way to manage the funds for the future of the charity. The Board has agreed with the recommendations of the sub-group that a significant proportion of funds should be invested to provide for both future security of the charity and to ensure that the capital is used most effectively and to be available when future projects are considered and to ensure that the long-term plans and services the charity provides can be continued into the foreseeable future.

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

Structure, Governance and Management

The charity was incorporated on 22 April 2009 and its governing document is the memorandum and articles of association. The charity is a company limited by guarantee.

The charity is governed by a Board of Directors, supported by working groups as required. The Board members are all Trustees and include Officers of the Charity.

The Board meets four times a year and the various working groups meet as required during the year.

The members of the Board are volunteers. New Board members are elected by the existing members up to a maximum of twelve in total.

Trustee Induction and Training

New Trustees are briefed on their legal obligations under charity law, the committee and decision-making processes, the business plan and recent financial performance of the Charity. During their induction they meet key employees and other trustees. Trustees are encouraged to attend appropriate external training events where these will facilitate the undertaking of their role. At the end of each three tenure the trustees are required to update their trustee training.

Organisational Structure

The Board delegates the day-to-day management of the affairs of the Charity to Chief Executive Officer with assistance from a Board member, Tarnia Hudson, who serves as the Honorary Administrator.

Board membership

In March 2013 the Board adopted, by unanimous agreement, a protocol to introduce a three-year rule from that date. Board members continue to actively seek new trustees, taking into consideration a good mix of professional skills including business, education and medical. A term of office for a director is 3 years, after which time he/she may be re-elected for a further 3-year term (details of current terms of office available on request).

Remuneration of key personnel

All members of staff employed by the charity have an annual appraisal in January following which salaries are set for the following 12 months. The appraisals are carried out by the Chief Executive Officer.

No Board member received any income or expenses for their work for the charity.

Related parties

The Charity owns the whole of the issued ordinary share capital of York Against Cancer Trading Company Limited, a company registered in England and Wales. The subsidiary is used for the raising of funds for the Charity through the sale of bought in goods through the Charity's two shops.

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

Risk management

The Trustees have assessed the major risks to which the charity is exposed, in particular those related to the operations and finances of the Charity and continues to take measures to reduce those risks to an acceptable minimum. The policy of only making new commitments when the funds are in hand is a very practical way of eliminating unnecessary financial risks. By its very nature a charity relies on fundraising, donations and legacies which can vary a great deal. Ongoing commitments are to our staff and to a range of time limited research and care projects.

The Board is proactive in identifying projects on which to spend its reserves, ensuring to find effective ways in which to fulfil the aims of York Against Cancer, whilst at the same time investing some funds to provide for future security.

Financial review and policies

The Charity's funds in 2023 decreased by £336,178 (2022 - decreased by £380,991). Prior to any adjustment for investments, the Charity made a deficit of £329,816 (2022 – deficit of £351,405). The largest new commitment in the year was £160,000 for the expansion of the Cancer Benefit Advice Service into the York Area.

The detail of funding of services and care activities can be found in note 6.

The principal funding sources are fund-raising, the trading shops, donations, and legacies. Gross income in 2023 amounted to £763,604 (2022 £1,468,175). These funds support the key objectives of the Charity, namely, to fund clinical research, to support people with cancer and to fund education about the disease.

The charity has continued to benefit from legacies during the year, and we are immensely grateful to the generous donors. Legacy income is unpredictable and is another reason why the charity must husband its resources in the most effective way to enable the services we provide to both continue and develop.

Investment powers and policy

The Trustees have a general power of investment and so have the discretion to invest in such investment assets as they see fit. The Trustees have set a policy that sufficient of the 'free reserves' should be invested to retain a reasonable liquidity to meet grant commitments.

Our policy is a medium low risk approach for the growth of the portfolio of investments. The investment managers have discretion about how the investments are managed within the policy parameters set by the Trustees.

The Investment Group oversees the investment management of the Charity's funds. The services of HSBC Private Bank and Ruffer were retained as investment managers during 2023. Funds not invested are held on deposit to earn interest.

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

The total return on the investment portfolio managed by HSBC for the year ended 31 December 2023, before fees, was 3.27% (2022 -7.53%). The total return on investment portfolio managed by Ruffer for the year ended 31 December 2023, before fees, was -6.6% (2022 7.4%).

Reserves Policy

The reserves policy is to ensure the charity holds sufficient funds for the continuation of our support services, whilst maintaining the ability to commitment to future projects. When the Leveson Centre was being planned the trustees understood that this would change the funding model needed for the Charity. The Leveson Centre will increase the operating costs of the charity as we bare all the costs for running the centre.

Cash reserves are accumulated before making a binding commitment to fund set term projects. The total funds held as at 31 December 2023 are £4,060,891 (2022 £4,397,069).

The Board is very mindful that the charity is wholly reliant on donated income and therefore has designated funds for future projects which are under consideration. This ensures its undesignated funds reflect the true level of reserves we hold for future operating commitments.

Undesignated Fund

These are reserves retained to provide working capital and funds for future projects. At the end of the financial year, the unrestricted undesignated reserves were £1,093,281 (2022 £1,151,686). The level of free reserves is £697,568 (after excluding lease commitments which we expect to be covered from future annual income). This is the equivalent of 12 months of our budgeted undesignated operating costs. It is the charity's policy to hold 12 months of our operating costs as the charity is largely reliant on donated and legacy income.

Excess reserves will be available for additional fixed term projects or grants not already under consideration.

Designated Funds

Designated funds are part of the unrestricted funds which trustees have earmarked for assets held for the use in the charity and specific projects. At the year end, The Charity had consolidated designated funds of £2,852,276 (2022 £3,109,980) details of which are given in Note 16 of the financial statements.

Restricted Funds

Restricted funds represent monies raised by the Charity from public appeals for specific projects. At the year end, the Charity had restricted funds of £115,334 (2022 £135,403) details of which are given in Note 17 to the financial statements.

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

Directors and Trustees Responsibilities

The purpose of this statement is to distinguish the Directors' and Trustees' responsibilities for the financial statements from those of the auditors as stated in their report.

Company and charity law require the Directors and Trustees to prepare financial statements which give a true and fair view of the Charitable Company's state of affairs at the end of its financial activities for that year. In preparing those financial statements the Trustees are required to:

- Select suitable accounting policies and then apply them consistently
- Make judgements and estimates that are reasonable and prudent;
- State whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements.
- Prepare the financial statements on the going concern basis unless it is inappropriate to assume that the Charitable Company will continue in operation.

The Directors and Trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the Charitable Company and enables them to ensure that the financial statements comply with the Companies Act 2006 and applicable charity law. They are also responsible for safeguarding the assets of the Charitable Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the Directors and Trustees are aware:

- There is no relevant information of which the Charitable Company's auditor is unaware; and
- The Directors and Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.

Approved by the Board on 6 August 2024 and signed on its behalf by:

Ian Yeowart
Director and Trustee

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

Reference and administrative details

Registered Charity	number 1130835	Company Limited by Guarantee	number 06884476
Principal Office and Trading Address		East Stand York Community Stadium Kathryn Avenue Huntington York YO32 9AF	
Company Secretary	Julie Pamela Russell		
Directors and Trustees	Andrew Proctor Angela Darby Rachel Goddard Michael John Stower Ian Yeowart Sarah Wearing	Dr Lynn Bartram (resigned 11 July 2023) Michael Sweet Robert Onyett Tarnia Hudson Prof Stephen Leveson Michael Patrick Shepherd (resigned 25 October 2023) William Mark Sessions (resigned 11 July 2023)	
	Trustee’s protocol available on request		
Accountants	HPH Chartered Accountants 54 Bootham York YO30 7XZ	Auditors	Henton & Co LLP Chartered Accountants 124 Acomb Road Holgate York YO24 4EY
Bankers	National Westminster Bank 1 Market Street York YO1 8SR	Solicitors	Harrowells Moorgate House Clifton Moorgate York YO30 4WY
Investment Advisors	HSBC Global Asset Management 78 St James’s Street London SW1A 1EJ		Ruffer LLP 80 Victoria Street London SW1E 5JL

**INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER
YEAR ENDED 31 DECEMBER 2023**

Opinion

We have audited the financial statements of York Against Cancer (the 'parent charitable company') and its subsidiary (the 'group') for the year ended 31 December 2023 which comprise the group statement of financial activities, the group balance sheet, the charitable company balance sheet, the group statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the state of the group's and the parent charitable company's affairs as at 31 December 2023 and of the groups incoming resources and application of resources, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the group and parent charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and parent charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

**INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER
YEAR ENDED 31 DECEMBER 2023**

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the trustees' report (incorporating the strategic report and the directors' report) for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the trustees' report have been prepared in accordance with applicable legal requirements.

Matter on which we are required to report by exception

In the light of the knowledge and understanding of the group and parent charitable company and their environment obtained in the course of the audit, we have not identified material misstatements in the trustees' report.

We have nothing to report in respect of the following matters where the Companies Act 2006 required us to report to you if, in our opinion:

- adequate accounting records have not been kept by the parent charitable company, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of Board of Trustees's remuneration specified by law are not made; or
- we have not obtained all the information and explanations necessary for the purposes of our audit.

Responsibilities of the trustees

As explained more fully in the trustees' responsibilities statement, the trustees, who are also the directors of the charity for the purpose of company law, are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the parent charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

**INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER
YEAR ENDED 31 DECEMBER 2023**

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

- We have obtained an understanding of the legal and regulatory framework applicable to the group and parent charitable company through discussions with senior management and review of the regulatory framework of any professional or membership bodies that the charitable company is a part of. The charitable company uses third parties to ensure that it remains up to date with changes and to review compliance with all its legal and regulatory requirements. In making our assessment of detecting irregularities, including fraud, we have discussed the issue with management who have advised that, other than changes to the work place to ensure that they are Covid-19 compliant, there have been no changes and the company remains compliant with its legal and regulatory requirement. Nothing has been brought to light in completing our audit work that contradicts this.
- The following laws and regulations have been identified as being of significance in the context of the group and charitable company; Companies Act 2006, Charities Act 2011, fundraising regulations, health and safety legislation, employment laws, data protection, and relevant tax laws.
- In making our assessment of the susceptibility of the group's and charitable company's financial statements to material misstatement, we have also considered how fraud might occur. No instances of material misstatement or fraud have been noted in the audit of the accounts for the year ended 31 December 2023.
- All matters regarding non-compliance with laws and regulations and fraud have been communicated to all members of the audit engagement team. The engagement partner has assessed that the engagement team has the appropriate competence and capabilities to identify or recognise non-compliance with laws and regulations, affected by the inherent difficulty in detecting irregularities, the effectiveness of the group's and charitable company's controls, and the nature, timing and extend of the audit procedures performed.

As part of an audit in accordance with ISAs (UK), we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the internal control.

YORK AGAINST CANCER

INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER YEAR ENDED 31 DECEMBER 2023

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the trustees.
- Conclude on the appropriateness of the trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the group's and charitable company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Use of our report

This report is made solely to the Charity's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Charity's members those matters we are required to state to them in an auditors report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Charity's members as a body, for our audit work, for this report, or for the opinions we have formed.

.....
Brett Davis (Senior Statutory Auditor)

For and on behalf of Henton & Co LLP

Chartered Accountants

Statutory Auditor

124 Acomb Road

York

YO24 4EY

Date: 6 August 2024

YORK AGAINST CANCER
CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES
AND INCOME AND EXPENDITURE ACCOUNT
FOR THE YEAR ENDED 31 DECEMBER 2023

	Note	Unrestricted General Fund £	Designated Funds £	Restricted Funds £	Year ended 31 Dec 2023 £	Year ended 31 Dec 2022 £
Income and endowments from:						
Donations and legacies	2	430,182	-	100	430,282	1,169,842
Other trading activities	3	287,169	-	-	287,169	261,895
Investments	4	46,153	-	-	46,153	36,438
Total		763,504	-	100	763,604	1,468,175
Expenditure on:						
Raising funds	5	321,182	-	-	321,182	259,611
Charitable activities	6	457,120	294,949	20,169	772,238	1,559,969
Total		778,302	294,949	20,169	1,093,420	1,819,580
Net income/(expenditure) before gains on investments		(14,798)	(294,949)	(20,069)	(329,816)	(351,405)
Net (losses)/gains on investments	11	(6,362)	-	-	(6,362)	(29,586)
Net income/(expenditure)		(21,160)	(294,949)	(20,069)	(336,178)	(380,991)
Transfers between funds	16	(37,245)	37,245	-	-	-
Net movement in funds		(58,405)	(257,704)	(20,069)	(336,178)	(380,991)
Reconciliation of funds:						
Total funds brought forward		1,151,686	3,109,980	135,403	4,397,069	4,778,060
Total funds carried forward		£ 1,093,281	£ 2,852,276	£ 115,334	£ 4,060,891	£ 4,397,069

The notes on pages 26 to 36 form part of these financial statements.

YORK AGAINST CANCER
(Registration number: 06884476)

BALANCE SHEET
AS AT 31 DECEMBER 2023

	Note	Charity 2023 £	Consolidated 2023 £	Charity 2022 £	Consolidated 2022 £
FIXED ASSETS					
Tangible Fixed Assets	12	998,691	1,033,276	826,241	866,230
Investments	11	2,987,058	2,987,057	3,516,498	3,516,497
		3,985,749	4,020,333	4,342,739	4,382,727
CURRENT ASSETS					
Stock		-	65,919	-	60,521
Debtors	13	726,455	583,982	1,043,825	912,677
Cash at Bank and in Hand		487,179	548,880	811,874	863,649
		1,213,634	1,198,781	1,855,699	1,836,847
CREDITORS: amounts falling due within one year	14	1,014,539	1,078,223	1,055,560	1,091,095
NET CURRENT ASSETS		199,095	120,558	800,139	745,752
TOTAL ASSETS LESS CURRENT LIABILITIES		4,184,844	4,140,891	5,142,878	5,128,479
CREDITORS: amounts falling due after one year	15	80,000	80,000	731,410	731,410
NET ASSETS		<u>£ 4,104,844</u>	<u>£ 4,060,891</u>	<u>£ 4,411,468</u>	<u>£ 4,397,069</u>
THE FUNDS OF THE CHARITY					
Unrestricted					
Undesignated	18	1,171,819	1,093,281	1,206,074	1,151,686
Designated	16,18	2,817,691	2,852,276	3,069,991	3,109,980
Restricted	17,18	115,334	115,334	135,403	135,403
TOTAL CHARITY FUNDS		<u>£ 4,104,844</u>	<u>£ 4,060,891</u>	<u>£ 4,411,468</u>	<u>£ 4,397,069</u>

Approved by the Trustees on 6 August 2024 and signed on its behalf by:

S B Wearing
Director and Trustee

The notes on pages 26 to 36 form part of these financial statements.

**YORK AGAINST CANCER
CONSOLIDATED CASHFLOW STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2023**

	Note	2023 £	2022 £
Cash flows from operating activities:			
Net cash used in operating activities	21	(484,244)	(226,911)
Cash flows from investing activities:			
Dividends, interest and rents from investments		46,153	36,438
Purchase of property, plant and equipment		(405,743)	(322,442)
Proceeds from sale of property		5,987	-
Proceeds from sales of investments		1,383,378	1,475,082
Purchase of investments		(860,300)	(944,981)
Net cash provided by investing activities		<u>169,475</u>	<u>244,097</u>
Change in cash and cash equivalents in the reporting period		(314,769)	17,186
Cash and cash equivalents at the beginning of the reporting period		<u>863,649</u>	<u>846,463</u>
Cash and cash equivalents at the end of the reporting period		<u><u>£ 548,880</u></u>	<u><u>£ 863,649</u></u>

The notes on pages 26 to 36 form part of these financial statements.

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

1. ACCOUNTING POLICIES

Legal entity

York Against Cancer is regulated by the Charities Commission (1130835), limited by guarantee and is registered in England and Wales. The address of the registered office and principal place of business is York Community Stadium, Kathryn Avenue, Huntington, York, England, YO32 9AF.

Basis of preparation

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The consolidated accounts include the results of the Charitable Company and its subsidiary undertaking. The results of the subsidiary are consolidated on a line by line basis.

No separate SOFA has been presented for the Charitable Company alone as permitted by the SORP.

The Charitable Company constitutes a public benefit entity as defined by FRS 102.

The accounts are presented in UK Sterling pounds (£).

Going Concern

The Charitable Company has cash resources and has no requirement for external funding. The Directors and Trustees have a reasonable expectation that the Charitable Company has adequate resources to continue in operational existence for the foreseeable future. They continue to believe the going concern basis of accounting appropriate in preparing the annual financial statements.

Income

Donations and legacies

Credit is taken for donations and subscriptions when they are received. Credit is taken for legacies when received or if, before receipt, there is sufficient evidence to provide the necessary certainty that the legacy will be received and the value of the incoming resources can be measured with sufficient reliability.

Other trading activities

Fundraising income - represents gross income from events.

Subsidiary's non-charitable trading turnover - represents gross income from York Against Cancer Trading Company Limited, the Charitable Company's trading subsidiary.

Investments

Investment income has been accounted for on an accruals basis.

Expenditure

Raising funds

Fundraising costs - represents the total costs of fundraising events and activities held during the year.

Non charitable trading expenditure - comprises of the direct costs and administrative costs of the Charitable Company's trading subsidiary, York Against Cancer Trading Company Limited.

Charitable activities

Direct costs - comprises of expenditure on various projects the Charitable Company is supporting and is accounted for in full when the Charitable Company commits to provide the funding.

Support costs - comprises of the salaries and office expenses of the Charitable Company.

Governance costs - comprises the costs associated directly with the management by the Directors/Trustees of the Charitable Company's activities, including audit fees and costs of meetings.

All costs are apportioned on an actual cost basis.

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

1. ACCOUNTING POLICIES (continued)

Pension costs

The Charitable Company operates a defined contribution money purchase pension scheme for specific employees. The assets of the scheme are invested and managed independently of the finances of the Charitable Company. The charge for pension costs represents the contributions payable in the year.

Fixed Assets

Individual fixed assets costing £200 or more are capitalised and included in the accounts at cost.

Tangible fixed assets are depreciated over their expected useful lives at the following annual rates:

Freehold/Leasehold property	at straight line over 50 years or life of lease
Equipment	
- Shop and office equipment	at straight line over 10 years
- Computer equipment	at straight line over 3 years
- Respite home equipment	at straight line over 4 years
- Motor vehicles	at 25% reducing balance

Stock

Stock is valued at the lower of cost and net realisable value. Cost is computed on a first in first out basis. Net realisable value is based on estimated selling price less the estimated cost of disposal.

Funds Structure

Unrestricted Funds are funds which are available for use or retention at the discretion of the Directors/Trustees, in accordance with the Charity's objects. Designated Funds represent unrestricted funds earmarked by the Directors/Trustees for particular purposes. Restricted Funds are subjected to restrictions on their expenditure imposed by the donor or through the terms of an appeal. Details of Designated and Restricted Funds are contained in Notes 16 and 17, respectively.

Investments

The investment portfolios have been valued at market value at 31 December 2023. The SOFA includes the net gains and losses on investments arising on revaluation at the year end and on disposals throughout the year. Realised gains and losses on sales of investments are calculated as the difference between the sale proceeds and opening market value. Unrealised gains and losses represent the movement between market values.

Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

Cash at bank and in hand

Cash at bank and cash in hand includes cash and any short term deposit accounts with a maturity of three months or less from the date of opening.

Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

Financial instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

Operating leases

Rentals paid under operating leases are charged in the SOFA on a straight line basis over the lease term.

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

2. DONATIONS AND LEGACIES	Unrestricted £	Restricted £	2023 £	2022 £
Donations and grants	185,442	100	185,542	228,697
In Memoriam	22,360	-	22,360	26,509
Legacies	217,380	-	217,380	909,636
Intangible income	5,000	-	5,000	5,000
	£ 430,182	£ 100	£ 430,282	£ 1,169,842

During the year the charity was notified of a potential further legacy income from various estates the timing and amounts still remain uncertain and therefore have not been provided for.

Intangible income comprises accounting services, a proportion of which is provided free of charge for the preparation of the Charitable Company and Subsidiary statutory accounts. A corresponding amount is included within governance costs.

3. OTHER TRADING ACTIVITIES	2023 £	2022 £
Fundraising income	129,554	136,121
Subsidiary's non-charitable trading turnover	157,615	125,774
	£ 287,169	£ 261,895

4. INVESTMENTS	2023 £	2022 £
Interest received	5,571	1,210
Dividends received	40,582	35,228
	£ 46,153	£ 36,438

5. ANALYSIS OF RAISING FUNDS	Unrestricted £	Restricted £	2023 £	2022 £
Advertising	7,097	-	7,097	6,639
Fundraising costs	109,013	-	109,013	80,727
Non charitable trading - other costs	140,780	-	140,780	115,039
Non charitable trading - staff costs	43,677	-	43,677	34,601
Non charitable trading - depreciation	5,404	-	5,404	5,405
Investment fees	15,211	-	15,211	17,200
	£ 321,182	£ -	£ 321,182	£ 259,611

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

6. ANALYSIS OF CHARITABLE ACTIVITIES

<i>Direct project costs:</i>	Unrestricted £	Restricted £	2023 £	2022 £
Research				
Jack Birch Unit	-	-	-	363,262
Clinical Trial Nurses	5,144	-	5,144	152,221
Support and Care				
Leveson Centre - direct	111,384	-	111,384	37,378
Leveson Centre -staff	53,049	-	53,049	-
Leveson Centre - depreciation	56,287	-	56,287	-
Psychology services	16,855	-	16,855	10,805
Complementary therapy	16,212	-	16,212	-
Respite property expenses	29,970	-	29,970	22,653
Minibus running costs - direct	10,311	100	10,411	11,882
Minibus running costs - staff costs	22,602	-	22,602	21,273
Mobile Chemotherapy Unit*	-	20,069	20,069	5,740
Transport - Rapid diagnostics	4,948	-	4,948	7,086
Cancer benefit advice service	160,000	-	160,000	-
Robotic surgery	-	-	-	680,000
One off costs	320	-	320	150
Education				
Education expenses	-	-	-	8,850
	487,082	20,169	507,251	1,321,300
Support costs:				
Staff costs	146,138	-	146,138	154,175
Staff training and travel	4,118	-	4,118	3,666
Rent, service charge and rates	35,885	-	35,885	16,871
Heat and light	4,465	-	4,465	3,756
Repairs and maintenance	132	-	132	1,510
Insurances	5,565	-	5,565	4,318
Printing, stationery and postage	4,271	-	4,271	4,913
Computer expenses	11,342	-	11,342	11,516
Telephone	816	-	816	800
Sundry expenses	8,680	-	8,680	4,176
Gains and losses on fixed assets	(3,332)	-	(3,332)	-
Depreciation	25,061	-	25,061	19,370
	243,141	-	243,141	225,071
Governance costs:				
Audit fees	7,440	-	7,440	4,560
Accountancy fees	7,760	-	7,760	7,400
Legal and professional fees	5,670	-	5,670	-
Bank charges	976	-	976	1,638
	21,846	-	21,846	13,598
Total charitable activities	£ 752,069	£ 20,169	£ 772,238	£ 1,559,969

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

7. NET INCOMING RESOURCES FOR THE YEAR

	2023 £	2022 £
This is stated after charging:		
Depreciation	86,752	24,775
Auditor's remuneration for audit services - charity	7,440	4,560

8. REMUNERATION AND EXPENSES OF TRUSTEES

None of the Trustees received any remuneration or benefits by virtue of being a trustee of the Charity and no Trustees were reimbursed any expenses incurred for services provided to the Charity.

9. STAFF COSTS

	2023 £	2022 £
Wages and salaries	237,607	185,048
Social security costs	15,396	11,194
Pension costs	8,550	7,602
Recruitment costs	930	3,120
Medical Insurance	2,517	3,085
Sub-contractor costs	6,424	-
	£ 271,424	£ 210,049

The average monthly head count was 10 staff (2022 8) and the average monthly number of full-time equivalent employees (including casual and part-time staff) during the year were as follows:

Projects	2	1
Trading	2	1
Management and administration	6	6

No employee received emoluments in excess of £60,000.

The key management personnel of the Charitable Company, comprise the directors and trustees, the CEO and Deputy CEO following the restructure. The total employee benefits of the key management personnel of the Charitable Company were £93,271 (2022 - £88,871).

10. SUBSIDIARY COMPANY

The Charitable Company owns the whole of the issued ordinary share capital of York Against Cancer Trading Company Limited. This company is registered in England and Wales (reg. no. 3405708) and its registered office is York Community Stadium, Kathryn Avenue, Huntington, York, England, YO32 9AF. The subsidiary is used for the raising of funds for the Charitable Company through the sale of bought in goods through the Charitable Company's shop and stalls. All activities have been consolidated on a line by line basis in the There is a loan account between the Charitable Company and the subsidiary. The balance on the loan account outstanding at the year end was £149,404 (2022 £138,024). Interest of £nil (2022 £nil) was charged during the year in respect of this loan.

A summary of the results of the subsidiary is shown below:

	2023 £	2022 £
Turnover	160,310	125,774
Cost of sales	(82,637)	(61,578)
Gross profit	77,673	64,196
Administrative expenses	(107,224)	(93,467)
Operating profit	(29,551)	(29,271)
Profit on ordinary activities before taxation	(29,551)	(29,271)
Taxation	-	-
Profit on ordinary activities after taxation	(29,551)	(29,271)
Amount gifted to York Against Cancer	-	-
Retained (withdrawn from)/within Subsidiary	£ (29,551)	£ (29,271)
Net Assets	£ (43,950)	£ (14,339)

YORK AGAINST CANCER

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023**

11. INVESTMENTS

Consolidated	2023 £	2022 £
Market value at 1 January 2023	3,516,497	4,076,184
Additions at cost	860,300	944,981
Disposals	(1,383,378)	(1,475,082)
Revaluations	(6,362)	(29,586)
Market value at 31 December 2023	<u>£ 2,987,057</u>	<u>£ 3,516,497</u>
Analysis of investments by class:		
Listed investments	<u>£ 2,987,057</u>	<u>£ 3,516,497</u>
The historical cost of the above investments amounts to:	<u>£ 2,710,556</u>	<u>£ 3,196,719</u>

The following material investments are over 5% by value of the investments held

	2023 Market value £	2022 Market value £
Ruffer Charity Assets Trust Account	1,611,882	1,832,547
	<u>£ 1,611,882</u>	<u>£ 1,832,547</u>

The Charitable Company holds all of the issued shares of its subsidiary undertaking York Against Cancer Trading Company Limited, at cost of £1, in addition to the above investments.

12. TANGIBLE FIXED ASSETS

	Property £	Motor Vehicles £	Equipment £	Charity Total £	Subsidiary - Shop Equipment £	Consolidated Total £
<i>Cost</i>						
At 1 January 2023	799,930	88,451	43,843	932,224	54,048	986,272
Additions in year	246,434	-	10,019	256,453	-	256,453
Disposals in year	-	(26,515)	-	(26,515)	-	(26,515)
At 31 December 2023	<u>1,046,364</u>	<u>61,936</u>	<u>53,862</u>	<u>1,162,162</u>	<u>54,048</u>	<u>1,216,210</u>
<i>Depreciation</i>						
At 1 January 2023	44,125	43,222	18,636	105,983	14,059	120,042
Charge for year	63,641	10,518	7,189	81,348	5,404	86,752
Disposals in year	-	(23,860)	-	(23,860)	-	(23,860)
At 31 December 2023	<u>107,766</u>	<u>29,880</u>	<u>25,825</u>	<u>163,471</u>	<u>19,463</u>	<u>182,934</u>
<i>Net book value</i>						
At 31 December 2023	<u>£ 938,598</u>	<u>£ 32,056</u>	<u>£ 28,037</u>	<u>£ 998,691</u>	<u>£ 34,585</u>	<u>£ 1,033,276</u>
At 31 December 2022	<u>£ 755,805</u>	<u>£ 45,229</u>	<u>£ 25,207</u>	<u>£ 826,241</u>	<u>£ 39,989</u>	<u>£ 866,230</u>

All fixed assets are held for direct charitable purposes in Designated Funds.

YORK AGAINST CANCER

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023**

13. DEBTORS	Charity 2023 £	Consolidated 2023 £	Charity 2022 £	Consolidated 2022 £
Amounts owed by subsidiary	149,404	-	138,024	-
Prepayments	34,138	41,069	13,396	20,272
Accrued income	542,913	542,913	892,405	892,405
Other debtors	-	-	-	-
	£ 726,455	£ 583,982	£ 1,043,825	£ 912,677

14. CREDITORS: amounts falling due within one year				
Trade creditors	14,785	24,562	176,204	182,320
Project creditors	891,796	891,796	827,466	827,466
Taxation and social security	6,484	16,656	3,802	4,201
Accruals	98,459	142,194	45,342	74,362
Other creditors	3,015	3,015	2,746	2,746
	£ 1,014,539	£ 1,078,223	£ 1,055,560	£ 1,091,095

15. CREDITORS: amounts falling due after one year				
Project creditors	£ 80,000	£ 80,000	£ 731,410	£ 731,410

16. DESIGNATED FUNDS (consolidated)

Designated Funds - 2023	Balance 01/01/2023 £	Income £	Expenditure £	Transfers £	Balance 31/12/2023 £
Leveson Centre	553,750	-	(60,750)	(250,000)	243,000
On demand services	66,000	-	(36,780)	36,780	66,000
Education Project	10,000	-	-	-	10,000
Health Welfare	114,000	-	(114,000)	-	-
Jack Birch Unit	1,500,000	-	-	-	1,500,000
Robotic Surgery Project	-	-	-	-	-
Fixed Assets Fund	866,230	-	(83,419)	250,465	1,033,276
Total	£ 3,109,980	£ -	£ (294,949)	£ 37,245	£ 2,852,276

Designated Funds - 2022	Balance 01/01/2022 £	Income £	Expenditure £	Transfers £	Balance 31/12/2022 £
Leveson Centre	466,500	-	-	87,250	553,750
On demand services	10,000	-	(7,086)	63,086	66,000
Education Project	-	-	(8,850)	18,850	10,000
Minibus	36,000	-	-	(36,000)	-
Health Welfare	-	-	-	114,000	114,000
Jack Birch Unit	-	-	-	1,500,000	1,500,000
Robotic Surgery Project	680,000	-	-	(680,000)	-
Fixed Assets Fund	405,171	-	(24,775)	485,834	866,230
Total	£ 1,597,671	£ -	£ (40,711)	£ 1,553,020	£ 3,109,980

Leveson Centre

The charity has set aside the remaining budget for improvements relating to the Leveson Centre as the year end and 5 years of lease costs.

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

16. DESIGNATED FUNDS (consolidated continued)

On demand services

The trustees have set aside monies to fund the following on demand services - patient travel for rapid diagnostics, complementary therapy and teenage psychology services. These services levels are set budgets at the beginning of each year based on current demand.

Education Project

The Board agreed to fund the annual budgeted costs of the Education Project which is aimed at raising the awareness of cancer to the public.

Minibus

The trustees have set aside monies for the purchase of a new minibus which was purchased in 2022.

Health Welfare

The board wish to fund an additional health welfare post for 3 years in the York area and have ring fenced the following monies.

Jack Birch Unit

The Jack Birch Unit grant is up for renewal in 2024 and the trustees wish to continue this support the on-going research. Investments of £1.5m has been designated to ensure the charity can fund the continued support in 2024.

Robotic Surgery Project

During the year the charity committed to support the NHS regarding its Robotic Surgery facilities. The commitment of £680,000 has been recognised in 2022 and will be paid over 3 years.

Fixed Asset Fund

This fund represents funds invested in tangible fixed assets.

17. RESTRICTED FUNDS (consolidated)

Restricted Funds - 2023	Balance 01/01/2023	Income	Expenditure	Transfers	Balance 31/12/2023
	£	£	£	£	£
Mobile Chemotherapy Unit	133,726	-	(20,069)	-	113,657
Minibus Appeal	-	100	(100)	-	-
Mouth Cancer	1,677	-	-	-	1,677
Total 2023	£ 135,403	£ 100	(£ 20,169)	£ -	£ 115,334

Restricted Funds - 2022	Balance 01/01/2022	Income	Expenditure	Transfers	Balance 31/12/2022
	£	£	£	£	£
Mobile Chemotherapy Unit	136,966	2,500	(5,740)	-	133,726
Minibus Appeal	-	2,500	-	(2,500)	-
Jack Birch Unit	-	10,000	(10,000)	-	-
Mouth Cancer	1,677	-	-	-	1,677
Total 2022	£ 138,643	£ 15,000	(£ 15,740)	(£ 2,500)	£ 135,403

Mobile Chemotherapy Unit

The Mobile Chemotherapy Unit Appeal relates to funds raised for the specific purpose of running the service.

Minibus Appeal

Monies were received for the running costs of the minibus in 2023 and the purchase of the new minibus which was in 2022.

Jack Birch Unit

Monies were received for support of the Jack Birch Unit which were used during 2022.

Mouth Cancer

Monies raised for the Head and Neck cancer department.

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

18. ANALYSIS OF GROUP NET ASSETS BETWEEN FUNDS

	General Funds £	Designated Funds £	Restricted Funds £	Total 2023 £
Fund balances at 31 December 2023 are represented by:				
Tangible fixed assets	-	1,033,276	-	1,033,276
Investments	1,487,057	1,500,000	-	2,987,057
Current assets	764,447	319,000	115,334	1,198,781
Current liabilities	(1,078,223)	-	-	(1,078,223)
Long term liabilities	(80,000)	-	-	(80,000)
	£ 1,093,281	£ 2,852,276	£ 115,334	£ 4,060,891
	General Funds £	Designated Funds £	Restricted Funds £	Total 2022 £
Fund balances at 31 December 2022 are represented by:				
Tangible fixed assets	-	866,230	-	866,230
Investments	3,516,497	-	-	3,516,497
Current assets	1,651,698	49,746	135,403	1,836,847
Current liabilities	(1,091,095)	-	-	(1,091,095)
Long term liabilities	(731,410)	-	-	(731,410)
	£ 3,345,690	£ 915,976	£ 135,403	£ 4,397,069

19. OPERATING LEASE COMMITMENTS

As at 31 December 2023 the group had the total minimum lease payments under operating leases at the end of the reporting period, for each of the following period:

	At 31 December 2023		At 31 December 2022	
	Land and buildings £	Office equipment £	Land and buildings £	Office equipment £
Total operating leases payable:				
Within one year	115,905	-	115,905	-
Between two and five years	312,714	-	335,370	-
After five years	210,094	-	278,273	-

20. RELATED PARTIES

During the year the Charitable Company paid £3,182 (2022 £3,097) to HPH Chartered Accountants for accountancy services and software costs, a firm in which the Charitable Company's Treasurer, Sarah Wearing, is a partner. At the year end there was £nil (2022 £nil) owing to HPH Chartered Accountants.

During 2023 trustees and related parties donated £6,100 (2022 - £116,384) to the charity.

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

21. CASH FLOW NOTES

RECONCILIATION OF NET MOVEMENT IN FUNDS TO NET CASH FLOW FROM OPERATING ACTIVITIES	2023 £	2022 £
Net income/(expenditure) for the reporting period	(336,178)	(380,991)
Adjustments for:		
Depreciation charges	86,752	24,775
Gains on sale of fixed assets	(3,332)	-
(Gains)/Losses on investments	6,362	29,586
Dividends, interest and rents from investments	(46,153)	(36,438)
(Increase)/Decrease in stocks	(5,398)	(5,345)
(Increase)/Decrease in debtors	328,695	(462,906)
Increase/(Decrease) in creditors	(514,992)	604,408
Net cash used in operating activities	£ (484,244)	£ (226,911)
ANALYSIS OF CASH AND CASH EQUIVALENTS		
Cash at bank and in hand	548,880	863,649
Total cash and cash equivalents	£ 548,880	£ 863,649

ANALYSIS OF CHANGES IN NET DEBT

	At 01/01/2023 £	Cash-flows £	At 31/12/2023 £
Cash	863,649	(314,769)	548,880

22. VOLUNTEERS

The Charity is fortunate to be supported by over 100 volunteers. Their activities include working in our shops, attending events, supporting the office, collections and baking. Without them the Charity could not achieve what it does; their support is a massive asset in both workforce and financial terms. Whilst going about their work they are also ambassadors for the Charity which encourages more people to volunteer and support.

With varied knowledge, skills and experience the volunteers make an invaluable group. Our thanks goes to them all – together we really do make a difference to cancer patients and their families.

YORK AGAINST CANCER
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

24. COMPARATIVE INFORMATION

	Unrestricted General Fund £	Designated Funds £	Restricted Funds £	Year ended 31 Dec 2022 £
Income and endowments from:				
Donations and legacies	1,154,842	-	15,000	1,169,842
Other trading activities	261,895	-	-	261,895
Investments	36,438	-	-	36,438
Total	1,453,175	-	15,000	1,468,175
Expenditure on:				
Raising funds	259,611	-	-	259,611
Charitable activities	1,503,518	40,711	15,740	1,559,969
Total	1,763,129	40,711	15,740	1,819,580
Net expenditure before losses on investments	(309,954)	(40,711)	(740)	(351,405)
Net gains on investments	(29,586)	-	-	(29,586)
Net income/(expenditure)	(339,540)	(40,711)	(740)	(380,991)
Transfers between funds	(1,550,520)	1,553,020	(2,500)	-
Net movement in funds	(1,890,060)	1,512,309	(3,240)	(380,991)
Reconciliation of funds:				
Total funds brought forward	3,041,746	1,597,671	138,643	4,778,060
Total funds carried forward	£ 1,151,686	£ 3,109,980	£ 135,403	£ 4,397,069

25. CAPITAL COMMITMENTS

At the year end the charity was committed to spend £nil (2022- £250,000) for the completion of the Leveson Centre fit out. The Leveson Centre fit out was completed in the year.

YORK AGAINST CANCER

England & Wales - Charity number 1130835

Accounts



YORK AGAINST CANCER

**A company limited by guarantee
and
A registered charity number 1130835**

REPORT AND ACCOUNTS

For the year ended

31 December 2022

**HPH
Chartered Accountants
54 Bootham
York
YO30 7XZ**

YORK AGAINST CANCER

CONTENTS

	Page
Chairman's Report	1
Trustees' Report	2 - 16
Auditor's Report	17 – 20
Statement of Financial Activities	21
Balance Sheet	22
Cash Flow Statement	23
Notes to the Financial Statements	24 - 34

YORK AGAINST CANCER

CHAIRMAN'S REPORT 2022

We at last started to see the end of restrictions that had severely hampered the valuable work that the Charity undertakes and getting back to being as normal as possible was a great tonic, with the opportunity to once again meet together at various functions and events being a very positive step.

Once again, we sadly lost a number of our volunteers and supporters throughout the year, and our thoughts go out to their families and friends. Each one of them supported the work of the Charity, and helped it continue to provide the important services and funding for research that we are recognised for.

A number of projects that were under evaluation last year have progressed. These include a £680,000 donation to the York and Scarborough Hospitals NHS Foundation Trust to enable it to acquire a new robotic surgical system, and the start of work on the Leveson Centre, a new cancer support centre located close to our main office at the Community Stadium. We also, at last, managed to source a replacement for the minibus.

Our small office team and mini-bus drivers continued to work hard throughout the year, and to them, our volunteers, and Board colleagues I would like to pass on my grateful thanks for continuing to support and promote the Charity.

Work of course continues, and the need to look forward and plan for our future funding requirements goes on to ensure we remain focused, and in a position to provide the important services for people touched by cancer – services that remain important as we expand on the outstanding work undertaken in the many areas that the Charity is involved in.

It is 35 years since the Charity was created by Professor Steve Leveson, then a consultant surgeon at St James' Hospital in Leeds, and fellow surgeon John Craven and University Researcher Dr. Colin Garner. Its longevity is not only down to their vision but is also a testament to the work undertaken by everybody who is or has been involved with the Charity.

Steve Leveson and his Wife Pat remain an integral part of the Charity, and with our committed army of volunteers, our small band of dedicated staff, and our many supporters the Charity remains in good hands.

Ian Yeowart
Chair York Against Cancer

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

The Directors (who are also the Trustees of the Charity and are listed below) are pleased to present their report of the Charitable Company for the year ended 31 December 2022.

Objectives and activities

The objects of the Charity are to raise funds to:

1. Foster and promote joint research between clinicians and research scientists in York and wider area and, by encouraging a more effective exchange of ideas and information, to advance the alleviation and cure of cancer.
2. Support treatment of cancer patients at York Hospital and the local area.
3. Fund education and information about cancer for patients and their families and the wider public.

The Trustees believe they have complied with the duty in section 4 of the 2006 Charities Act to have due regard to guidance published by the Charity Commission in respect of public benefit.

Aims and strategies

The Charity aims to provide support to cancer patients and the community through the: -

- funding and the provision of services and resources for patients and their families
- funding of research programmes
- funding of education initiatives

Achievements and performance

SUPPORT ACTIVITIES

The Office Team

The office team have settled into their new working environment within York Stadium and are building business relationships with other key stakeholders. They continue to deal with the complex operational challenges that arise, and they do this with great resolve and in a positive manner. Each member of the team has their own responsibilities; however, they support each other with day-to-day tasks, ensuring the smooth operation of the charity and everyone receives the support they need. They respond quickly to any requests and challenges they are faced with, and this is recognised as a key strength of the team.

Services and posts supported by York Against Cancer

- **Health Welfare Advisor - Scarborough**

The charity continues to support the Citizens Advice North Yorkshire (CANY) in their work with cancer patients in the Scarborough area: ensuring that they receive the help to which they are entitled. The area of specialist help includes the following areas.

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

SUPPORT ACTIVITIES

ISSUE	Patients concerns
· Benefits	97%
· Charitable applications	15%
· Health & Community Care	5%
· Debt	2%
· Financial services	4%
· Employment	2%
· Housing	5%
· Travel & Transport	6%

It is hoped we will be able to replicate the above post to be based in York and to operate out of the Leveson Centre.

Supported positions are initially given for a fixed term (usually two or three years) and then reviewed by the Board. This is done to ensure that the money so generously raised by our supporters is used in the most efficient way.

- **Teenage Psychology Support**

YAC funds a psychologist who specialises in supporting young people when they or their family is affected by cancer. This service is funded on a need basis, during 2022 the charity spent £11k on this service. The psychologist receives her referrals from Clinical Nurse Specialists, Oncologists and G. P's.

- **Mobile Chemotherapy Unit**



The Mobile Chemotherapy Unit (MCU) takes chemotherapy services to the wider areas of the York & Scarborough Hospital Trust, in Malton, Selby, Scarborough and Bridlington, this has enabled the charity to widen its reach. The MCU has helped thousands of patients the time-consuming and tiring journeys to the hospital in York. During 2022 we continued to fund the cost of servicing and repairs to keep the MCU on the road.

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

SUPPORT ACTIVITIES

- **Minibus**

Our minibus service continues to be popular; we provide free transport for patients going to St James hospital in Leeds for radiotherapy treatments. During 2022 we provided 867 single trips to Leeds – radiotherapy is given daily (Mon-Fri) and length of treatments can range from 3 to 7 weeks. If the demand is low, we use the YAC car, making the service more efficient and if we need to we use volunteer drivers.

In 2022 we purchased a new Minibus as pictured.



The following are a few comments received from users of the minibus service.

'Thank you for what you do – your minibus service is amazing and appreciated.'

'Just to say thank you. The bus to Leeds was a God send. It was good fun with the people on the bus.'

'Thank you for your kindness and help getting to St James hospital.'

- **The provision of patient transport to Rapid Diagnostic appointments.**

Patients needing to access diagnosis appointments quickly are offered a rapid diagnostic appointment, this may not be at their nearest hospital which can create problems with attendance. YAC was approached at the end of 2021 asking if we could help with transport. A proposal was put to the YAC board and during 2022 we provided transport to 36 patients at an approximate cost of £2k.


DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

SUPPORT ACTIVITIES


- **Respite Properties**

The Respite house in Filey continues to provide a welcome break for cancer patients, during 2022 90 patients, their family and friends enjoyed a stay. Many families donate their deposit as way of a thank you and we encourage them to give us feedback, this ensures we hear about their stay and of course so we can act on any improvements needed.

The following are a few comments we have received.



'Thank you for all you do for cancer patients. We had an amazing break and will treasure all the memories.'



'We just wanted to say a huge thank you, for making it possible for us all to have a lovely few days together, stress free.'



'I cannot thank you enough. My holiday in the Filey house was just what I needed. It has done me the world of good after home alone, lockdown and cancer treatment. My friends and I enjoyed a walk by the sea, strolling around Filey and coming back to a cosy house with a beautiful comforting log fire.'



'Thank you so much, our stay in Filey was wonderful and beyond our expectations.'

- **Da Vinci surgical robot.**

In 2022 the YAC board were approached by the York and Scarborough Hospitals NHS Foundation Trust with a proposal to part fund a Da Vinci surgical robot. After the YAC board being shown a presentation which demonstrated this innovative technology they agreed to fund. Surgery performed via the surgical robot is less invasive than open surgery, allowing better precision in difficult to access areas than traditional key-hole surgery, leading to fewer complications, shorter recovery times and overall better outcomes. The board agreed to contribute £680k towards the instruments, training and running costs covering the period 2022-23 to 2024-25; not only does this provide the Trust with a brilliant surgical instrument but it is an investment in advanced technology. By June the robot was fully operational, and it was reported that its value was already being seen.

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

SUPPORT ACTIVITIES

- **The Cancer Support Centre – later named The Leveson Centre**

The board of Trustees decided that providing support to local cancer patients via a cancer support Centre was much needed and to create such a facility away from the hospital setting would be a great asset for anyone affected by cancer.

The board agreed to a 10-year lease and set a budget for the fit-out and adaptation of the space.



The whole process was supported by a project team including designers, project management team, builders and including a YAC project team who met fortnightly to make decisions and deal with any issues or concerns as they arose. The project took most of 2022 and with a completion date within the first quarter of 2023.

What your donations do...

Your donations are invaluable to keeping us going and doing all we can to support people affected by cancer.

- £10 → Chat with a cancer support specialist
- £20 → Single minibus trip for 1 patient
- £25 → Complementary therapy treatment
- £50 → 1 night away in our respite home for a family



DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

RESEARCH ACTIVITIES

Clinical Research Nurse and Assistant posts at York Hospital

During 2022 this funding enabled 6 new studies to commence, they were looking at a variety of cancers, cancer genetics and early cancer detection. There are also an additional 13 cancer studies open, 12 of these quickly hit the target number of recruits which would not have been achieved without the YAC funded personnel. The YAC posts also help support some of our long-standing studies, at present there are 25 studies in follow up, many of these studies have 10+ year follow ups.

Excitingly, there are another 14 studies about to be set up in the coming months, and these are in the areas of Haematology, Bowel, Breast, and Head and Neck cancer.

Jack Birch Unit (University of York)

The Charity is committed to another 1 year and 9 months supporting the work of the Jack Birch Unit. The roles supported by York Against Cancer are: -

Director of the Jack Birch Unit

Assistant Director

Laboratory technician

Administrative assistant

Research Fellow in Informatics at the Jack Birch Unit is also being supported from 2019 to 2024.

Jack Birch Unit of Molecular Carcinogenesis – Annual Report 2022

The Jack Birch Unit published five research papers in scientific journals this year, covering various aspects of our research. This included a paper presenting evidence supporting Dr Simon Baker's theory that bladder cancer may be caused by a virus. The importance of this work resulted in Simon then being invited to speak at conferences in Palm Springs, Edinburgh and Cambridge!

In March, several of us took part in the 4th Bladder Cancer Translational Research Meeting in London. Then, in October, several members of the team journeyed to Barcelona to the International Bladder Cancer Network conference. Andrew Mason gave a well-received talk, whilst PhD students Ryan Elliott and Vlad Ungureanu presented posters about their research. Andrew and Vlad also presented to the Northern Bioinformatics User Group (NorthernBUG) in Bradford, where Andrew discussed how data from bladder cancer samples can be used to inform patient treatment. Andrew has now finished his YAC-sponsored independent fellowship and moved into the University lectureship position agreed at the time of his appointment. As a result, "cancer informatics" (including large data handling and analysis) is being embedded in biomedical teaching and research at the University and I would like to highlight the critical role that YAC has played in this transformation. Andrew will continue as a key member of the JBU team for his future research.



Dr Simon Baker with the rest of the JBU team in 2022

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

RESEARCH ACTIVITIES

In October, Rachael Moore joined us as a PhD student funded by the Medical Research Council. She is investigating Natural Killer cells and their role in eliminating cancerous cells from normal tissues. During the year we had several undergraduate and masters students working with us, including Lexy (Denise) Barraza, originally from Mexico, who stayed on as a research assistant after the completion of her Master's course. We said farewell to two longstanding members of staff: Dr Jenny Hinley took up training to be a midwife and Dr Jo Pearson took a break and has since returned to work with another cancer group. To fill the vacancy left, we promoted Raphael Slip as our new Technical Team Manager for the JBU. Amongst other activities, several JBU staff took part in the YAC awareness days held in May and October and several female members took part in March in the International Day of Women and Girls in Science.

One of the highlights this year was the conferring of an honorary degree by the University of York to Professor Steve Leveson in recognition of his career in surgery, his role as a cofounder of York Against Cancer and his contribution to the research of the Jack Birch Unit. The University is organising an event for all fundraisers in 2023.

Last, but not least, I would like to thank York Against Cancer Board, fundraisers and supporters for the research support we receive. I also gratefully acknowledge the invaluable contribution that our scientific and clinical collaborators make to the quality and output of our research.



*Prof Steve Leveson on
Graduation Day.*

**Professor Jenny Southgate, Director,
Jack Birch Unit of Molecular Carcinogenesis, University of York**

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

EDUCATION ACTIVITIES

The Cancer Awareness and Prevention group continues to work to spread information about cancer across as wide a range of the public as possible with an emphasis on young people.

York Against Cancer Awareness and Education Committee Report 2022

I would like to thank my fellow members of the group who have continued to work hard during 2022. Our small but committed team has continued to hold hybrid meetings, face to face and zoom.

The Enthuse partnership restarted in May after being stalled due to Covid. Simon Baker has worked closely with the STEM team and with the teachers from participating schools. The focus was to gather data from the schools and to produce relevant lesson plans and to arrange teacher visits the JBU labs and the YAC offices to enable them to find out more about both organisations.

We distributed 911 sun hats to 24 primary schools in the York and surrounding area. Our committed volunteers assisted with the delivery to the participating schools.

We held two awareness days during 2022, in May at the community stadium and in October in the City Centre, both were successful.

As always, the priority of the group is to ensure making the biggest difference with our limited resource. Our recent focus has been to look at local cancer screening uptakes and to compare with the national statistics. This year we looked specifically at bowel cancer screening as it was deemed this screening could be improved upon in Yorkshire. A drinks mat was designed and handed out at events which included both awareness days.

The group is also looking at the local geography and underrepresented groups comparing cancer statistics looking for areas which need our focus. We have contacts within the clinical commissioning group from whom we can get the detailed data on which we can act on in the future.

We are looking at widening our reach across the whole of York and North and East of Yorkshire in collaboration with the communications committee.

As the focus of the group is awareness it was decided the group should be renamed Awareness and Education.

Thank you to the YAC team and the Awareness and Education group members.

Lynn Bartram

Chair, Education and Awareness group

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

FUNDRAISING

The retail outlets, at Huntington and the Hospital have continued to be an invaluable source of income and the hospital shop provides a very useful 'shop front' for the charity. The sterling work done by our volunteers; and our staff in the office has yet again given up many hours in the evening and at weekends to help raise funds and spread the message about York Against Cancer. The links with the local business community have again proved a great benefit to the charity. With all these efforts from our employed staff and volunteers the charity is able to provide more much-needed support to many in the local community.

York Against Cancer is committed to maintaining high standards of fundraising and retail activity. The Charity is registered with the Fundraising Regulator. The Charity has recognised and begun to put in place a comprehensive policy for fundraising. The Charity does not use any third parties to act on its behalf in relation to fundraising. No complaints were received by the charity during 2022 in relation to its fundraising activities.

Fundraising report 2022

This year we have been able to continue rebuilding our fundraising activities which has been a very exciting time for York Against Cancer. We have been able to have more of our regular events again including our awareness days, the golf day and York Rocks Against Cancer. We were so pleased to be able to hold the York Against Cancer Christmas Lunch again this year and also have our in-town Awareness Day – it has been fantastic to see everyone again at all of our events over the course of the year.

As well as holding our own events we have been supported brilliantly by our volunteers, the general public and local businesses who have fundraised for us in various ways including, sponsored walks, head shaves, pantomimes and The Press Cash for Charity initiative. We are also always incredibly grateful to be supported by our volunteers who have helped us this year by attending events, participating in can collections, holding stalls, working in our shops, baking and donating goods for us to sell.

Overall, we have been able to get a lot of our events back in the diary and resume a sense of normality. We are very much looking forward to the next year, fundraising at our established events as well as new opportunities including The Yorkshire 10 Mile and The Total Warrior.

I'd like to take the opportunity to say a big thank you to all of our amazing supporters, with their hard work and efforts York Against Cancer is able to continue what it set out to do – care for, support and educate the people of York and the surrounding areas and also fund ground-breaking research in The Jack Birch Unit at The University of York.

Lauren Hudson

Head of Fundraising and Executive Assistant

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

FUTURE PLANNING

The Board have continued their consistently adopted policy of only making commitments when the finance for these is already in place. The Board are mindful of the responsibility of ensuring that the generous donations received are used in the most effective manner possible to meet with the aims of the charity. With a sudden increase in legacies over the last few years the board established a Finance Sub-group to consider the most effective way to manage the funds for the future of the charity. The Board has agreed with the recommendations of the sub-group that a significant proportion of funds should be invested to provide for both future security of the charity and to ensure that the capital is used most effectively and to be available when future projects are considered and to ensure that the long-term plans and services the charity provides can be continued into the foreseeable future.

Future projects to operate out of the Leveson Centre include: -

- Provision of holistic financial and benefits advice / support – via the Citizen Advice York (CAY)
- Complementary Therapy
- Group sessions (including Pre-habilitation)
- Psycho-Oncology support

Structure, Governance and Management

The charity was incorporated on 22 April 2009 and its governing document is the memorandum and articles of association. The charity is a company limited by guarantee.

The charity is governed by a Board of Directors, supported by working groups as required. The Board members are all Trustees and include Officers of the Charity.

The Board meets four times a year and the various working groups meet as required during the year.

The members of the Board are volunteers. New Board members are elected by the existing members up to a maximum of twelve in total.

Trustee Induction and Training

New Trustees are briefed on their legal obligations under charity law, the committee and decision-making processes, the business plan and recent financial performance of the Charity. During their induction they meet key employees and other trustees. Trustees are encouraged to attend appropriate external training events where these will facilitate the undertaking of their role. At the end of each three tenure the trustees are required to update their trustee training.

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

Organisational Structure

The Board delegates the day-to-day management of the affairs of the Charity to one Board member, Tarnia Hudson, who serves as the Honorary Administrator.

The members of staff employed by the Charity during the year were:

Julie Russell	General Manager, from 4 April CEO
Heather Atkinson	Office & Accounts Manager, from 4 April Deputy CEO and Head of Finance
Lauren Hudson	Personal Assistant to General Manager, from 4 April Head of Fundraising
Nicola Doherty	Office & Volunteer coordinator, from 4 April Head of Administration and Volunteer coordinator
Jill Hutchinson	Head of Retail from 7 March
Jenna Hunton	Retail Assistant from 11 May
Hayley Johnson	Head of Engagement P/T until 17 November
Neil Johnson	Minibus Driver P/T
Garry Stanton	Minibus Driver P/T

Board membership

In March 2013 the Board adopted, by unanimous agreement, a protocol to introduce a three-year rule from that date. Board members continue to actively seek new trustees, taking into consideration a good mix of professional skills including business, education and medical. A term of office for a director is 3 years, after which time he/she may be re-elected for a further 3-year term (details of current terms of office available on request).

Remuneration of key personnel

All members of staff employed by the charity have an annual appraisal in January following which salaries are set for the following 12 months. The appraisals are carried out by the General Manager.

No Board member received any income or expenses for their work for the charity.

Related parties

The Charity owns the whole of the issued ordinary share capital of York Against Cancer Trading Company Limited, a company registered in England and Wales. The subsidiary is used for the raising of funds for the Charity through the sale of bought in goods through the Charity's two shops.

Risk management

The Trustees have assessed the major risks to which the charity is exposed, in particular those related to the operations and finances of the Charity and continues to take measures to reduce those risks to an acceptable minimum. The policy of only making new commitments when the funds are in hand is a very practical way of eliminating unnecessary financial risks. By its very nature a charity relies on fundraising, donations and legacies which can vary a great deal. Ongoing commitments are to our staff and to a range of time limited research and care projects.

The Board is proactive in identifying projects on which to spend its reserves, ensuring to find effective ways in which to fulfil the aims of York Against Cancer, whilst at the same time investing some funds to provide for future security.

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

Financial review and policies

The Charity's funds in 2022 decreased by £380,991 (2021 - increased by £495,416). Prior to any adjustment for investments, the Charity made a deficit of £351,405 (2021 - surplus of £109,854). The largest commitments in the year were: -

- £680,000 – Funding for Da Vinci surgical robot spread over 3 years.
- £363,262 – Support for the Jack Birch Units research
- £152,221 – Support for another 2 years for the clinical trial nurses
- £432,228 – Investment in the Leveson Centre fitout

The detail of funding of projects can be found in note 6.

The principal funding sources are fund-raising, the trading shops, donations, and legacies. Gross income in 2022 amounted to £1,468,175 (2021 £647,704). These funds support the key objectives of the Charity, namely, to fund clinical research, to support people with cancer and to fund education about the disease.

The charity has continued to benefit from legacies during the year, and we are immensely grateful to the generous donors. Legacy income is unpredictable and is another reason why the charity must husband its resources in the most effective way to enable the services we provide to both continue and develop.

Investment powers and policy

The Trustees have a general power of investment and so have the discretion to invest in such investment assets as they see fit. The Trustees have set a policy that sufficient of the 'free reserves' should be invested to retain a reasonable liquidity to meet grant commitments.

Our policy is a medium low risk approach for the growth of the portfolio of investments. The investment managers have discretion about how the investments are managed within the policy parameters set by the Trustees.

The Investment Group oversees the investment management of the Charity's funds. The services of HSBC Private Bank and Ruffer were retained as investment managers during 2022. Funds not invested are held on deposit to earn interest.

The total return on the investment portfolio managed by HSBC for the year ended 31 December 2022, before fees, was -7.53% (2021 10.99%). The total return on investment portfolio managed by Ruffer for the year ended 31 December 2022, before fees, was 7.4% (2021 11.80%).

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

Reserves Policy

The reserves policy is to ensure the charity holds sufficient funds for the continuation of our support services, whilst maintaining the ability to commitment to future projects. When the Leveson Centre was being planned the trustees understood that this would change the funding model needed for the Charity. The Leveson Centre will increase the operating costs of the charity as we bare all the costs for running the centre.

Cash reserves are accumulated before making a binding commitment to fund set term projects. The total funds held as at 31 December 2022 are £4,397,069 (2021 £4,778,060).

The Board is very mindful that the charity is wholly reliant on donated income and therefore has designated funds for future projects which are under consideration. This ensures its undesignated funds reflect the true level of reserves we hold for future operating commitments.

Undesignated Fund

These are reserves retained to provide working capital and funds for future projects. At the end of the financial year, the unrestricted undesignated reserves were £1,151,686 (2021 £3,041,746). These have decreased as the trustees have designated significant funds to the Leveson Centre, Jack Birch Unit and Health Welfare. The level of free reserves is £725,888 (after excluding lease commitments which we expect to be covered from future annual income). This is the equivalent of 14 months of our budgeted undesignated operating costs. It is the charity's policy to hold 12 months of our operating costs as the charity is largely reliant on donated and legacy income.

Excess reserves will be available for additional fixed term projects or grants not already under consideration.

Designated Funds

Designated funds are part of the unrestricted funds which trustees have earmarked for assets held for the use in the charity and specific projects. At the year end, The Charity had consolidated designated funds of £3,109,980 (2021 £1,597,671) details of which are given in Note 16 of the financial statements.

Restricted Funds

Restricted funds represent monies raised by the Charity from public appeals for specific projects. At the year end, the Charity had restricted funds of £135,403 (2021 £138,643) details of which are given in Note 17 to the financial statements.

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

Directors and Trustees Responsibilities

The purpose of this statement is to distinguish the Directors' and Trustees' responsibilities for the financial statements from those of the auditors as stated in their report.

Company and charity law require the Directors and Trustees to prepare financial statements which give a true and fair view of the Charitable Company's state of affairs at the end of its financial activities for that year. In preparing those financial statements the Trustees are required to:

- Select suitable accounting policies and then apply them consistently
- Make judgements and estimates that are reasonable and prudent;
- State whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements.
- Prepare the financial statements on the going concern basis unless it is inappropriate to assume that the Charitable Company will continue in operation.

The Directors and Trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the Charitable Company and enables them to ensure that the financial statements comply with the Companies Act 2006 and applicable charity law. They are also responsible for safeguarding the assets of the Charitable Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the Directors and Trustees are aware:

- There is no relevant information of which the Charitable Company's auditor is unaware; and
- The Directors and Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

Approved by the Board on 6 June 2023 and signed on its behalf by:

Ian Yeowart
Director and Trustee

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

Reference and administrative details

Registered Charity	number 1130835	Company Limited by Guarantee	number 06884476
Principal Office and Trading Address	East Stand York Community Stadium Kathryn Avenue Huntington York YO32 9AF		
Company Secretary	Julie Pamela Russell		
Directors and Trustees	Andrew Proctor Angela Darby Rachel Goddard Michael John Stower William Mark Sessions Ian Yeowart Sarah Wearing	Dr Lynn Bartram Michael Sweet Robert Onyett Tarnia Hudson Prof Stephen Leveson Michael Patrick Shepherd	
	Trustee's protocol available on request		
Accountants	HPH Chartered Accountants 54 Bootham York YO30 7XZ	Auditors	Hentons & Co LLP Chartered Accountants 124 Acomb Road Holgate York YO24 4EY
Bankers	National Westminster Bank 1 Market Street York YO1 8SR	Solicitors	Harrowells Moorgate House Clifton Moorgate York YO30 4WY
Investment Advisors	HSBC Global Asset Management 78 St James's Street London SW1A 1EJ		Ruffer LLP 80 Victoria Street London SW1E 5JL

**INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER
YEAR ENDED 31 DECEMBER 2022**

Opinion

We have audited the financial statements of York Against Cancer (the 'parent charitable company') and its subsidiary (the 'group') for the year ended 31 December 2022 which comprise the group statement of financial activities, the group balance sheet, the charitable company balance sheet, the group statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the state of the group's and the parent charitable company's affairs as at 31 December 2022 and of the groups incoming resources and application of resources, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the group and parent charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and parent charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

**INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER
YEAR ENDED 31 DECEMBER 2022**

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the trustees' report (incorporating the strategic report and the directors' report) for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the trustees' report have been prepared in accordance with applicable legal requirements.

Matter on which we are required to report by exception

In the light of the knowledge and understanding of the group and parent charitable company and their environment obtained in the course of the audit, we have not identified material misstatements in the trustees' report.

We have nothing to report in respect of the following matters where the Companies Act 2006 required us to report to you if, in our opinion:

- adequate accounting records have not been kept by the parent charitable company, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of Board of Trustees's remuneration specified by law are not made; or
- we have not obtained all the information and explanations necessary for the purposes of our audit.

Responsibilities of the trustees

As explained more fully in the trustees' responsibilities statement, the trustees, who are also the directors of the charity for the purpose of company law, are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the parent charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

**INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER
YEAR ENDED 31 DECEMBER 2022**

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

- We have obtained an understanding of the legal and regulatory framework applicable to the group and parent charitable company through discussions with senior management and review of the regulatory framework of any professional or membership bodies that the charitable company is a part of. The charitable company uses third parties to ensure that it remains up to date with changes and to review compliance with all its legal and regulatory requirements. In making our assessment of detecting irregularities, including fraud, we have discussed the issue with management who have advised that, other than changes to the work place to ensure that they are Covid-19 compliant, there have been no changes and the company remains compliant with its legal and regulatory requirement. Nothing has been brought to light in completing our audit work that contradicts this.
- The following laws and regulations have been identified as being of significance in the context of the group and charitable company; Companies Act 2006, Charities Act 2011, fundraising regulations, health and safety legislation, employment laws, data protection, and relevant tax laws.
- In making our assessment of the susceptibility of the group's and charitable company's financial statements to material misstatement, we have also considered how fraud might occur. No instances of material misstatement or fraud have been noted in the audit of the accounts for the year ended 31 December 2022.
- All matters regarding non-compliance with laws and regulations and fraud have been communicated to all members of the audit engagement team. The engagement partner has assessed that the engagement team has the appropriate competence and capabilities to identify or recognise non-compliance with laws and regulations, affected by the inherent difficulty in detecting irregularities, the effectiveness of the group's and charitable company's controls, and the nature, timing and extend of the audit procedures performed.

As part of an audit in accordance with ISAs (UK), we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the internal control.

YORK AGAINST CANCER

INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER YEAR ENDED 31 DECEMBER 2022

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the trustees.
- Conclude on the appropriateness of the trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the group's and charitable company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Use of our report

This report is made solely to the Charity's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Charity's members those matters we are required to state to them in an auditors report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Charity's members as a body, for our audit work, for this report, or for the opinions we have formed.

.....
Brett Davis (Senior Statutory Auditor)

For and on behalf of Hentons & Co LLP

Chartered Accountants

Statutory Auditor

124 Acomb Road

York

YO24 4EY

Date: 6 June 2023

YORK AGAINST CANCER
CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES
AND INCOME AND EXPENDITURE ACCOUNT
FOR THE YEAR ENDED 31 DECEMBER 2022

	Note	Unrestricted General Fund £	Designated Funds £	Restricted Funds £	Year ended 31 Dec 2022 £	Year ended 31 Dec 2021 £
Income and endowments from:						
Donations and legacies	2	1,154,842	-	15,000	1,169,842	403,515
Other trading activities	3	261,895	-	-	261,895	199,087
Investments	4	36,438	-	-	36,438	45,102
Total		1,453,175	-	15,000	1,468,175	647,704
Expenditure on:						
Raising funds	5	259,611	-	-	259,611	199,970
Charitable activities	6	1,503,518	40,711	15,740	1,559,969	337,880
Total		1,763,129	40,711	15,740	1,819,580	537,850
Net income/(expenditure) before gains on investments		(309,954)	(40,711)	(740)	(351,405)	109,854
Net (losses)/gains on investments	11	(29,586)	-	-	(29,586)	385,562
Net income/(expenditure)		(339,540)	(40,711)	(740)	(380,991)	495,416
Transfers between funds	16	(1,550,520)	1,553,020	(2,500)	-	-
Net movement in funds		(1,890,060)	1,512,309	(3,240)	(380,991)	495,416
Reconciliation of funds:						
Total funds brought forward		3,041,746	1,597,671	138,643	4,778,060	4,282,644
Total funds carried forward		£ 1,151,686	£ 3,109,980	£ 135,403	£ 4,397,069	£ 4,778,060

The notes on pages 24 to 34 form part of these financial statements.

YORK AGAINST CANCER
(Registration number: 06884476)

BALANCE SHEET
AS AT 31 DECEMBER 2022

	Note	Charity 2022 £	Consolidated 2022 £	Charity 2021 £	Consolidated 2021 £
FIXED ASSETS					
Tangible Fixed Assets	12	826,241	866,230	362,264	405,171
Investments	11	3,516,498	3,516,497	4,076,185	4,076,184
		4,342,739	4,382,727	4,438,449	4,481,355
CURRENT ASSETS					
Stock		-	60,521	-	55,176
Debtors	13	1,043,825	912,677	540,858	449,771
Cash at Bank and in Hand		811,874	863,649	819,603	846,463
		1,855,699	1,836,847	1,360,461	1,351,410
CREDITORS: amounts falling due within one year	14	1,055,560	1,091,095	498,519	517,503
NET CURRENT ASSETS		800,139	745,752	861,942	833,907
TOTAL ASSETS LESS CURRENT LIABILITIES		5,142,878	5,128,479	5,300,391	5,315,262
CREDITORS: amounts falling due after one year	15	731,410	731,410	537,202	537,202
NET ASSETS		<u>£ 4,411,468</u>	<u>£ 4,397,069</u>	<u>£ 4,763,189</u>	<u>£ 4,778,060</u>
THE FUNDS OF THE CHARITY					
Unrestricted					
Undesignated	18	1,206,074	1,151,686	3,069,782	3,041,746
Designated	16,18	3,069,991	3,109,980	1,554,764	1,597,671
Restricted	17,18	135,403	135,403	138,643	138,643
TOTAL CHARITY FUNDS		<u>£ 4,411,468</u>	<u>£ 4,397,069</u>	<u>£ 4,763,189</u>	<u>£ 4,778,060</u>

Approved by the Trustees on 6 June 2023 and signed on its behalf by:

S B Wearing
Director and Trustee

The notes on pages 24 to 34 form part of these financial statements.

**YORK AGAINST CANCER
CONSOLIDATED CASHFLOW STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2022**

	Note	2022 £	2021 £
Cash flows from operating activities:			
Net cash used in operating activities	21	(226,911)	(335,263)
Cash flows from investing activities:			
Dividends, interest and rents from investments		36,438	45,102
Purchase of property, plant and equipment		(322,442)	(64,330)
Proceeds from sale of property		-	251,731
Proceeds from sales of investments		1,475,082	1,838,749
Purchase of investments		(944,981)	(1,788,361)
Net cash provided by investing activities		<u>244,097</u>	<u>282,891</u>
Change in cash and cash equivalents in the reporting period		17,186	(52,372)
Cash and cash equivalents at the beginning of the reporting period		<u>846,463</u>	<u>898,835</u>
Cash and cash equivalents at the end of the reporting period		<u>£ 863,649</u>	<u>£ 846,463</u>

The notes on pages 24 to 34 form part of these financial statements.

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022

1. ACCOUNTING POLICIES

Legal entity

York Against Cancer is regulated by the Charities Commission (1130835), limited by guarantee and is registered in England and Wales. The address of the registered office and principal place of business is York Community Stadium, Kathryn Avenue, Huntington, York, England, YO32 9AF.

Basis of preparation

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The consolidated accounts include the results of the Charitable Company and its subsidiary undertaking. The results of the subsidiary are consolidated on a line by line basis.

No separate SOFA has been presented for the Charitable Company alone as permitted by the SORP.

The Charitable Company constitutes a public benefit entity as defined by FRS 102.

The accounts are presented in UK Sterling pounds (£).

Going Concern

The Charitable Company has cash resources and has no requirement for external funding. The Directors and Trustees have a reasonable expectation that the Charitable Company has adequate resources to continue in operational existence for the foreseeable future. They continue to believe the going concern basis of accounting appropriate in preparing the annual financial statements.

Income

Donations and legacies

Credit is taken for donations and subscriptions when they are received. Credit is taken for legacies when received or if, before receipt, there is sufficient evidence to provide the necessary certainty that the legacy will be received and the value of the incoming resources can be measured with sufficient reliability.

Other trading activities

Fundraising income - represents gross income from events.

Subsidiary's non-charitable trading turnover - represents gross income from York Against Cancer Trading Company Limited, the Charitable Company's trading subsidiary.

Investments

Investment income has been accounted for on an accruals basis.

Expenditure

Raising funds

Fundraising costs - represents the total costs of fundraising events and activities held during the year.

Non charitable trading expenditure - comprises of the direct costs and administrative costs of the Charitable Company's trading subsidiary, York Against Cancer Trading Company Limited.

Charitable activities

Direct costs - comprises of expenditure on various projects the Charitable Company is supporting and is accounted for in full when the Charitable Company commits to provide the funding.

Support costs - comprises of the salaries and office expenses of the Charitable Company.

Governance costs - comprises the costs associated directly with the management by the Directors/Trustees of the Charitable Company's activities, including audit fees and costs of meetings.

All costs are apportioned on an actual cost basis.

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022

1. ACCOUNTING POLICIES (continued)

Pension costs

The Charitable Company operates a defined contribution money purchase pension scheme for specific employees. The assets of the scheme are invested and managed independently of the finances of the Charitable Company. The charge for pension costs represents the contributions payable in the year.

Fixed Assets

Individual fixed assets costing £200 or more are capitalised and included in the accounts at cost.

Tangible fixed assets are depreciated over their expected useful lives at the following annual rates:

Freehold/Leasehold property	at straight line over 50 years or life of lease
Equipment	
- Shop and office equipment	at straight line over 10 years
- Computer equipment	at straight line over 3 years
- Respite home equipment	at straight line over 4 years
- Motor vehicles	at 25% reducing balance

Stock

Stock is valued at the lower of cost and net realisable value. Cost is computed on a first in first out basis. Net realisable value is based on estimated selling price less the estimated cost of disposal.

Funds Structure

Unrestricted Funds are funds which are available for use or retention at the discretion of the Directors/Trustees, in accordance with the Charity's objects. Designated Funds represent unrestricted funds earmarked by the Directors/Trustees for particular purposes. Restricted Funds are subjected to restrictions on their expenditure imposed by the donor or through the terms of an appeal. Details of Designated and Restricted Funds are contained in Notes 16 and 17, respectively.

Investments

The investment portfolios have been valued at market value at 31 December 2022. The SOFA includes the net gains and losses on investments arising on revaluation at the year end and on disposals throughout the year. Realised gains and losses on sales of investments are calculated as the difference between the sale proceeds and opening market value. Unrealised gains and losses represent the movement between market values.

Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

Cash at bank and in hand

Cash at bank and cash in hand includes cash and any short term deposit accounts with a maturity of three months or less from the date of opening.

Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

Financial instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

Operating leases

Rentals paid under operating leases are charged in the SOFA on a straight line basis over the lease term.

Government grants

These government grants relate to the COVID grants for retail closures issued to the subsidiary trading company.

YORK AGAINST CANCER

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022**

2. DONATIONS AND LEGACIES	Unrestricted £	Restricted £	2022 £	2021 £
Donations and grants	213,697	15,000	228,697	158,533
In Memoriam	26,509	-	26,509	19,852
Legacies	909,636	-	909,636	206,699
Government grant	-	-	-	13,431
Intangible income	5,000	-	5,000	5,000
	£ 1,154,842	£ 15,000	£ 1,169,842	£ 403,515

During the year the charity was notified of a potential further £157,000 in legacy income from various estates the timing and amounts still remain uncertain and therefore have not been provided for.

Intangible income comprises accounting services, a proportion of which is provided free of charge for the preparation of the Charitable Company and Subsidiary statutory accounts. A corresponding amount is included within governance costs.

3. OTHER TRADING ACTIVITIES	2022 £	2021 £
Fundraising income	136,121	99,601
Subsidiary's non-charitable trading turnover	125,774	99,486
	£ 261,895	£ 199,087

4. INVESTMENTS	2022 £	2021 £
Interest received	1,210	627
Dividends received	35,228	44,475
	£ 36,438	£ 45,102

5. ANALYSIS OF RAISING FUNDS	Unrestricted £	Restricted £	2022 £	2021 £
Advertising	6,639	-	6,639	11,292
Fundraising costs	80,727	-	80,727	36,933
Non charitable trading - other costs	115,039	-	115,039	110,546
Non charitable trading - staff costs	34,601	-	34,601	21,123
Non charitable trading - depreciation	5,405	-	5,405	5,156
Investment fees	17,200	-	17,200	14,920
	£ 259,611	£ -	£ 259,611	£ 199,970

YORK AGAINST CANCER

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022**

6. ANALYSIS OF CHARITABLE ACTIVITIES

<i>Direct project costs:</i>	Unrestricted £	Restricted £	2022 £	2021 £
Research				
Jack Birch Unit	353,262	10,000	363,262	-
Clinical Trial Nurses	152,221	-	152,221	95,051
Support and Care				
Cancer Care Centre - Old	-	-	-	6,511
Leveson Centre	37,378	-	37,378	-
Respite property expenses	22,653	-	22,653	21,103
Minibus running costs - direct	11,882	-	11,882	12,248
Minibus running costs - staff costs	21,273	-	21,273	20,439
Mobile Chemotherapy Unit*	-	5,740	5,740	(104,381)
Transport - Rapid diagnostics	7,086	-	7,086	-
Psychology services	10,805	-	10,805	4,040
Robotic surgery	680,000	-	680,000	-
One off costs	150	-	150	-
Health Care Assistant	-	-	-	12,818
Health Welfare Advisor	-	-	-	73,444
Education				
Education expenses	8,850	-	8,850	2,588
	1,305,560	15,740	1,321,300	143,861
*During 2021 the underspend on the Mobile Chemotherapy Unit was released as the project cost less than initially budgeted. Running costs will be covered by the restricted funds in future years.				
Support costs:				
Staff costs	154,175	-	154,175	139,079
Staff training and travel	3,666	-	3,666	2,553
Rent, service charge and rates	16,871	-	16,871	21,779
Heat and light	3,756	-	3,756	1,837
Repairs and maintenance	1,510	-	1,510	173
Insurances	4,318	-	4,318	3,416
Printing, stationery and postage	4,913	-	4,913	4,870
Computer expenses	11,516	-	11,516	7,819
Telephone	800	-	800	2,693
Sundry expenses	4,176	-	4,176	6,384
Gains and losses on fixed assets	-	-	-	(28,554)
Depreciation	19,370	-	19,370	16,168
	225,071	-	225,071	178,217
Governance costs:				
Audit fees	4,560	-	4,560	4,560
Accountancy fees	7,400	-	7,400	7,507
Legal fees	-	-	-	2,182
Bank charges	1,638	-	1,638	1,553
	13,598	-	13,598	15,802
Total charitable activities	£ 1,544,229	£ 15,740	£ 1,559,969	£ 337,880

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022

7. NET INCOMING RESOURCES FOR THE YEAR

	2022 £	2021 £
This is stated after charging:		
Depreciation	24,775	21,324
Auditor's remuneration for audit services - charity	4,560	4,560

8. REMUNERATION AND EXPENSES OF TRUSTEES

None of the Trustees received any remuneration or benefits by virtue of being a trustee of the Charity and no Trustees were reimbursed any expenses incurred for services provided to the Charity.

9. STAFF COSTS

	2022 £	2021 £
Wages and salaries	185,048	160,955
Social security costs	11,194	8,614
Pension costs	7,602	6,701
Recruitment costs	3,120	-
Medical Insurance	3,085	4,371
	£ 210,049	£ 180,641

The average monthly head count was 8 staff (2021 8) and the average monthly number of full-time equivalent employees (including casual and part-time staff) during the year were as follows:

Projects	1	1
Trading	1	1
Management and administration	6	6

No employee received emoluments in excess of £60,000.

The key management personnel of the Charitable Company, comprise the directors and trustees, the CEO and Deputy CEO following the restructure. The total employee benefits of the key management personnel of the Charitable Company were £88,781 (2021 - £50,303).

10. SUBSIDIARY COMPANY

The Charitable Company owns the whole of the issued ordinary share capital of York Against Cancer Trading Company Limited. This company is registered in England and Wales (reg. no. 3405708) and its registered office is York Community Stadium, Kathryn Avenue, Huntington, York, England, YO32 9AF. The subsidiary is used for the raising of funds for the Charitable Company through the sale of bought in goods through the Charitable Company's shop and stalls. All activities have been consolidated on a line by line basis in the There is a loan account between the Charitable Company and the subsidiary. The balance on the loan account outstanding at the year end was £138,024 (2021 £92,808). Interest of £nil (2021 £186) was charged during the year in respect of this loan.

A summary of the results of the subsidiary is shown below:

	2022 £	2021 £
Turnover	125,774	99,486
Cost of sales	(61,578)	(64,071)
Gross profit	64,196	35,415
Administrative expenses	(93,467)	(72,754)
Operating profit	(29,271)	(37,339)
Other operating income	-	15,333
Interest payable	-	(186)
Profit on ordinary activities before taxation	(29,271)	(22,192)
Taxation	-	-
Profit on ordinary activities after taxation	(29,271)	(22,192)
Amount gifted to York Against Cancer	-	-
Retained (withdrawn from)/within Subsidiary	£ (29,271)	£ (22,192)
Net Assets	£ (14,399)	£ 14,871

YORK AGAINST CANCER

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022**

11. INVESTMENTS

Consolidated	2022 £	2021 £
Market value at 1 January 2022	4,076,184	3,741,010
Additions at cost	944,981	1,788,361
Disposals	(1,475,082)	(1,838,749)
Revaluations	(29,586)	385,562
	<u>£ 3,516,497</u>	<u>£ 4,076,184</u>
Market value at 31 December 2022		
	<u>£ 3,516,497</u>	<u>£ 4,076,184</u>
Analysis of investments by class:		
Listed investments	<u>£ 3,516,497</u>	<u>£ 4,076,184</u>
The historical cost of the above investments amounts to:	<u>£ 3,196,719</u>	<u>£ 3,633,156</u>

The following material investments are over 5% by value of the investments held

	2022 Market value £	2021 Market value £
Ruffer Charity Assets Trust Account	1,832,547	2,231,923
	<u>£ 1,832,547</u>	<u>£ 2,231,923</u>

The Charitable Company holds all of the issued shares of its subsidiary undertaking York Against Cancer Trading Company Limited, at cost of £1, in addition to the above investments.

12. TANGIBLE FIXED ASSETS

	Property £	Motor Vehicles £	Equipment £	Charity Total £	Subsidiary - Shop Equipment £	Consolidated Total £
<i>Cost</i>						
At 1 January 2022	367,702	41,515	40,333	449,550	51,561	501,111
Additions in year	432,228	46,936	4,183	483,347	2,487	485,834
Disposals in year		-	(673)	(673)		(673)
At 31 December 2022	<u>799,930</u>	<u>88,451</u>	<u>43,843</u>	<u>932,224</u>	<u>54,048</u>	<u>986,272</u>
<i>Depreciation</i>						
At 1 January 2022	36,771	37,342	13,173	87,286	8,654	95,940
Charge for year	7,354	5,880	6,136	19,370	5,405	24,775
Disposals in year		-	(673)	(673)		(673)
At 31 December 2022	<u>44,125</u>	<u>43,222</u>	<u>18,636</u>	<u>105,983</u>	<u>14,059</u>	<u>120,042</u>
<i>Net book value</i>						
At 31 December 2022	<u>£ 755,805</u>	<u>£ 45,229</u>	<u>£ 25,207</u>	<u>£ 826,241</u>	<u>£ 39,989</u>	<u>£ 866,230</u>
At 31 December 2021	<u>£ 330,931</u>	<u>£ 4,173</u>	<u>£ 27,160</u>	<u>£ 362,264</u>	<u>£ 42,907</u>	<u>£ 405,171</u>

All fixed assets are held for direct charitable purposes in Designated Funds.

YORK AGAINST CANCER

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022**

13. DEBTORS	Charity 2022 £	Consolidated 2022 £	Charity 2021 £	Consolidated 2021 £
Amounts owed by subsidiary	138,024	-	92,809	-
Prepayments	13,396	20,272	6,488	6,596
Accrued income	892,405	892,405	430,000	430,000
Other debtors	-	-	11,561	13,175
	£ 1,043,825	£ 912,677	£ 540,858	£ 449,771

**14. CREDITORS: amounts falling due
within one year**

Trade creditors	176,204	182,320	2,445	3,488
Project creditors	827,466	827,466	476,711	476,711
Taxation and social security	3,802	4,201	3,146	6,325
Accruals	45,342	74,362	14,187	28,949
Other creditors	2,746	2,746	2,030	2,030
	£ 1,055,560	£ 1,091,095	£ 498,519	£ 517,503

**15. CREDITORS: amounts falling due
after one year**

Project creditors	£ 731,410	£ 731,410	£ 537,202	£ 537,202
-------------------	------------------	------------------	------------------	------------------

16. DESIGNATED FUNDS (consolidated)

Designated Funds - 2022	Balance 01/01/2022 £	Income £	Expenditure £	Transfers £	Balance 31/12/2022 £
Leveson Centre	466,500	-	-	87,250	553,750
On demand services	10,000	-	(7,086)	63,086	66,000
Education Project	-	-	(8,850)	18,850	10,000
Minibus	36,000	-	-	(36,000)	-
Health Welfare	-	-	-	114,000	114,000
Jack Birch Unit	-	-	-	1,500,000	1,500,000
Robotic Surgery Project	680,000	-	-	(680,000)	-
Fixed Assets Fund	405,171	-	(24,775)	485,834	866,230
Total	£ 1,597,671	£ -	£ (40,711)	£ 1,553,020	£ 3,109,980

Designated Funds - 2021	Balance 01/01/2021 £	Income £	Expenditure £	Transfers £	Balance 31/12/2021 £
Leveson Centre	-	-	-	466,500	466,500
On demand services	10,000	-	-	-	10,000
Education Project	-	-	(2,588)	2,588	-
Minibus	28,000	-	-	8,000	36,000
Robotic Surgery Project	-	-	-	680,000	680,000
Fixed Assets	585,342	-	7,230	(187,401)	405,171
Complementary Therapy	6,364	-	(6,364)	-	-
Cancer Care Centre	5,382	-	(5,382)	-	-
Total	£ 635,088	£ -	£ (7,104)	£ 969,687	£ 1,597,671

Leveson Centre

The charity has set aside the remaining budget for improvements relating to the Leveson Centre as the year end and 5 years of lease costs.

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022

16. DESIGNATED FUNDS (consolidated continued)

On demand services

The trustees have set aside monies to fund the following on demand services - patient travel for rapid diagnostics, complementary therapy and teenage psychology services. These services levels are set budgets at the beginning of each year based on current demand.

Education Project

The Board agreed to fund the annual budgeted costs of the Education Project which is aimed at raising the awareness of cancer to the public.

Minibus

The trustees have set aside monies for the purchase of a new minibus which was purchased in the year.

Health Welfare

The board wish to fund an additional health welfare post for 3 years in the York area and have ring fenced the following monies.

Jack Birch Unit

The Jack Birch Unit grant is up for renewal in 2024 and the trustees wish to continue this support the on-going research. Investments of £1.5m has been designated to ensure the charity can fund the continued support in 2024.

Robotic Surgery Project

During the year the charity committed to support the NHS regarding its Robotic Surgery facilities. The commitment of £680,000 has been recognised in the current year and will be paid over 3 years.

Fixed Asset Fund

This fund represents funds invested in tangible fixed assets.

Complementary Therapy

The Board is committed to a service level agreement with York Hospital to provide the funding for a therapist post from 1 April 2019 to 31 March 2021.

Cancer Care Centre

The Board was committed to a service level agreement with York Hospital to provide the funding for 3 administrator posts from 1 April 2019 to 31 March 2021.

17. RESTRICTED FUNDS (consolidated)

	Balance 01/01/2022	Income	Expenditure	Transfers	Balance 31/12/2022
	£	£	£	£	£
Restricted Funds - 2022					
Mobile Chemotherapy Unit	136,966	2,500	(5,740)	-	133,726
Minibus Appeal	-	2,500	-	(2,500)	-
Jack Birch Unit	-	10,000	(10,000)	-	-
Mouth Cancer	1,677	-	-	-	1,677
Total 2022	£ 138,643	£ 15,000	(£ 15,740)	(£ 2,500)	£ 135,403
	Balance 01/01/2021	Income	Expenditure	Transfers	Balance 31/12/2021
	£	£	£	£	£
Restricted Funds - 2021					
Mobile Chemotherapy Unit	142,348	-	(5,382)	-	136,966
Mouth Cancer	1,677	-	-	-	1,677
Total 2021	£ 144,025	£ -	(£ 5,382)	£ -	£ 138,643

Mobile Chemotherapy Unit

The Mobile Chemotherapy Unit Appeal relates to funds raised for the specific purpose of running the service.

Minibus Appeal

Monies were received for the purchase of a new minibus which was purchased in the year.

Jack Birch Unit

Monies were received for support of the Jack Birch Unit which were used during the year.

Mouth Cancer

Monies raised for the Head and Neck cancer department.

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022

18. ANALYSIS OF GROUP NET ASSETS BETWEEN FUNDS

	General Funds £	Designated Funds £	Restricted Funds £	Total 2022 £
Fund balances at 31 December 2022 are represented by:				
Tangible fixed assets	-	866,230	-	866,230
Investments	2,016,497	1,500,000	-	3,516,497
Current assets	957,694	743,750	135,403	1,836,847
Current liabilities	(1,091,095)	-	-	(1,091,095)
Long term liabilities	(731,410)	-	-	(731,410)
	£ 1,151,686	£ 3,109,980	£ 135,403	£ 4,397,069
	General Funds £	Designated Funds £	Restricted Funds £	Total 2021 £
Fund balances at 31 December 2021 are represented by:				
Tangible fixed assets	-	405,171	-	405,171
Investments	4,076,184	-	-	4,076,184
Current assets	1,163,021	49,746	138,643	1,351,410
Current liabilities	(517,503)	-	-	(517,503)
Long term liabilities	(537,202)	-	-	(537,202)
	£ 4,184,500	£ 454,917	£ 138,643	£ 4,778,060

19. OPERATING LEASE COMMITMENTS

As at 31 December 2022 the group had the total minimum lease payments under operating leases at the end of the reporting period, for each of the following period:

	At 31 December 2022		At 31 December 2021	
	Land and buildings £	Office equipment £	Land and buildings £	Office equipment £
Total operating leases payable:				
Within one year	115,905	-	40,298	-
Between two and five years	335,370	-	45,684	-
After five years	278,273	-	2,486	-

20. RELATED PARTIES

During the year the Charitable Company paid £3,097 (2021 £2,829) to HPH Chartered Accountants for accountancy services and software costs, a firm in which the Charitable Company's Treasurer, Sarah Wearing, is a partner. At the year end there was £nil (2021 £107) owing to HPH Chartered Accountants.

During the year the Charitable Company paid £nil (2021 £2,160) to Harrowells Solicitors for legal fees, a firm in which the Charitable Company's Director, Robert Onyett, is a director.

During 2021 the wife of a director Ian Yeowart was paid £1,300 for temporary employment cover. No payments were made in 2022.

During the year trustees and related parties donated £116,384 (2021 £50,100) to the charity.

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022

21. CASH FLOW NOTES

RECONCILIATION OF NET MOVEMENT IN FUNDS TO NET CASH FLOW FROM OPERATING ACTIVITIES	2022 £	2021 £
Net income/(expenditure) for the reporting period	(380,991)	495,416
Adjustments for:		
Depreciation charges	24,775	21,324
Gains on sale of fixed assets	-	(28,554)
(Gains)/Losses on investments	29,586	(385,562)
Dividends, interest and rents from investments	(36,438)	(45,102)
(Increase)/Decrease in stocks	(5,345)	119
Increase in debtors	(462,906)	12,514
(Increase)/Decrease in creditors	604,408	(405,418)
Net cash used in operating activities	£ (226,911)	£ (335,263)
ANALYSIS OF CASH AND CASH EQUIVALENTS		
Cash at bank and in hand	863,649	846,463
Total cash and cash equivalents	£ 863,649	£ 846,463

ANALYSIS OF CHANGES IN NET DEBT

	At 01/01/2022 £	Cash-flows £	At 31/12/2022 £
Cash	846,463	15,542	862,005

22. VOLUNTEERS

The Charity is fortunate to be supported by over 100 volunteers. Their activities include working in our shops, attending events, supporting the office, collections and baking. Without them the Charity could not achieve what it does; their support is a massive asset in both workforce and financial terms. Whilst going about their work they are also ambassadors for the Charity which encourages more people to volunteer and support.

With varied knowledge, skills and experience the volunteers make an invaluable group. Our thanks goes to them all – together we really do make a difference to cancer patients and their families.

YORK AGAINST CANCER
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022

24. COMPARATIVE INFORMATION

	Unrestricted General Fund £	Designated Funds £	Restricted Funds £	Year ended 31 Dec 2021 £
Income and endowments from:				
Donations and legacies	403,515	-	-	403,515
Other trading activities	199,087	-	-	199,087
Investments	45,102	-	-	45,102
Total	647,704	-	-	647,704
Expenditure on:				
Raising funds	199,970	-	-	199,970
Charitable activities	325,394	7,104	5,382	337,880
Total	525,364	7,104	5,382	537,850
Net expenditure before losses on investments	122,340	(7,104)	(5,382)	109,854
Net gains on investments	385,562	-	-	385,562
Net income/(expenditure)	507,902	(7,104)	(5,382)	495,416
Transfers between funds	(969,687)	969,687	-	-
Net movement in funds	(461,785)	962,583	(5,382)	495,416
Reconciliation of funds:				
Total funds brought forward	3,503,531	635,088	144,025	4,282,644
Total funds carried forward	£ 3,041,746	£ 1,597,671	£ 138,643	£ 4,778,060

25. CAPITAL COMMITMENTS

At the year end the charity was committed to spend £250,000 for the completion of the Leveson Centre fit out. These funds have been designated.

YORK AGAINST CANCER

England & Wales - Charity number 1130835

Accounts



YORK AGAINST CANCER

**A company limited by guarantee
and
A registered charity number 1130835**

REPORT AND ACCOUNTS

For the year ended

31 December 2021

**HPH
Chartered Accountants
54 Bootham
York
YO30 7XZ**

YORK AGAINST CANCER

CONTENTS

	Page
Chairman's Report	1
Trustees' Report	2 - 13
Auditor's Report	14 – 17
Statement of Financial Activities	18
Balance Sheet	19
Cash Flow Statement	20
Notes to the Financial Statements	21 - 31

YORK AGAINST CANCER

CHAIRMAN'S REPORT 2021

2021 remained a challenging year with lockdowns continuing and numerous restrictions on personal liberty running throughout much of the year. As a result, much of our work was again affected, but as the months passed, we were at last getting back to something like normal.

It was a great tonic to see many of our volunteers as the year progressed, and as most of you will be much aware we have, at last, moved into our new premises at the Community Stadium.

Our small team continued to work hard throughout the year, and to them, our volunteers, and Board colleagues I would like to pass on my grateful thanks for continuing to promote the Charity during a really difficult period.

Work of course continued, and the need to strategically plan for our future requirements goes on to ensure we remain in a position to continue the important services for people touched by cancer – services that will be ever more important as we consolidate and expand on the outstanding work undertaken in the many areas that the Charity is involved in.

We sadly lost a number of our volunteers throughout the year, and our thoughts go out to their families, and we wish them well for the future. Every one of them supported the day to day work of the Charity, and helped the Charity to continue to provide the important services and funding for research that the we are recognised for.

Despite the ongoing restrictions, our minibus service continued to operate in difficult conditions, and special thanks go to drivers Ian and Neil for providing this vitally important service when many other cancer services were still curtailed by the NHS. Ian retired in May and subsequently welcomed Garry. Working in the office, promoting the Charity or driving our minibus our small and important band of dedicated staff are the daily face of York Against Cancer, and ably supported by our committed army of volunteers, the Charity remains in good hands.

A number of projects are under evaluation for the coming year, and I very much hope the Chair's report for 2022 will be much more representative of the positive things the Charity is able to deliver.

Ian Yeowart

Chair York Against Cancer

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2021

The Directors (who are also the Trustees of the Charity and are listed below) are pleased to present their report of the Charitable Company for the year ended 31 December 2021.

Objectives and activities

The objects of the Charity are to raise funds to:

1. Foster and promote joint research between clinicians and research scientists in York and wider area and, by encouraging a more effective exchange of ideas and information, to advance the alleviation and cure of cancer.
2. Support treatment of cancer patients at York Hospital and the local area.
3. Fund education and information about cancer for patients and their families and the wider public.

The Trustees believe they have complied with the duty in section 4 of the 2006 Charities Act to have due regard to guidance published by the Charity Commission in respect of public benefit.

Aims and strategies

The Charity aims to provide support to cancer patients and the community through the: -

- funding and the provision of services and resources for patients and their families
- funding of research programmes
- funding of education initiatives

Achievements and performance

SUPPORT ACTIVITIES

Support Team

The small team of hardworking office staff deal effectively with all aspects of the day-to-day operation of the charity, and it is worth noting that during 2021 there has been an inevitable impact on fundraising and charity/staff/board morale and the charity have striven to deal with those demands and risen to meet the challenges head on.

The relocation of the office and one of the retail outlets into the York Community Stadium was managed by the staff and was completed on the May 14th. As well as an increased amount of much needed space, the new environment facilitates opportunities to form new relationships with stakeholders.

The team's work is sometimes challenging as they deal with people facing cancer and on occasions, this can impact on their resolve, however, they deal with this together and their teamwork is impressive. The team are friendly and often are found smiling. The way it is possible for our manager and her staff to respond quickly to any requests or challenges is a key strength for York Against Cancer as a local charity.

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2021

SUPPORT ACTIVITIES

Mobile Chemotherapy Unit



The Mobile Chemotherapy Unit (MCU) takes chemotherapy services to the wider areas of the York & Scarborough Hospital Trust, in Malton, Selby, Scarborough and Bridlington, this has enabled the charity to widen its reach. The MCU has helped thousands of patients the time-consuming and tiring journeys to the hospital in York. During the Covid pandemic the MCU was repurposed and used as a standalone cancer department at the Scarborough hospital site.

Respite Properties

The Respite house in Filey continues to provide a welcome break; cancer patients and their families are offered either a three-day weekend or four-day weekday break. The many letters of appreciation we receive are an indication of how much a short break in the luxurious surroundings is appreciated.

During 2021 the YAC board decided to sell the Whitby apartment; the property had been popular however there were increasing problems with the upkeep of the property. The board, are looking into extending this service, in the near future, and are through exploring opportunities to buy an additional property.

Minibus

Our minibus service has also been affected by Covid, for a few months it was not able to run but as soon as the restrictions allowed it resume, however, with a restricted number of passengers. It continues to be an excellent and much-valued service of transporting patients to St. James' Hospital.

The thoughtful and kind approach of our minibus drivers has also again been very much appreciated.



YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2021

SUPPORT ACTIVITIES

Posts and services supported by York Against Cancer

In addition to the team directly employed by the charity there are other support workers whose salary costs are paid by York Against Cancer. These posts are itemised below and illustrate the range of activities supported by the Board:

- **Health Care Assistant**

The Health Care Assistant continued to provide support for families affected by cancer until November 2021. These appointments are made in conjunction with the NHS to provide support for patients and their families; support which is not available through the normal NHS services.

- **Complementary Therapy**

Complementary therapy arranged through the Cancer Care Centre has been significantly affected by Covid-19 and patients have been offered complementary therapy and other services virtually until April 2021.

- **Clinical Research Nurse and Assistant posts at York Hospital**

During the pandemic, some research nurses were still able to keep some Oncology Research going and three new studies were opened near the year end.

- **Health Welfare Advisor**

The charity continues to support the Citizens Advice Bureau in their work with cancer patients at Scarborough hospital: this work provides support for those having cancer treatment and based at Scarborough to ensure that they receive all the help to which they are entitled.

All these supported positions are initially given for a fixed term (usually two or three years) and then reviewed by the Board. This is done to ensure that the money so generously raised by our supporters is used in the most efficient way.

The services have been hindered by the closure of the Cancer Care Centre at the hospital during the year. The charity committed to opening a new centre fully funded by the charity. The Leveson Centre is due to open in 2022 at the York Community Stadium. The Centre will offer a wide range of holistic cancer support services to complement the clinical treatments provided at York Hospital.

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2021

RESEARCH ACTIVITIES

Jack Birch Unit (University of York)

The Charity is committed to another 3 years supporting the work of the Jack Birch Unit. The roles supported by York Against Cancer are: -

Director of the Jack Birch Unit

Assistant Director

Laboratory technician

Administrative assistant

Research Fellow in Informatics at the Jack Birch Unit is also being supported from 2019 to 2024.

Jack Birch Unit of Molecular Carcinogenesis

For the JBU, 2021 was a challenging year with limits on occupancy in the labs and constant changing of rules applied variously to staff and students. We faced some difficulties with obtaining laboratory supplies and our usual collection of surgical samples from our NHS colleagues took a big hit. Nevertheless, the JBU esprit de corps kicked in and the group worked together as a team, with weekly laboratory meetings and bimonthly lab management meetings held via zoom. Placement Masters and Undergraduate students, hoping for lab experience were most affected, as their projects became virtual. One third year BSc student, Sophie Curran worked with the YAC office on a successful science communications project looking at the use of Instagram to spread information to younger people about the risks and early signs of cancer.

We had a few staff changes. Richard Gawne joined Dr Andrew Mason's group as a bioinformatician and Katie Skinner left to take up her PhD position in Atlanta. Ben Jarvis completed a Masters by Research and left to take up a PhD position in Manchester. Dr Sreemoti Banerjee moved to a postdoc job in Leeds and Dr Annu Joseph joined us as a postdoc on a new Wellcome LEAP grant on kidney engineering – part of a collaboration with colleagues at University College London and the Universities of Edinburgh and Manchester.

In October 2021, Simon Baker caught COVID in the delta wave, testing positive 48 hours before the most important interview of his career. So we are delighted to report that following his interview, Simon was awarded a prestigious Kidney Research UK fellowship to continue his work in the JBU. YAC funding has been critical to Simon's work, which is investigating a childhood virus as the possible cause of bladder cancer and he could not have achieved any of this without YAC's support.



YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2021

RESEARCH ACTIVITIES

One of the advantages with zoom is that we were able to participate in virtual workshops and meetings with international audiences. For a flavour of these, Dr Andrew Mason organised a very successful workshop on Disruptive 'Omics Technologies in Molecular Medicine in March, and I chaired, and Dr Simon Baker presented at, sessions of the 3rd Bladder Cancer Translational Research Meeting in May. Between us, the JBU published eight scientific papers and one book chapter during 2021.

As the labs became more accessible in late 2021, Lauren and Hayley visited the JBU to take away some news stories to share with YAC. I am always delighted to show off our brilliant laboratories to visitors, so please do feel free to contact the YAC office or me directly, if you would like to arrange a visit.

I would like to thank York Against Cancer Board, fundraisers and supporters for the research support we receive. I also gratefully acknowledge the invaluable contribution that our scientific and clinical collaborators make to the quality and output of our research.

**Professor Jenny Southgate, Director,
Jack Birch Unit of Molecular Carcinogenesis, University of York**

EDUCATION ACTIVITIES

The Cancer Awareness and Prevention group continues to work to spread information about cancer across as wide a range of the public as possible with an emphasis on young people.

York Against Cancer Education and Awareness Committee Report 2021.

Firstly, can I pass on my thanks to Stuart Parker (outgoing Chair) and the other members of the team who have continued to work hard despite the constraints of the Covid -19 pandemic. Our small but committed team has continued to meet via zoom this year.

The Enthuse partnership remained stalled due to the pandemic, but the funding will be rolled forward to a point in time when teachers are able to participate in the project. I hope we will have a positive update on this project in 2022.

After not being able to distribute sun hats and sun awareness leaflets into schools in 2020, we are pleased to announce that in 2021 this annual delivery restarted. Our committed volunteers help us with the distribution to the participating schools.

We held a cancer awareness day at Vanguard for the first time, this proved to be successful. The day helped launch the sale of our Christmas cards and drew attention to the relocation of the shop to the Community Stadium site. The committee recommended to the Board that we consider having two awareness day's a year – one in the city centre and one at Vanguard/Community Stadium.

We have distributed 317 picture books to schools to support children who are affected by cancer. Thank you to the office and volunteers who supported this project and delivered books into local schools.

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2021

EDUCATION ACTIVITIES

Stuart mentioned in his 2020 report that the committee had undertaken a brainstorming session, during 2021 we narrowed our ideas down! With Covid restricting our work with schools, the committee decided to look at how we could raise awareness in the community of signs and symptoms of cancers and the screening that is available. We wanted to focus our attention on underrepresented groups or cancers with poor screening uptakes. Unfortunately, it has taken longer to access this information than we anticipated so we have not made as much progress as we would all have liked.

In collaboration with the Communication committee, we have had preliminary discussions on how to achieve a physical as well as a digital presence across the whole YAC region.

Thank you to Julie and her team, as well as to committee members Stuart, Simon, Joan and Jane. We hope that 2022 will see an increase in our committee membership, that Enthuse takes off and we are able to put into action our plans for raising awareness as well as continuing our work with primary schools.

Lynn Bartram

Chair, Education and Awareness group

FUTURE PLANNING

The Board have continued their consistently adopted policy of only making commitments when the finance for these is already in place. The Board are mindful of the responsibility of ensuring that the generous donations received are used in the most effective manner possible to meet with the aims of the charity. With a sudden increase in legacies over the last few years the board established a Finance Sub-group to consider the most effective way to manage the funds for the future of the charity. The Board has agreed with the recommendations of the sub-group that a significant proportion of funds should be invested to provide for both future security of the charity and to ensure that the capital is used most effectively and to be available when future projects are considered and to ensure that the long-term plans and services the charity provides can be continued into the foreseeable future.

Future projects include: -

- **Robotic Surgery** – Supporting the running costs of new robotic surgery equipment used in cancer treatments at York Hospital over 3 years.
- **The Leveson Centre** – Fit out and running costs of a new centre to offer a wide range of holistic cancer support services.
- **Current projects** – Ongoing support for current committed projects.

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2021

FUNDRAISING

The retail outlets, at Huntington and the Hospital have continued to be an invaluable source of income and the hospital shop provides a very useful 'shop front' for the charity. The sterling work done by our volunteers; and our staff in the office has yet again given up many hours in the evening and at weekends to help raise funds and spread the message about York Against Cancer. The links with the local business community have again proved a great benefit to the charity. With all these efforts from our employed staff and volunteers the charity is able to provide more much-needed support to many in the local community.

York Against Cancer is committed to maintaining high standards of fundraising and retail activity. The Charity is registered with the Fundraising Regulator. The Charity has recognised and begun to put in place a comprehensive policy for fundraising. The Charity does not use any third parties to act on its behalf in relation to fundraising. No complaints were received by the charity during 2021 in relation to its fundraising activities.

Fundraising report 2021

Following on from 2020, 2021 proved to be another tricky year for fundraising. We had some events planned that had to be postponed or just simply did not happen - for example York Rocks Against Cancer. However, we did still have some larger fundraisers, such as the golf day and the Dragon Boat race, that did go ahead and were very successful. This year, we have been supported by Marks and Spencers Vangarde, Forest of Galtres golf club, Sainsburys Monks Cross, JWP Creers and Iceland at Clifton Moor.

Our supporters have done a fantastic job moving with the times and finding ways to fundraise even though we could not be together, something just as simple as a group of friends putting £1 away each week raised £370. We also benefitted from the Jack Birch Unit who launched a successful run/walk 50k in 10 days fundraiser for us while we were still locked down. The combination of our own events and support from the local people of York and the surrounding areas has meant that, although some momentum has been lost, York Against Cancer has been kept going through a really difficult time. We are so grateful to the people who take the time to raise money for us, we simply would not be here without their help.

Overall, we have managed to carry on where we can and adapt where necessary to make the most of the events, we have been able to hold. We have also been able to broaden our income stream by improving our online donating facilities as well as encouraging online donations and investing in tap to donate. We are so grateful to all our supporters who have continued their support through another tricky year. We are very much looking forward to a brighter year ahead.

Lauren Hudson

Head of Fundraising and Executive Assistant

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2021

Structure, Governance and Management

The charity was incorporated on 22 April 2009 and its governing document is the memorandum and articles of association. The charity is a company limited by guarantee.

The charity is governed by a Board of Directors, supported by working groups as required. The Board members are all Trustees and include Officers of the Charity.

The Board meets four times a year and the various working groups meet as required during the year.

The members of the Board are volunteers. New Board members are elected by the existing members up to a maximum of twelve in total.

Trustee Induction and Training

New Trustees are briefed on their legal obligations under charity law, the committee and decision-making processes, the business plan and recent financial performance of the Charity. During their induction they meet key employees and other trustees. Trustees are encouraged to attend appropriate external training events where these will facilitate the undertaking of their role. At the end of each three tenure the trustees are required to update their trustee training.

Organisational Structure

The Board delegates the day-to-day management of the affairs of the Charity to one Board member, Tarnia Hudson, who serves as the Honorary Administrator.

The members of staff employed by the Charity during the year were:

Julie Russell	General Manager
Heather Atkinson	Office & Accounts Manager
Lauren Hudson	Personal Assistant to General Manager
Nicola Doherty	Office & Volunteer coordinator
Helen Watkinson	Retail Manager until 26 th November 2021
Francine Clee	PR & Communications Officer P/T until 14 th May 2021
Hayley Johnson	Communications Manager P/T from 5 th July 2021
Ian Stephenson	Minibus Driver P/T until 25 th May 2021
Neil Johnson	Minibus Driver P/T
Garry Stanton	Minibus Driver P/T from 27 th May 2021

Board membership

In March 2013 the Board adopted, by unanimous agreement, a protocol to introduce a three-year rule from that date. Board members continue to actively seek new trustees, taking into consideration a good mix of professional skills including business, education and medical. A term of office for a director is 3 years, after which time he/she may be re-elected for a further 3-year term up to a maximum of 9 years in total (details of current terms of office available on request).

Remuneration of key personnel

All members of staff employed by the charity have an annual appraisal in January following which salaries are set for the following 12 months. The appraisals are carried out by the General Manager.

No Board member received any income or expenses for their work for the charity.

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2021

Related parties

The Charity owns the whole of the issued ordinary share capital of York Against Cancer Trading Company Limited, a company registered in England and Wales. The subsidiary is used for the raising of funds for the Charity through the sale of bought in goods through the Charity's two shops.

Risk management

The Trustees have assessed the major risks to which the charity is exposed, in particular those related to the operations and finances of the Charity and continues to take measures to reduce those risks to an acceptable minimum. The policy of only making new commitments when the funds are in hand is a very practical way of eliminating unnecessary financial risks. By its very nature a charity relies on fundraising, donations and legacies which can vary a great deal. Ongoing commitments are to our staff and to a range of time limited research and care projects. The relocation to the York Community Stadium in May 2021 provides greater storage and office space and a retail outlet with a good footfall.

It should be emphasised that supporting staff not directly employed by York Against Cancer is always done on a time-limited basis (typically two years) which is renewed as appropriate provided funds are available. The Board is proactive in identifying projects on which to spend its reserves, ensuring to find effective ways in which to fulfil the aims of York Against Cancer, whilst at the same time investing some funds to provide for future security.

Financial review and policies

The Charity's funds in 2021 increased by £495,416. Large investment gains have further increased the surplus made. Prior to any adjustment for investments, the Charity made a surplus of £109,854 (2020 deficit of £146,787). The charity only generated a surplus in the year as the Mobile Chemotherapy Unit came in under budget in prior years and the excess commitment of £109,763 was released in the year. The future running costs of the unit will be cover by the remaining restricted fund.

The principal funding sources are fund-raising, the trading shops, donations, and legacies. Gross income in 2021 amounted to £647,704 (2020 £389,859). These funds support the key objectives of the Charity, namely, to fund clinical research, to support people with cancer and to fund education about the disease.

The charity has continued to benefit from legacies during the year, and we are immensely grateful to the generous donors. Legacy income is unpredictable and is another reason why the charity must husband its resources in the most effective way to enable the services we provide to both continue and develop.

£143,861 (2020 £163,187) was committed on project expenditure, to support the Charity's ongoing projects. The already committed projects cash spend was a further £447,546.

Due to COVID-19 there were limited additional projects taken on this year however two large projects not let confirmed at the year-end have been since committed two since the year end. These are the Robotic Surgery and The Leveson Centre.

The detail of funding of projects can be found in note 6.

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2021

Investment powers and policy

The Trustees have a general power of investment and so have the discretion to invest in such investment assets as they see fit. The Trustees have set a policy that sufficient of the 'free reserves' should be invested to retain a reasonable liquidity to meet grant commitments.

Our policy is a medium low risk approach for the growth of the portfolio of investments. The investment managers have discretion about how the investments are managed within the policy parameters set by the Trustees.

The Investment Group oversees the investment management of the Charity's funds. The services of HSBC Private Bank and Ruffer were retained as investment managers during 2021. Funds not invested are held on deposit to earn interest.

The total return on the investment portfolio managed by HSBC for the year ended 31 December 2021, before fees, was 10.99% (2020 0.43%). The total return on investment portfolio managed by Ruffer for the year ended 31 December 2021, before fees, was 11.80% (2020 11.88%).

Reserves Policy

The reserves policy is to generate a stable and sustainable return to fund grant making, to ensure continued financial security and to provide for contingencies. Cash reserves are accumulated before making a binding commitment to fund a project due to the nature and uncertainty of the income streams. The total funds held as at 31 December 2021 are £4,778,060 (2020 £4,282,644).

The Board is very mindful that the charity has a substantial reserve of funds at present after the receipt of some large legacies. The board is actively seeking to find effective ways in which these can be utilized to fulfil the aims of York Against Cancer, whilst at the same time investing some funds to provide for future security.

Undesignated Fund

These are free reserves retained to provide working capital and funds for future projects. At the end of the financial year, the free reserves were £3,041,746 (2020 £3,503,531) accumulated largely due to the receipt of several generous legacies, which by their very nature are unpredictable. The level of free reserves will enable the Charity to give significant support to worthwhile projects which make a measurable impact.

Designated Funds

Designated funds are part of the unrestricted funds which trustees have earmarked for assets held for the use in the charity and specific projects. At the year end, The Charity had consolidated designated funds of £1,597,671 (2020 £635,088) details of which are given in Note 16 of the financial statements.

Restricted Funds

Restricted funds represent monies raised by the Charity from public appeals for specific projects. At the year end, the Charity had restricted funds of £138,643 (2020 £144,025) details of which are given in Note 17 to the financial statements.

COVID-19 has had a significant impact on donations and fundraising since April 2020. The charity has significant reserves brought forward and these will be used to help support the charity adapt where needed and keep its on-going commitments.

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2021

Directors and Trustees Responsibilities

The purpose of this statement is to distinguish the Directors' and Trustees' responsibilities for the financial statements from those of the auditors as stated in their report.

Company and charity law require the Directors and Trustees to prepare financial statements which give a true and fair view of the Charitable Company's state of affairs at the end of its financial activities for that year. In preparing those financial statements the Trustees are required to:

- Select suitable accounting policies and then apply them consistently
- Make judgements and estimates that are reasonable and prudent;
- State whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements.
- Prepare the financial statements on the going concern basis unless it is inappropriate to assume that the Charitable Company will continue in operation.

The Directors and Trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the Charitable Company and enables them to ensure that the financial statements comply with the Companies Act 2006 and applicable charity law. They are also responsible for safeguarding the assets of the Charitable Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the Directors and Trustees are aware:

- There is no relevant information of which the Charitable Company's auditor is unaware; and
- The Directors and Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

Approved by the Board on 22 September 2022 and signed on its behalf by:

Ian Yeowart
Director and Trustee

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2021

Reference and administrative details

Registered Charity	number 1130835	Company Limited by Guarantee	number 06884476
Principal Office and Trading Address	East Stand York Community Stadium Kathryn Avenue Huntington York YO32 9AF		
Company Secretary	Julie Pamela Russell		
Directors and Trustees	Andrew Proctor Angela Darby Rachel Goddard Michael John Stower William Mark Sessions Ian Yeowart Sarah Wearing	Dr Lynn Bartram Michael Sweet Robert Onyett Tarnia Hudson Prof Stephen Leveson Michael Patrick Shepherd	
	Trustee's protocol available on request		
Accountants	HPH Chartered Accountants 54 Bootham York YO30 7XZ	Auditors	Hentons & Co LLP Chartered Accountants 124 Acomb Road Holgate York YO24 4EY
Bankers	National Westminster Bank 1 Market Street York YO1 8SR	Solicitors	Harrowells Moorgate House Clifton Moorgate York YO30 4WY
Investment Advisors	HSBC Global Asset Management 78 St James's Street London SW1A 1EJ		Ruffer LLP 80 Victoria Street London SW1E 5JL

**INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER
YEAR ENDED 31 DECEMBER 2021**

Opinion

We have audited the financial statements of York Against Cancer (the 'parent charitable company') and its subsidiary (the 'group') for the year ended 31 December 2021 which comprise the group statement of financial activities, the group balance sheet, the charitable company balance sheet, the group statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the state of the group's and the parent charitable company's affairs as at 31 December 2021 and of the groups incoming resources and application of resources, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the group and parent charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and parent charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

**INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER
YEAR ENDED 31 DECEMBER 2021**

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the trustees' report (incorporating the strategic report and the directors' report) for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the trustees' report have been prepared in accordance with applicable legal requirements.

Matter on which we are required to report by exception

In the light of the knowledge and understanding of the group and parent charitable company and their environment obtained in the course of the audit, we have not identified material misstatements in the trustees' report.

We have nothing to report in respect of the following matters where the Companies Act 2006 required us to report to you if, in our opinion:

- adequate accounting records have not been kept by the parent charitable company, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of Board of Trustees's remuneration specified by law are not made; or
- we have not obtained all the information and explanations necessary for the purposes of our audit.

Responsibilities of the trustees

As explained more fully in the trustees' responsibilities statement, the trustees, who are also the directors of the charity for the purpose of company law, are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the parent charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

**INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER
YEAR ENDED 31 DECEMBER 2021**

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

- We have obtained an understanding of the legal and regulatory framework applicable to the group and parent charitable company through discussions with senior management and review of the regulatory framework of any professional or membership bodies that the charitable company is a part of. The charitable company uses third parties to ensure that it remains up to date with changes and to review compliance with all its legal and regulatory requirements. In making our assessment of detecting irregularities, including fraud, we have discussed the issue with management who have advised that, other than changes to the work place to ensure that they are Covid-19 compliant, there have been no changes and the company remains compliant with its legal and regulatory requirement. Nothing has been brought to light in completing our audit work that contradicts this.
- The following laws and regulations have been identified as being of significance in the context of the group and charitable company; Companies Act 2006, Charities Act 2011, fundraising regulations, health and safety legislation, employment laws, data protection, and relevant tax laws.
- In making our assessment of the susceptibility of the group's and charitable company's financial statements to material misstatement, we have also considered how fraud might occur. No instances of material misstatement or fraud have been noted in the audit of the accounts for the year ended 31 December 2021.
- All matters regarding non-compliance with laws and regulations and fraud have been communicated to all members of the audit engagement team. The engagement partner has assessed that the engagement team has the appropriate competence and capabilities to identify or recognise non-compliance with laws and regulations, affected by the inherent difficulty in detecting irregularities, the effectiveness of the group's and charitable company's controls, and the nature, timing and extend of the audit procedures performed.

As part of an audit in accordance with ISAs (UK), we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the internal control.

YORK AGAINST CANCER

INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER

YEAR ENDED 31 DECEMBER 2021

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the trustees.
- Conclude on the appropriateness of the trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the group's and charitable company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Use of our report

This report is made solely to the Charity's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Charity's members those matters we are required to state to them in an auditors report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Charity's members as a body, for our audit work, for this report, or for the opinions we have formed.

.....
Brett Davis (Senior Statutory Auditor)

For and on behalf of Hentons

Chartered Accountants

Statutory Auditor

124 Acomb Road

York

YO24 4EY

Date: 22 September 2022

YORK AGAINST CANCER
CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES
AND INCOME AND EXPENDITURE ACCOUNT
FOR THE YEAR ENDED 31 DECEMBER 2021

	Note	Unrestricted General Fund £	Designated Funds £	Restricted Funds £	Year ended 31 Dec 2021 £	Year ended 31 Dec 2020 £
Income and endowments from:						
Donations and legacies	2	403,515	-	-	403,515	182,705
Other trading activities	3	199,087	-	-	199,087	157,863
Investments	4	45,102	-	-	45,102	49,291
Total		647,704	-	-	647,704	389,859
Expenditure on:						
Raising funds	5	199,970	-	-	199,970	181,336
Charitable activities	6	325,394	7,104	5,382	337,880	355,310
Total		525,364	7,104	5,382	537,850	536,646
Net income/(expenditure) before gains on investments		122,340	(7,104)	(5,382)	109,854	(146,787)
Net gains on investments	11	385,562	-	-	385,562	171,077
Net income/(expenditure)		507,902	(7,104)	(5,382)	495,416	24,290
Transfers between funds	16	(969,687)	969,687	-	-	-
Net movement in funds		(461,785)	962,583	(5,382)	495,416	24,290
Reconciliation of funds:						
Total funds brought forward		3,503,531	635,088	144,025	4,282,644	4,258,354
Total funds carried forward		£ 3,041,746	£ 1,597,671	£ 138,643	£ 4,778,060	£ 4,282,644

The notes on pages 21 to 31 form part of these financial statements.

YORK AGAINST CANCER
(Registration number: 06884476)

BALANCE SHEET
AS AT 31 DECEMBER 2021

	Note	Charity 2021 £	Consolidated 2021 £	Charity 2020 £	Consolidated 2020 £
FIXED ASSETS					
Tangible Fixed Assets	12	362,264	405,171	573,526	585,342
Investments	11	4,076,185	4,076,184	3,741,011	3,741,010
		4,438,449	4,481,355	4,314,537	4,326,352
CURRENT ASSETS					
Stock		-	55,176	-	55,295
Debtors	13	540,858	449,771	551,936	462,285
Cash at Bank and in Hand		819,603	846,463	827,681	898,835
		1,360,461	1,351,410	1,379,617	1,416,415
CREDITORS: amounts falling due within one year	14	498,519	517,503	487,559	499,107
NET CURRENT ASSETS		861,942	833,907	892,058	917,308
TOTAL ASSETS LESS CURRENT LIABILITIES		5,300,391	5,315,262	5,206,595	5,243,660
CREDITORS: amounts falling due after one year	15	537,202	537,202	961,016	961,016
NET ASSETS		<u>£ 4,763,189</u>	<u>£ 4,778,060</u>	<u>£ 4,245,579</u>	<u>£ 4,282,644</u>
THE FUNDS OF THE CHARITY					
Unrestricted					
Undesignated	18	3,069,782	3,041,746	3,478,282	3,503,531
Designated	16,18	1,554,764	1,597,671	623,272	635,088
Restricted	17,18	138,643	138,643	144,025	144,025
TOTAL CHARITY FUNDS		<u>£ 4,763,189</u>	<u>£ 4,778,060</u>	<u>£ 4,245,579</u>	<u>£ 4,282,644</u>

Approved by the Trustees on 21 September 2022 and signed on its behalf by:

S B Wearing
Director and Trustee

The notes on pages 21 to 31 form part of these financial statements.

**YORK AGAINST CANCER
CONSOLIDATED CASHFLOW STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2021**

	Note	2021 £	2020 £
Cash flows from operating activities:			
Net cash used in operating activities	21	(335,263)	(363,320)
Cash flows from investing activities:			
Dividends, interest and rents from investments		45,102	49,291
Purchase of property, plant and equipment		(64,330)	(2,990)
Proceeds from sale of property		251,731	-
Proceeds from sales of investments		1,838,749	1,095,488
Purchase of investments		(1,788,361)	(1,117,345)
Net cash provided by investing activities		<u>282,891</u>	<u>24,444</u>
Change in cash and cash equivalents in the reporting period		(52,372)	(338,876)
Cash and cash equivalents at the beginning of the reporting period		<u>898,835</u>	<u>1,237,711</u>
Cash and cash equivalents at the end of the reporting period		<u><u>£ 846,463</u></u>	<u><u>£ 898,835</u></u>

The notes on pages 21 to 31 form part of these financial statements.

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

1. ACCOUNTING POLICIES

Legal entity

York Against Cancer is regulated by the Charities Commission (1130835), limited by guarantee and is registered in England and Wales. The address of the registered office and principal place of business is York Community Stadium, Kathryn Avenue, Huntington, York, England, YO32 9AF.

Basis of preparation

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The consolidated accounts include the results of the Charitable Company and its subsidiary undertaking. The results of the subsidiary are consolidated on a line by line basis.

No separate SOFA has been presented for the Charitable Company alone as permitted by the SORP.

The Charitable Company constitutes a public benefit entity as defined by FRS 102.

The accounts are presented in UK Sterling pounds (£).

Going Concern

The Charitable Company has cash resources and has no requirement for external funding. The cash and investments held are sufficient to see the Charitable Company through the financial impact of COVID-19. The Directors and Trustees have a reasonable expectation that the Charitable Company has adequate resources to continue in operational existence for the foreseeable future. They continue to believe the going concern basis of accounting appropriate in preparing the annual financial statements.

Income

Donations and legacies

Credit is taken for donations and subscriptions when they are received. Credit is taken for legacies when received or if, before receipt, there is sufficient evidence to provide the necessary certainty that the legacy will be received and the value of the incoming resources can be measured with sufficient reliability.

Other trading activities

Fundraising income - represents gross income from events.

Subsidiary's non-charitable trading turnover - represents gross income from York Against Cancer Trading Company Limited, the Charitable Company's trading subsidiary.

Investments

Investment income has been accounted for on an accruals basis.

Expenditure

Raising funds

Fundraising costs - represents the total costs of fundraising events and activities held during the year.

Non charitable trading expenditure - comprises of the direct costs and administrative costs of the Charitable Company's trading subsidiary, York Against Cancer Trading Company Limited.

Charitable activities

Direct costs - comprises of expenditure on various projects the Charitable Company is supporting and is accounted for in full when the Charitable Company commits to provide the funding.

Support costs - comprises of the salaries and office expenses of the Charitable Company.

Governance costs - comprises the costs associated directly with the management by the Directors/Trustees of the Charitable Company's activities, including audit fees and costs of meetings.

All costs are apportioned on an actual cost basis.

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

1. ACCOUNTING POLICIES (continued)

Pension costs

The Charitable Company operates a defined contribution money purchase pension scheme for specific employees. The assets of the scheme are invested and managed independently of the finances of the Charitable Company. The charge for pension costs represents the contributions payable in the year.

Fixed Assets

Individual fixed assets costing £200 or more are capitalised and included in the accounts at cost.

Tangible fixed assets are depreciated over their expected useful lives at the following annual rates:

Freehold/Leasehold property	at straight line over 50 years
Equipment	
- Shop and office equipment	at straight line over 10 years
- Computer equipment	at straight line over 3 years
- Respite home equipment	at straight line over 4 years
- Motor vehicles	at 25% reducing balance

Stock

Stock is valued at the lower of cost and net realisable value. Cost is computed on a first in first out basis. Net realisable value is based on estimated selling price less the estimated cost of disposal.

Funds Structure

Unrestricted Funds are funds which are available for use or retention at the discretion of the Directors/Trustees, in accordance with the Charity's objects. Designated Funds represent unrestricted funds earmarked by the Directors/Trustees for particular purposes. Restricted Funds are subjected to restrictions on their expenditure imposed by the donor or through the terms of an appeal. Details of Designated and Restricted Funds are contained in Notes 16 and 17, respectively.

Investments

The investment portfolios have been valued at market value at 31 December 2021. The SOFA includes the net gains and losses on investments arising on revaluation at the year end and on disposals throughout the year. Realised gains and losses on sales of investments are calculated as the difference between the sale proceeds and opening market value. Unrealised gains and losses represent the movement between market values.

Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

Cash at bank and in hand

Cash at bank and cash in hand includes cash and any short term deposit accounts with a maturity of three months or less from the date of opening.

Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

Financial instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

Operating leases

Rentals paid under operating leases are charged in the SOFA on a straight line basis over the lease term.

Government grants

These government grants relate to the COVID grants for retail closures issued to the subsidiary trading company.

YORK AGAINST CANCER

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021**

2. DONATIONS AND LEGACIES	Unrestricted £	Restricted £	2021 £	2020 £
Donations	158,533	-	158,533	118,189
In Memoriam	19,852	-	19,852	24,957
Legacies	206,699	-	206,699	13,225
Government grant	13,431	-	13,431	21,334
Intangible income	5,000	-	5,000	5,000
	<u>£ 403,515</u>	<u>£ -</u>	<u>£ 403,515</u>	<u>£ 182,705</u>

Intangible income comprises accounting services, a proportion of which is provided free of charge for the preparation of the Charitable Company and Subsidiary statutory accounts. A corresponding amount is included within governance costs.

3. OTHER TRADING ACTIVITIES	2021 £	2020 £
Fundraising income	99,601	72,639
Subsidiary's non-charitable trading turnover	99,486	85,224
	<u>£ 199,087</u>	<u>£ 157,863</u>

4. INVESTMENTS	2021 £	2020 £
Interest received	627	2,696
Dividends received	44,475	46,595
	<u>£ 45,102</u>	<u>£ 49,291</u>

5. ANALYSIS OF RAISING FUNDS	Unrestricted £	Restricted £	2021 £	2020 £
Advertising	11,292	-	11,292	7,900
Fundraising costs	36,933	-	36,933	65,847
Non charitable trading - other costs	110,546	-	110,546	70,995
Non charitable trading - staff costs	21,123	-	21,123	22,165
Non charitable trading - depreciation	5,156	-	5,156	2,515
Investment fees	14,920	-	14,920	11,914
	<u>£ 199,970</u>	<u>£ -</u>	<u>£ 199,970</u>	<u>£ 181,336</u>

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021

6. ANALYSIS OF CHARITABLE ACTIVITIES

<i>Direct project costs:</i>	Unrestricted £	Restricted £	2021 £	2020 £
Research				
Clinical Trial Nurses	95,051	-	95,051	19,239
Support and Care				
Cancer Care Centre - Old	6,511	-	6,511	26,330
Complementary therapy	-	-	-	29,541
Health Care Assistant	12,818	-	12,818	7,865
Respite property expenses	21,103	-	21,103	29,257
Minibus running costs - direct	12,248	-	12,248	7,029
Minibus running costs - staff costs	20,439	-	20,439	18,533
Mobile Chemotherapy Unit*	(109,763)	5,382	(104,381)	321
Psychology services	4,040	-	4,040	5,680
Restricted grants	-	-	-	12,222
Health Welfare Advisor	73,444	-	73,444	-
Education				
Education expenses	2,588	-	2,588	7,170
	138,479	5,382	143,861	163,187
*During the year the underspend on the Mobile Chemotherapy Unit was released as the project cost less than initially budgeted. Running costs are covered by the restricted funds.				
Support costs:				
Staff costs	139,079	-	139,079	134,916
Staff training and travel	2,553	-	2,553	1,702
Rent, service charge and rates	21,779	-	21,779	4,352
Heat and light	1,837	-	1,837	1,666
Repairs and maintenance	173	-	173	1,932
Insurances	3,416	-	3,416	2,963
Printing, stationery and postage	4,870	-	4,870	4,856
Computer expenses	7,819	-	7,819	7,867
Telephone	2,693	-	2,693	1,710
Sundry expenses	6,384	-	6,384	3,953
Gains and losses on fixed assets	(28,554)	-	(28,554)	-
Depreciation	16,168	-	16,168	13,500
	178,217	-	178,217	179,417
Governance costs:				
Audit fees	4,560	-	4,560	3,480
Accountancy fees	7,507	-	7,507	7,663
Legal fees	2,182	-	2,182	-
Bank charges	1,553	-	1,553	1,563
	15,802	-	15,802	12,706
Total charitable activities	£ 332,498	£ 5,382	£ 337,880	£ 355,310

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

7. NET INCOMING RESOURCES FOR THE YEAR

	2021 £	2020 £
This is stated after charging:		
Depreciation	21,324	18,530
Auditor's remuneration for audit services - charity	4,560	3,480

8. REMUNERATION AND EXPENSES OF TRUSTEES

None of the Trustees received any remuneration or benefits by virtue of being a trustee of the Charity and no Trustees were reimbursed any expenses incurred for services provided to the Charity.

9. STAFF COSTS

	2021 £	2020 £
Wages and salaries	160,955	155,368
Social security costs	8,614	8,710
Pension costs	6,701	7,104
Medical Insurance	4,371	4,432
	<u>£ 180,641</u>	<u>£ 175,614</u>

The average monthly head count was 8 staff (2020 8) and the average monthly number of full-time equivalent employees (including casual and part-time staff) during the year were as follows:

Projects	1	1
Trading	1	1
Management and administration	6	6

No employee received emoluments in excess of £60,000.

The key management personnel of the Charitable Company, comprise the directors and trustees and the General Manager. The total employee benefits of the key management personnel of the Charitable Company were £50,303 (2020 - £49,937).

10. SUBSIDIARY COMPANY

The Charitable Company owns the whole of the issued ordinary share capital of York Against Cancer Trading Company Limited. This company is registered in England and Wales (reg. no. 3405708) and its registered office is York Community Stadium, Kathryn Avenue, Huntington, York, England, YO32 9AF. The subsidiary is used for the raising of funds for the Charitable Company through the sale of bought in goods through the Charitable Company's shop and stalls. All activities have been consolidated on a line by line basis in the There is a loan account between the Charitable Company and the subsidiary. The balance on the loan account outstanding at the year end was £92,808 (2020 £95,637). Interest of £186 (2020 £141) was charged during the year in respect of this loan.

A summary of the results of the subsidiary is shown below:

	2021 £	2020 £
Turnover	99,486	85,224
Cost of sales	<u>(64,071)</u>	<u>(46,891)</u>
Gross profit	35,415	38,333
Administrative expenses	<u>(72,754)</u>	<u>(48,953)</u>
Operating profit	(37,339)	(10,620)
Other operating income	15,333	11,334
Interest payable	<u>(186)</u>	<u>(141)</u>
Profit on ordinary activities before taxation	(22,192)	573
Taxation	-	-
Profit on ordinary activities after taxation	(22,192)	573
Amount gifted to York Against Cancer	-	-
Retained (withdrawn from)/within Subsidiary	<u>£ (22,192)</u>	<u>£ 573</u>
Net Assets	<u>£ 14,871</u>	<u>£ 37,063</u>

YORK AGAINST CANCER

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021**

11. INVESTMENTS

Consolidated	2021 £	2020 £
Market value at 1 January 2021	3,741,010	3,548,076
Additions at cost	1,788,361	1,117,345
Disposals	(1,838,749)	(1,095,488)
Revaluations	385,562	171,077
Market value at 31 December 2021	£ 4,076,184	£ 3,741,010
Analysis of investments by class:		
Listed investments	£ 4,076,184	£ 3,741,010
The historical cost of the above investments amounts to:	£ 3,633,156	£ 3,521,243

The following material investments are over 5% by value of the investments held

	2021 Market value £	2020 Market value £
HSBC FTSE All Share Index	-	302,095
Ruffer Charity Assets Trust Account	2,231,923	2,010,192
	£ 2,231,923	£ 2,312,287

The Charitable Company holds all of the issued shares of its subsidiary undertaking York Against Cancer Trading Company Limited, at cost of £1, in addition to the above investments.

12. TANGIBLE FIXED ASSETS

	Property £	Motor Vehicles £	Equipment £	Charity Total £	Subsidiary - Shop Equipment £	Consolidated Total £
<i>Cost</i>						
At 1 January 2021	635,602	41,515	46,469	723,586	34,871	758,457
Additions in year	-	-	27,943	27,943	36,387	64,330
Disposals in year	(267,900)	-	(34,079)	(301,979)	(19,697)	(321,676)
At 31 December 2021	367,702	41,515	40,333	449,550	51,561	501,111
<i>Depreciation</i>						
At 1 January 2021	72,727	35,951	41,382	150,060	23,055	173,115
Charge for year	10,033	1,391	4,744	16,168	5,156	21,324
Disposals in year	(45,989)	-	(32,953)	(78,942)	(19,557)	(98,499)
At 31 December 2021	36,771	37,342	13,173	87,286	8,654	95,940
<i>Net book value</i>						
At 31 December 2021	£ 330,931	£ 4,173	£ 27,160	£ 362,264	£ 42,907	£ 405,171
At 31 December 2020	£ 562,875	£ 5,564	£ 5,087	£ 573,526	£ 11,816	£ 585,342

All fixed assets are held for direct charitable purposes in Designated Funds.

YORK AGAINST CANCER

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021**

13. DEBTORS	Charity 2021 £	Consolidated 2021 £	Charity 2020 £	Consolidated 2020 £
Amounts owed by subsidiary	92,809	-	95,637	-
Prepayments	6,488	6,596	9,250	13,902
Accrued income	430,000	430,000	446,909	448,243
Other debtors	11,561	13,175	140	140
	£ 540,858	£ 449,771	£ 551,936	£ 462,285

**14. CREDITORS: amounts falling due
within one year**

Trade creditors	2,445	3,488	30,378	33,524
Project creditors	476,711	476,711	444,038	444,038
Taxation and social security	3,146	6,325	3,128	8,730
Accruals	14,187	28,949	8,893	11,693
Other creditors	2,030	2,030	1,122	1,122
	£ 498,519	£ 517,503	£ 487,559	£ 499,107

**15. CREDITORS: amounts falling due
after one year**

Project creditors	£ 537,202	£ 537,202	£ 961,016	£ 961,016
-------------------	------------------	------------------	------------------	------------------

16. DESIGNATED FUNDS (consolidated)

The Charitable Company transfers to designated funds sufficient resources to meet such commitments, as shown below.

Designated Funds - 2021	Balance 01/01/2021 £	Income £	Expenditure £	Transfers £	Balance 31/12/2021 £
Cancer Care Centre	5,382	-	(5,382)	-	-
Cancer Care Centre - New Centre	-	-	-	466,500	466,500
Complementary Therapy	6,364	-	(6,364)	-	-
Education Project	-	-	(2,588)	2,588	-
Minibus	28,000	-	-	8,000	36,000
Patient Travel	10,000	-	-	-	10,000
Robotic Surgery Project	-	-	-	680,000	680,000
Fixed Assets Fund	585,342	-	7,230	(187,401)	405,171
Total	£ 635,088	£ -	£ (7,104)	£ 969,687	£ 1,597,671

Designated Funds - 2020	Balance 01/01/2020 £	Income £	Expenditure £	Transfers £	Balance 31/12/2020 £
Cancer Care Centre	31,500	-	(26,118)	-	5,382
Complementary Therapy	35,480	-	(29,116)	-	6,364
Education Project	-	-	(7,170)	7,170	-
Minibus	-	-	-	28,000	28,000
Patient Travel	-	-	-	10,000	10,000
Fixed Assets	600,882	-	(18,530)	2,990	585,342
Total	£ 667,862	£ -	£ (80,934)	£ 48,160	£ 635,088

Cancer Care Centre

The Board is committed to a service level agreement with York Hospital to provide the funding for 3 administrator posts from 1 April 2019 to 31 March 2021.

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

16. DESIGNATED FUNDS (consolidated continued)

Cancer Care Centre - New Centre

The charity has set aside an initial budget for the provision of a new cancer care centre to be spent over the next year.

Complementary Therapy

The Board is committed to a service level agreement with York Hospital to provide the funding for a therapist post from 1 April 2019 to 31 March 2021.

Minibus

The trustees have set aside monies for the purchase of a new minibus which will be purchased next year.

Patient Travel

The trustees have set aside monies to fund Patient Travel and this will be reviewed next year once demand is known.

Robotic Surgery Project

During the year the charity started conversations with the NHS regarding supporting the Robotic Surgery facilities. Since the year end a formal commitment was made of £680,000.

Fixed Asset Fund

This fund represents funds invested in tangible fixed assets.

Education Project

The Board agreed to fund the annual budgeted costs of the Education Project which is aimed at raising the awareness of cancer to the public.

17. RESTRICTED FUNDS (consolidated)

	Balance 01/01/2021	Income	Expenditure	Transfers	Balance 31/12/2021
Restricted Funds - 2021	£	£	£	£	£
Mobile Chemotherapy Unit	142,348	-	(5,382)	-	136,966
Mouth Cancer	1,677	-	-	-	1,677
Total 2021	£ 144,025	£ -	(£ 5,382)	£ -	£ 138,643
	Balance 01/01/2020	Income	Expenditure	Transfers	Balance 31/12/2020
Restricted Funds - 2020	£	£	£	£	£
Mobile Chemotherapy Unit	142,069	600	(321)	-	142,348
Prostate Cancer	12,222	-	(12,222)	-	-
Mouth Cancer	1,677	-	-	-	1,677
Total 2020	£ 155,968	£ 600	(£ 12,543)	£ -	£ 144,025

Mobile Chemotherapy Unit

The Mobile Chemotherapy Unit Appeal relates to funds raised for the specific purpose of running the service.

Prostate Cancer

50% of the R U taking the P monies raised where to be allocated to prostate cancer research.

Mouth Cancer

Monies raised for the Head and Neck cancer department.

YORK AGAINST CANCER

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021**

18. ANALYSIS OF GROUP NET ASSETS BETWEEN FUNDS

	General Funds £	Designated Funds £	Restricted Funds £	Total 2021 £
Fund balances at 31 December 2021 are represented by:				
Tangible fixed assets	-	405,171	-	405,171
Investments	3,396,184	680,000	-	4,076,184
Current assets	700,267	512,500	138,643	1,351,410
Current liabilities	(517,503)	-	-	(517,503)
Long term liabilities	(537,202)	-	-	(537,202)
	£ 3,041,746	£ 1,597,671	£ 138,643	£ 4,778,060

	General Funds £	Designated Funds £	Restricted Funds £	Total 2020 £
Fund balances at 31 December 2020 are represented by:				
Tangible fixed assets	-	585,342	-	585,342
Investments	3,741,010	-	-	3,741,010
Current assets	1,222,644	49,746	144,025	1,416,415
Current liabilities	(499,107)	-	-	(499,107)
Long term liabilities	(961,016)	-	-	(961,016)
	£ 3,503,531	£ 635,088	£ 144,025	£ 4,282,644

19. OPERATING LEASE COMMITMENTS

As at 31 December 2021 the group had the total minimum lease payments under operating leases at the end of the reporting period, for each of the following period:

	At 31 December 2021		At 31 December 2020	
	Land and buildings £	Office equipment £	Land and buildings £	Office equipment £
Total operating leases payable:				
Within one year	40,298	-	15,000	-
Between two and five years	127,610	-	-	-

20. RELATED PARTIES

During the year the Charitable Company paid £2,829 (2020 £2,620) to HPH Chartered Accountants for accountancy services and software costs, a firm in which the Charitable Company's Treasurer, Sarah Wearing, is a partner. At the year end there was £107 (2020 £nil) owing to HPH Chartered Accountants.

During the year the Charitable Company paid £2,160 (2020 £nil) to Harrowells Solicitors for legal fees, a firm in which the Charitable Company's Director, Robert Onyett, is a director.

During the year the wife of a director Ian Yeowart was paid £1,300 for temporary employment cover.

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

21. CASH FLOW NOTES

RECONCILIATION OF NET MOVEMENT IN FUNDS TO NET CASH FLOW FROM OPERATING ACTIVITIES	2021 £	2020 £
Net income/(expenditure) for the reporting period	495,416	24,290
Adjustments for:		
Depreciation charges	21,324	18,530
Gains on sale of fixed assets	(28,554)	-
(Gains)/Losses on investments	(385,562)	(171,077)
Dividends, interest and rents from investments	(45,102)	(49,291)
Increase in stocks	119	1,964
Increase in debtors	12,514	232,045
(Increase)/Decrease in creditors	(405,418)	(419,781)
Net cash used in operating activities	£ (335,263)	£ (363,320)
ANALYSIS OF CASH AND CASH EQUIVALENTS		
Cash at bank and in hand	846,463	898,835
Total cash and cash equivalents	£ 846,463	£ 898,835

ANALYSIS OF CHANGES IN NET DEBT

	At 01/01/2021 £	Cash-flows £	At 31/12/2021 £
Cash	898,835	(52,372)	846,463

22. VOLUNTEERS

The Charity is fortunate to be supported by over 100 volunteers. Their activities include working in our shops, attending events, supporting the office, collections and baking. Without them the Charity could not achieve what it does; their support is a massive asset in both workforce and financial terms. Whilst going about their work they are also ambassadors for the Charity which encourages more people to volunteer and support.

With varied knowledge, skills and experience the volunteers make an invaluable group. Our thanks goes to them all – together we really do make a difference to cancer patients and their families.

YORK AGAINST CANCER
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021

24. COMPARATIVE INFORMATION

	Unrestricted			Year ended
	General	Designated	Restricted	31 Dec
	Fund	Funds	Funds	2020
	£	£	£	£
Income and endowments from:				
Donations and legacies	182,105	-	600	182,705
Other trading activities	157,863	-	-	157,863
Investments	49,291	-	-	49,291
Total	389,259	-	600	389,859
Expenditure on:				
Raising funds	181,336	-	-	181,336
Charitable activities	261,833	80,934	12,543	355,310
Total	443,169	80,934	12,543	536,646
Net expenditure before losses on investments	(53,910)	(80,934)	(11,943)	(146,787)
Net gains on investments	171,077	-	-	171,077
Net income/(expenditure)	117,167	(80,934)	(11,943)	24,290
Transfers between funds	(48,160)	48,160	-	-
Net movement in funds	69,007	(32,774)	(11,943)	24,290
Reconciliation of funds:				
Total funds brought forward	3,434,524	667,862	155,968	4,258,354
Total funds carried forward	£ 3,503,531	£ 635,088	£ 144,025	£ 4,282,644

YORK AGAINST CANCER

England & Wales - Charity number 1130835

Accounts

Company Number 06884476

YORK AGAINST CANCER
A company limited by guarantee
and
A registered charity number 1130835

REPORT AND ACCOUNTS

For the year ended
31 December 2020

HPH
Chartered Accountants
54 Bootham
York
YO30 7XZ

YORK AGAINST CANCER

CONTENTS

	Page
Founders	1
Chairman's Report	2
Trustees' Report	3 - 15
Auditor's Report	16 – 19
Statement of Financial Activities	20
Balance Sheet	21
Cash Flow Statement	22
Notes to the Financial Statements	23 - 33

YORK AGAINST CANCER

Founders

Prof Stephen Leveson

Mr John Craven

Prof Colin Garner

YORK AGAINST CANCER

CHAIRMAN'S REPORT 2020

I am sure I don't need to remind anybody about the impact Covid 19 has had during the year. It has had a significant effect on the day to day work that we all undertake, including the work of the Charity.

During the year our small and dedicated workforce led by General Manager Julie Russell remained to the fore in ensuring we delivered on our promise to support those in need, both individuals and families whenever circumstances allowed, and I am grateful for their dedication during what has been a very difficult time.

As you will be aware we have been forced to make a number of difficult decisions in the short term due to the on-going restrictions, but we look forward to the Charity being back and fully functioning in the not too distant future.

In the meantime, work continues, and while some events are on hold, the need to strategically plan for our future requirements goes on to ensure we remain in a position to continue the important services for people touched by cancer – services that will be even more important as we consolidate and expand on the outstanding work undertaken in the many areas that the Charity is involved in.

Our move to our new shop and offices at Vangarde Monks Cross did not take place as expected, and the continuing delay has been a source of frustration. The move is now planned in 2021 and will hopefully have happened by the time you read this. This will put the Charity far more central from an awareness point of view.

A number of Board member colleagues have retired this year, and we would like to record our thanks to Keith Hayton, Pat Kay, Gordon Topping and John Yeomans for the many years of hard work and dedication they have given. We also sadly lost a number of supporters and volunteers, and our thoughts go out to their families, and we wish them well for the future.

Every one of them supported the day to day work of the Charity, and our volunteers, our staff and all those who help in their own way enable us to continue to provide the important services and funding for research that the Charity is recognised for.

Despite the many restrictions, our minibus service was able to operate in difficult conditions at times, and our thanks go to Ian and Neil for providing this important service when many other cancer services were severely curtailed by the NHS. Working in the office, promoting the Charity or driving our minibus our small and important band of dedicated staff are the daily face of York Against Cancer, and ably supported by our committed army of volunteers, the Charity remains in good hands.

We have missed the regular involvement of our wonderful volunteers, but we know when things start to return to normal you will once again provide support in our shops and at numerous events throughout the year.

Ian Yeowart
Chair York Against Cancer

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2020

The Directors (who are also the Trustees of the Charity and are listed below) are pleased to present their report of the Charitable Company for the year ended 31 December 2020.

Objectives and activities

The objects of the Charity are to raise funds to:

1. Foster and promote joint research between clinicians and research scientists in York and wider area and, by encouraging a more effective exchange of ideas and information, to advance the alleviation and cure of cancer.
2. Support treatment of cancer patients at York Hospital and the local area.
3. Fund education and information about cancer for patients and their families and the wider public.

The Trustees believe they have complied with the duty in section 4 of the 2006 Charities Act to have due regard to guidance published by the Charity Commission in respect of public benefit.

Aims and strategies

The Charity aims to provide support to cancer patients and the community through the: -

- funding of research programmes
- funding and the provision of services and resources for patients and their families
- funding of education initiatives

Achievements and performance

Research

Jack Birch Unit (University of York)

The Charity is committed to another 4 years supporting the work of the Jack Birch Unit. The roles supported by York Against Cancer are: -

Director of the Jack Birch Unit
Laboratory technician

Assistant Director
Administrative assistant

Research Fellow in Informatics at the Jack Birch Unit is also being supported from 2019 to 2024. A more in-depth report of the work of the Unit is detailed on pages 7 and 8.

Developments in the Year and Future Planning

The Board have continued their consistently adopted policy of only making commitments when the finance for these is already in place. The Board are mindful of the responsibility of ensuring that the generous donations received are used in the most effective manner possible to meet with the aims of the charity. With a sudden influx of a large legacy in 2016 the board established a Finance Sub-group to consider the most effective way to manage the funds for the future of the charity. The Board has agreed with the recommendations of the sub-group that a significant proportion of funds should be invested to provide for both future security of the charity and to ensure that the capital is used most effectively and to be available when future projects are considered and to ensure that the long-term plans and services the charity provides can be continued into the foreseeable future.

YORK AGAINST CANCER

CHAIRMAN'S REPORT 2020

I am sure I don't need to remind anybody about the impact Covid 19 has had during the year. It has had a significant effect on the day to day work that we all undertake, including the work of the Charity.

During the year our small and dedicated workforce led by General Manager Julie Russell remained to the fore in ensuring we delivered on our promise to support those in need, both individuals and families whenever circumstances allowed, and I am grateful for their dedication during what has been a very difficult time.

As you will be aware we have been forced to make a number of difficult decisions in the short term due to the on-going restrictions, but we look forward to the Charity being back and fully functioning in the not too distant future.

In the meantime, work continues, and while some events are on hold, the need to strategically plan for our future requirements goes on to ensure we remain in a position to continue the important services for people touched by cancer – services that will be even more important as we consolidate and expand on the outstanding work undertaken in the many areas that the Charity is involved in.

Our move to our new shop and offices at Vangarde Monks Cross did not take place as expected, and the continuing delay has been a source of frustration. The move is now planned in 2021 and will hopefully have happened by the time you read this. This will put the Charity far more central from an awareness point of view.

A number of Board member colleagues have retired this year, and we would like to record our thanks to Keith Hayton, Pat Kay, Gordon Topping and John Yeomans for the many years of hard work and dedication they have given. We also sadly lost a number of supporters and volunteers, and our thoughts go out to their families, and we wish them well for the future.

Every one of them supported the day to day work of the Charity, and our volunteers, our staff and all those who help in their own way enable us to continue to provide the important services and funding for research that the Charity is recognised for.

Despite the many restrictions, our minibus service was able to operate in difficult conditions at times, and our thanks go to Ian and Neil for providing this important service when many other cancer services were severely curtailed by the NHS. Working in the office, promoting the Charity or driving our minibus our small and important band of dedicated staff are the daily face of York Against Cancer, and ably supported by our committed army of volunteers, the Charity remains in good hands.

We have missed the regular involvement of our wonderful volunteers, but we know when things start to return to normal you will once again provide support in our shops and at numerous events throughout the year.

Ian Yeowart
Chair York Against Cancer

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2020

The Directors (who are also the Trustees of the Charity and are listed below) are pleased to present their report of the Charitable Company for the year ended 31 December 2020.

Objectives and activities

The objects of the Charity are to raise funds to:

1. Foster and promote joint research between clinicians and research scientists in York and wider area and, by encouraging a more effective exchange of ideas and information, to advance the alleviation and cure of cancer.
2. Support treatment of cancer patients at York Hospital and the local area.
3. Fund education and information about cancer for patients and their families and the wider public.

The Trustees believe they have complied with the duty in section 4 of the 2006 Charities Act to have due regard to guidance published by the Charity Commission in respect of public benefit.

Aims and strategies

The Charity aims to provide support to cancer patients and the community through the: -

- funding of research programmes
- funding and the provision of services and resources for patients and their families
- funding of education initiatives

Achievements and performance

Research

Jack Birch Unit (University of York)

The Charity is committed to another 4 years supporting the work of the Jack Birch Unit. The roles supported by York Against Cancer are: -

Director of the Jack Birch Unit
Laboratory technician

Assistant Director
Administrative assistant

Research Fellow in Informatics at the Jack Birch Unit is also being supported from 2019 to 2024. A more in-depth report of the work of the Unit is detailed on pages 7 and 8.

Developments in the Year and Future Planning

The Board have continued their consistently adopted policy of only making commitments when the finance for these is already in place. The Board are mindful of the responsibility of ensuring that the generous donations received are used in the most effective manner possible to meet with the aims of the charity. With a sudden influx of a large legacy in 2016 the board established a Finance Sub-group to consider the most effective way to manage the funds for the future of the charity. The Board has agreed with the recommendations of the sub-group that a significant proportion of funds should be invested to provide for both future security of the charity and to ensure that the capital is used most effectively and to be available when future projects are considered and to ensure that the long-term plans and services the charity provides can be continued into the foreseeable future.

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2020

The members of the Board are constantly looking at the needs of cancer patients and cancer services in the area to see where an investment could provide a significant improvement to the cancer services.

The delay in the Monks Cross development will mean that the charity will remain on the Huntington site for the present and the date for moving will be 2021.

The charity has continued to benefit from legacies during the year which give a great boost to the charity's funds, and we are immensely grateful to these generous people. Legacy income is, unpredictable and is another reason why the charity must husband its resources in the most effective way to enable the services we provide to both continue and develop.

Mobile Chemotherapy Unit

In recent years, the charity has worked on raising its profile, both locally and in a wider area of North and East Yorkshire with a successful rebranding exercise. With the Mobile Chemotherapy Unit project coming to fruition which takes chemotherapy services to the wider areas of the York Teaching Hospital, at Malton, Selby, Scarborough and Bridlington, it has enabled the charity to widen its reach. This has helped thousands of patients the time-consuming and tiring journeys to the hospital in York. In its first full year of operation the unit has been very well received by both medical staff and patients.

It also significantly increased the capacity of the hospital to provide the chemotherapy services to meet the needs of patients. Our fundraisers have been actively raising funds to help with the running costs of the enterprise.

Respite Properties

The holiday homes at Filey and Whitby continue to provide a welcome break, each in its own special environment. The many letters of appreciation we receive are an indication of how much a short break in these luxurious surroundings are appreciated. The YAC board is looking into extending this service through exploring opportunities to buy an additional property.

Dermatoscope Project

The dermatoscope project, launched 3 years previously, has continued to expand and develop and is really beginning to make an impact to help the early diagnosis of skin cancer, by which these specially designed photo units have been supplied to all GP practices in the area, has made the early diagnosis of skin cancer not only easier and more efficient but has greatly reduced the waiting time for patients to see a consultant. This model of this project has been picked up by other areas and is now being replicated in other hospitals

Supporting patients

The Health Care Assistant have continued to provide support for families affected by cancer. These appointments are made in conjunction with the NHS to provide support for patients and their families; support which is not available through the normal NHS services. This year complementary therapy arranged through the Cancer Care Centre has been significantly affected by Covid-19 and patients have been offered complementary therapy and other services virtually. Our minibus service has also been affected by Covid, for a few months it was not able to run but as soon as the restrictions allowed it resume, however, with a restricted number of passengers. It continues to be an excellent and much-valued service of transporting patients to St. James' Hospital.

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2020

Health Welfare Advisor

The charity continues to support the Citizens Advice Bureau in their work with cancer patients at Scarborough hospital: this work provides support for those having cancer treatment and based at Scarborough to ensure that they receive all the help to which they are entitled.

Management Report

The small team of hardworking office staff deal effectively with all aspects of the day-to-day operation of the charity, and it is worth noting that during 2020 that there has been an inevitable impact on fundraising and charity/staff/board morale and the charity have striven to deal with those demands and risen to meet the challenges head on.

The teams work is sometimes challenging as they deal with people facing cancer and on occasions this can impact on their resolve, they deal with this together and their teamwork is impressive. The team are friendly and often are found smiling. The way it is possible for our manager and her staff to respond quickly to any requests or challenges is a key strength for York Against Cancer as a local charity.

Minibus

We continue to get very encouraging feedback from the users of the minibus, the Whitby apartment and the Filey holiday home. The members of staff have worked in close co-operation with the Cancer Care Centre and this has enabled the apartment to be used by some very deserving cases. The thoughtful and kind approach of our minibus drivers has also again been very much appreciated.

The people supported by York Against Cancer

Although the people directly employed by the charity are those listed above there are, in addition, those who are employed directly by others but whose salary costs are paid by York Against Cancer. All these posts are supported as the work done by these people directly enables the charity to achieve its goals. These posts are itemised below and illustrate the range of activities supported by the Board:

JBU - Director of the Jack Birch Unit

Assistant Director

Laboratory technician

Administrative assistant

Administrators at the Cancer Care Centre (3 staff covering 37 hours)

Health Care Assistant (part-time)

Complementary therapists (one full-time equivalent)

Clinical Research Nurse and Assistant posts at York Hospital (two-year funding to end of 2021)

Research Fellow in Informatics at the Jack Birch Unit (from 2019 to 2024)

All these supported positions are initially given for a fixed term (usually two or three years) and then reviewed by the Board. This is done to ensure that the money so generously raised by our supporters is used in the most efficient way.

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2020

Education

The Cancer Awareness and Prevention group continues to work to spread information about cancer across as wide a range of the public as possible with an emphasis on young people. The work of the group is reported separately on page 9.

Fundraising

The retail outlets, at Huntington and the Hospital have continued to be an invaluable source of income and the hospital shop provides a very useful 'shop front' for the charity. The sterling work done by our volunteers; and our staff in the office has yet again given up many hours in the evening and at weekends to help raise funds and spread the message about York Against Cancer. The links with the local business community have again proved a great benefit to the charity. With all these efforts from our employed staff and volunteers the charity is able to provide more much-needed support to many in the local community. Compared to many charities, it is remarkable to consider that York Against Cancer does not employ a fundraiser as such and we are totally reliant on our supporters and volunteers for the funding we receive.

York Against Cancer is committed to maintaining high standards of fundraising and retail activity. The Charity is registered with the Fundraising Regulator. The Charity has recognised and begun to put in place a comprehensive policy for fundraising. The Charity does not use any third parties to act on its behalf in relation to fundraising. No complaints were received by the charity during 2019 in relation to its fundraising activities. For further information on fundraising activities undertaken during the year see page 10.

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2020

**Jack Birch Unit of Molecular Carcinogenesis
Annual Report 2020**

What a year that was! I don't think there's anyone unaffected by the pandemic, but it's not all been bad news on the JBU front.

Back in January 2020 I attended the University of York Graduation Ceremony where York Against Cancer were conferred onto the College of Benefactors as a founding member. In late February, I visited India with a couple of University colleagues under the Global Challenges Research Fund programme to explore potential collaborations. Here we met many enthusiastic researchers with common interests in carcinogenesis mediated through contamination of water courses by heavy metals, such as cadmium. Then, just before lockdown, Simon Baker attended the Bladder Cancer Translational Meeting in Birmingham to present his work towards a new personalised therapy for Bladder Cancer.

Then came lockdown. Amazingly, Simon carried on lab work throughout the first lockdown as he had ongoing experimental work. This research resulted in a publication in a leading scientific journal and was featured on the front cover. The paper describes the "signatures" left by carcinogens and brings important new insight for understanding the causes of bladder cancer.

Although lockdown meant we could not travel, we were able to participate remotely by zoom in various scientific conferences, including the International Bladder Cancer Network in October (at which Simon presented). Our clinical fellow, Debora Morgante presented her research to the Biomaterials and Tissue Engineering Group meeting and won first prize. We also "Zoomed" into schools to spread the word about York Against Cancer, our research and the possibilities of scientific careers.

Of our staff and students. Jen returned from maternity leave in April; Edgar (Zhen Liu) returned to China to finish writing up his PhD and our York Against Cancer PhD student, Tom Crighton submitted his PhD thesis titled "Hippo and Sonic Hedgehog signalling pathway modulation of human urothelial tissue homeostasis". We were joined by Ryan Ellis as our latest York Against Cancer-funded student and by Ben Jarvis, a one-year Masters by Research student. Vlad Ungureanu also joined us as a PhD student based between the Departments of Electronic Engineering and Biology, and jointly supervised by Andrew Mason, among others. As our York Against Cancer-funded Independent Research Fellow, Andrew continues to develop the informatics capability of the JBU, including hiring Katie Skinner for one-year as a bioinformatician before she starts a PhD in cancer bioinformatics in the USA in Autumn 2021.

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2020

We missed running our cake stalls to raise funds for York Against Cancer but managed to raise £380 through the – you've guessed it – zoom quiz that Andrew Mason ran in November.



The JBU group carried on having weekly research meetings on zoom throughout the year.

As always, we are extremely grateful for research support from York Against Cancer, who help towards funding several salaries of staff in the Jack Birch Unit – plus the research fellowship of Dr Andrew Mason. Finally, I would like to acknowledge the invaluable contribution that our scientific and clinical collaborators make to the quality and output of our research.

**Professor Jenny Southgate, Director,
Jack Birch Unit of Molecular Carcinogenesis, University of York**

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2020

Cancer Education and Awareness Team

Annual Report 2020

I became interim chair of the committee in January, following John Molyneux who has served for many years with the last 6 years as chair. John has been very enthusiastic and hardworking and was particularly supportive when I joined the committee. Last year also saw Steve Leveson and Keith Hayton stepping down. Both have been important members of our committee as well as key figures in the history of York Against Cancer.

I'm very pleased to report the activities of the committee for 2020 which, of course, were overshadowed by the Covid-19 Pandemic. The committee has met virtually, via Zoom, and many of our efforts have been adversely affected. With this in mind, I would like to outline our progress in 2020.

Following Simon Baker's hard work, the Enthuse partnership with local schools was due to start in early 2020. However, the Covid-19 pandemic struck and schools were forced to close. Throughout the year education has been severely disrupted and the project could not get underway. The funding provided will be rolled forward from the point that teachers are able to focus on the scheme.

Simon has also discussed with York University the possibility of making the Campus smoke free. Unfortunately, for logistical reasons, this could not be implemented. However, it was agreed to stop the sale of tobacco on Campus.

Because of school closures, we were unable to carry out our annual delivery of sun hats and sun awareness leaflets to primary schools. We will resume this important activity as soon as permitted.

Julie Russell and I continued our regular meetings [again virtual of course] with Dr. Dan Cottingham, the lead GP for cancer care at the CCG. It has been very helpful to share information regarding, for example, cancer screening programmes and the very encouraging success of the use of YAC funded dermato-scopes in Primary Care.

Again, unfortunately we were unable to hold our annual cancer awareness day in York city centre due to Covid-19 restrictions.

Lynn Bartram who sits on the committee is a Primary School Head. She highlighted the issue of providing support to children who are affected by cancer either through family or other contacts. Julie Russell and Lynn worked together to define a collection of age specific books which can be supplied to children requiring help. York Against Cancer will fund the supply of these books into schools.

In November the committee held a virtual brain-storming meeting to bring forward ideas which might form a development plan for 2021. Lively and interesting discussion resulted in suggestions that ranged from local and online media, through theatre workshops in schools to a medicinal herb garden. All projects to raise cancer awareness in our community.

Following a change of the York Against Cancer Terms of Reference in early 2020, I stood as interim chair of the committee through 2020. Lynn Bartram, who also sits on the main board, kindly agreed to become chair of the Education and Awareness committee in January 2021. I'm sure that her knowledge and experience in education will be invaluable in taking the work of the committee and York Against Cancer forward.

Stuart Parker - Interim Chair

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2020

Fundraising report 2020

As we started 2020, we could not have envisaged what we were facing regarding the pandemic, internationally, nationally, and locally. As the country went into lock down it meant that all our planned fundraising events were postponed. It was obvious quite early on that the charities fundraising income would be severely impacted by the situation but as a health related and caring charity our priority was to do everything to keep our fundraisers, supporters, volunteers, and staff safe.

Our regular fundraisers were contacted, new dates were discussed and diarised. This demonstrated that our faithful band of fundraisers were not going to let a pandemic stop them supporting us in the future. This is heart-warming and shows what our charity means to the people of York and the wider area of North and East Yorkshire.

Some fundraisers were determined to continue and either adapted their events to be Covid friendly or in fact changing their event to become a virtual event. It has made us and many of our fundraisers think about fundraising in a different way and in fact given it another dimension and virtual events are more than likely a thing of the future.

The situation has also given us the time to consider our fundraising methods; what we do, how we do them and in fact are there better, more efficient, and more profitable ways of fundraising.

Here are a few examples of how fundraising has continued during 2020

- Local band 'Sister madly' held a virtual concert on Facebook live raising £585
- The Jack Birch Unit held a zoom quiz which raised £380
- The York Peddlers set themselves a challenge to cycle 10,000 miles. They did by cycling individually and adding up their miles. They raised a huge £5,700

In conclusion, 2020 has been a difficult year for us but we are optimistic about the future and we look forward to working with our fundraisers and supporters long into the future.

Thank you to everyone who have fundraised and to those also who have plans to raise money for us we really do appreciate you all – thank you for your contributions.

Julie Russell
General Manager

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2020

Structure, Governance and Management

The charity was incorporated on 22 April 2009 and its governing document is the memorandum and articles of association. The charity is a company limited by guarantee.

The charity is governed by a Board of Directors, supported by working groups as required. The Board members are all Trustees and include Officers of the Charity.

The Board meets four times a year and the various working groups meet as required during the year.

The members of the Board are volunteers. New Board members are elected by the existing members up to a maximum of twelve in total.

Trustee Induction and Training

New Trustees are briefed on their legal obligations under charity law, the committee and decision-making processes, the business plan and recent financial performance of the Charity. During their induction they meet key employees and other trustees. Trustees are encouraged to attend appropriate external training events where these will facilitate the undertaking of their role. At the end of each three tenure the trustees are required to update their trustee training.

Organisational Structure

The Board delegates the day-to-day management of the affairs of the Charity to one Board member, Keith Hayton, who serves as the Honorary Administrator (resigned 7 July 2020). This responsibility was taken on by Tarnia Hudson (commenced July 2020).

The members of staff employed by the Charity during the year were:

Julie Russell	General Manager
Heather Atkinson	Office & Accounts Manager
Lauren Hudson	Personal Assistant to General Manager from 9 th March 2020
Nicola Doherty	P.A. to General Manager until 7 th February 2020 – Office & Volunteer coordinator 10 th February 2020
Helen Watkinson	Retail Manager part-time until 7 th February 2020, full-time from 10 th February 2020
Francine Clee	PR & Communications Officer (part-time)
Ian Stephenson	Minibus Driver (part-time)
Neil Johnson	Minibus Driver (part-time)

Board membership

In March 2013 the Board adopted, by unanimous agreement, a protocol to introduce a three-year rule from that date. Board members continue to actively seek new trustees, taking into consideration a good mix of professional skills including business, education and medical. A term of office for a director is 3 years, after which time he/she may be re-elected for a further 3-year term up to a maximum of 9 years in total (details of current terms of office available on request).

Remuneration of key personnel

All members of staff employed by the charity have an annual appraisal in January following which salaries are set for the following 12 months. The appraisals are carried out by the General Manager.

No Board member received any income or expenses for their work for the charity.

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2020

Related parties

The Charity owns the whole of the issued ordinary share capital of York Against Cancer Trading Company Limited, a company registered in England and Wales. The subsidiary is used for the raising of funds for the Charity through the sale of bought in goods through the Charity's two shops.

Risk management

The Trustees have assessed the major risks to which the charity is exposed, in particular those related to the operations and finances of the Charity and continues to take measures to reduce those risks to an acceptable minimum. The policy of only making new commitments when the funds are in hand is a very practical way of eliminating unnecessary financial risks. By its very nature a charity relies on fundraising, donations and legacies which can vary a great deal. Ongoing commitments are to our staff, to a range of time limited research and care projects and to the leasehold of the new premises at the LNER community stadium with a delayed move in 2021. The move will provide greater storage and office space and a retail outlet with a good footfall. The trustees have calculated the move is necessary for the further development of the work of the charity. It should be emphasised that supporting staff not directly employed by York Against Cancer is always done on a time-limited basis (typically two years) which is renewed as appropriate provided funds are available.

The Board is very mindful that the charity has a substantial reserve of funds and seeks to find effective ways in which these can be utilised to fulfil the aims of York Against Cancer, whilst at the same time investing some funds to provide for future security.

Financial review and policies

The Charity's funds in 2020 increased by £24,290. Large investment gains have reduced the deficit significantly. Prior to any adjustment for investments, the Charity made a deficit of £146,787 (2019 deficit of £498,309). The charity was expecting a deficit as it utilises some of the excess free reserves for charitable purposes.

The principal funding sources are fund-raising, the trading shops, donations, legacies and members' subscriptions. Gross income in 2020 amounted to £389,859 (2019 £1,708,583). These funds support the key objectives of the Charity, namely, to fund clinical research, to support people with cancer and to fund education about the disease.

£163,187 was committed on project expenditure, to support the Charity's ongoing projects. Due to COVID-19 there were limited additional projects taken on this year. The detail of funding of projects can be found in note 6.

Investment powers and policy

The Trustees have a general power of investment and so have the discretion to invest in such investment assets as they see fit. The Trustees have set a policy that sufficient of the 'free reserves' should be invested to retain a reasonable liquidity to meet grant commitments.

Our policy is a medium low risk approach for the growth of the portfolio of investments. The investment managers have discretion about how the investments are managed within the policy parameters set by the Trustees.

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2020

The Investment Group oversees the investment management of the Charity's funds. The services of HSBC Private Bank and Ruffer were retained as investment managers during 2020. Funds not invested are held on deposit to earn interest.

The total return on the investment portfolio managed by HSBC for the year ended 31 December 2020, before fees, was 0.43% (2019 14.67%). The total return on investment portfolio managed by Ruffer for the year ended 31 December 2020, before fees, was 11.8% (2019 6.8%).

Reserves Policy

The reserves policy is to generate a stable and sustainable return to fund grant making, to ensure continued financial security and to provide for contingencies. Cash reserves are accumulated before making a binding commitment to fund a project due to the nature and uncertainty of the income streams. The total funds held as at 31 December 2020 are £4,282,644 (2019 £4,258,354).

The Board is very mindful that the charity has a substantial reserve of funds at present after the receipt of some large legacies. The board is actively seeking to find effective ways in which these can be utilized to fulfil the aims of York Against Cancer, whilst at the same time investing some funds to provide for future security.

Undesignated Fund

These are free reserves retained to provide working capital and funds for future projects. At the end of the financial year, the free reserves were £3,503,531 (2019 £3,434,524) accumulated largely due to the receipt of several generous legacies, which by their very nature are unpredictable. The level of free reserves will enable the Charity to give significant support to worthwhile projects which make a measurable impact.

Designated Funds

Designated funds are part of the unrestricted funds which trustees have earmarked for assets held for the use in the charity and specific projects. At the year end, The Charity had consolidated designated funds of £635,088 (2019 £667,862) details of which are given in Note 16 of the financial statements.

Restricted Funds

Restricted funds represent monies raised by the Charity from public appeals for specific projects. At the year end, the Charity had restricted funds of £144,025 (2019 £155,968) details of which are given in Note 17 to the financial statements.

COVID-19 has had a significant impact on donations and fundraising since April 2020 as events have been either cancelled or postponed. The charity has significant reserves brought forward and these will be used to help support the charity adapt where needed and keep its on-going commitments.

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2020

Directors and Trustees Responsibilities

The purpose of this statement is to distinguish the Directors' and Trustees' responsibilities for the financial statements from those of the auditors as stated in their report.

Company and charity law require the Directors and Trustees to prepare financial statements which give a true and fair view of the Charitable Company's state of affairs at the end of its financial activities for that year. In preparing those financial statements the Trustees are required to:

- Select suitable accounting policies and then apply them consistently
- Make judgements and estimates that are reasonable and prudent;
- State whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements.
- Prepare the financial statements on the going concern basis unless it is inappropriate to assume that the Charitable Company will continue in operation.

The Directors and Trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the Charitable Company and enables them to ensure that the financial statements comply with the Companies Act 2006 and applicable charity law. They are also responsible for safeguarding the assets of the Charitable Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the Directors and Trustees are aware:

- There is no relevant information of which the Charitable Company's auditor is unaware; and
- The Directors and Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

Approved by the Board on 14 September 2021 and signed on its behalf by:

Ian Yeowart
Director and Trustee

YORK AGAINST CANCER

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2020

Reference and administrative details

Registered Charity number 1130835

Company Limited number 06884476
by Guarantee

Principal Office and Trading Address

31 - 33 North Moor Road
Huntington
York
YO32 9QN

Company Secretary Julie Pamela Russell

Directors and
Trustees

Andrew Proctor
Angela Darby
Rachel Goddard
Michael John Stower
William Mark Sessions
Ian Yeowart
Sarah Wearing
Tarnia Hudson
Prof Stephen Leveson
Michael Patrick Shepherd

Dr Lynn Bartram (appointed September 2020)
Michael Sweet (appointed September 2020)
Robert Onyett (appointed September 2020)
John Francis Yeomans (resigned 7 July 2020)
Edward Keith Hayton (resigned 7 July 2020)
Patricia Anne Kay (resigned 7 July 2020)
Gordon Andrew Topping (resigned February 2020)

Trustee's protocol / length of service document available on request

Accountants

HPH
Chartered Accountants
54 Bootham
York
YO30 7XZ

Auditors

Townends Accountants LLP
Chartered Accountants
Fulford Lodge
1 Heslington Lane
Fulford
York
YO10 4HW

Bankers

National Westminster Bank
1 Market Street
York
YO1 8SR

Solicitors

Harrowells
Moorgate House
Clifton Moorgate
York
YO30 4WY

Investment Advisors

HSBC Global Asset
Management
78 St James's Street
London
SW1A 1EJ

Ruffer LLP
80 Victoria Street
London
SW1E 5JL

YORK AGAINST CANCER

COMPANY LIMITED BY GUARANTEE

INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER

YEAR ENDED 31 DECEMBER 2020

Opinion on financial statements

We have audited the financial statements of York Against Cancer for the year ended 31 December 2020, which comprise the Statement of Financial Activities, the Balance Sheet, the Cash Flow Statement, the Income and Expenditure Account and related notes. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards including Financial Reporting Standard FRS102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the company's affairs as at 31 December 2020 and of its incoming resources and application of resources for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the Charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustee's use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the original financial statements were authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The trustees are responsible for the other information. The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

YORK AGAINST CANCER

COMPANY LIMITED BY GUARANTEE

INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER

YEAR ENDED 31 DECEMBER 2020

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the trustees' report (incorporating the strategic report and the directors' report) for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the trustees' report (incorporating the strategic report and the directors' report) have been prepared in accordance with applicable legal requirements.

Matter on which we are required to report by exception

In the light of the knowledge and understanding of the Charity and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees' Annual Report.

We have nothing to report in respect of the following matters where the Companies Act 2006 required us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of Board of Trustees's remuneration specified by law are not made; or
- we have not obtained all the information and explanations necessary for the purposes of our audit.

Responsibilities of the trustees

As explained more fully in the trustees' responsibilities statement set out on page 14, the trustees are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the Charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the Charity or to cease operations, or have no realistic alternative but to do so.

Our responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

YORK AGAINST CANCER

COMPANY LIMITED BY GUARANTEE

INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER

YEAR ENDED 31 DECEMBER 2020

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

- We have obtained an understanding of the legal and regulatory framework applicable to the Charity through discussions with senior management and review of the regulatory framework of any professional or membership bodies that the Charity is a part of. The Charity uses third parties to ensure that it remains up to date with changes and to review compliance with all its legal and regulatory requirements. In making our assessment of detecting irregularities, including fraud, we have discussed the issue with management who have advised that, other than changes to the work place to ensure that they are Covid-19 compliant, there have been no changes and the Charity remains compliant with its legal and regulatory requirement. Nothing has been brought to light in completing our audit work that contradicts this.
- The following laws and regulations have been identified as being of significance in the context of the Charity; Companies Act 2006, Charities Act 2011, fundraising regulations, health and safety legislation, employment laws, data protection, and relevant tax laws.
- In making our assessment of the susceptibility of the Charity's financial statements to material misstatement, we have also considered how fraud might occur. No instances of material misstatement or fraud have been noted in the audit of the accounts for the year ended 31 December 2020.
- All matters regarding non-compliance with laws and regulations and fraud have been communicated to all members of the audit engagement team. The engagement partner has assessed that the engagement team has the appropriate competence and capabilities to identify or recognise non-compliance with laws and regulations, affected by the inherent difficulty in detecting irregularities, the effectiveness of the Charity's controls, and the nature, timing and extent of the audit procedures performed.

As part of an audit in accordance with ISAs (UK), we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the internal control.

YORK AGAINST CANCER

COMPANY LIMITED BY GUARANTEE

INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER

YEAR ENDED 31 DECEMBER 2020

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the director.
- Conclude on the appropriateness of the director's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Charity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Charity to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Use of our report

This report is made solely to the Charity's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Charity's members those matters we are required to state to them in an auditors report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Charity's members as a body, for our audit work, for this report, or for the opinions we have formed.

.....
Paul Sharpe FCA (Senior Statutory Auditor)

**For and on behalf of
Townends Accountants LLP
Chartered Accountants & Statutory Auditor**

Date: 14 September 2021

Carlisle Street
Goole
East Riding of Yorkshire
DN14 5DX

YORK AGAINST CANCER
CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES
AND INCOME AND EXPENDITURE ACCOUNT
FOR THE YEAR ENDED 31 DECEMBER 2020

	Note	Unrestricted General Fund £	Designated Funds £	Restricted Funds £	Year ended 31 Dec 2020 £	Year ended 31 Dec 2019 £
Income and endowments from:						
Donations and legacies	2	182,105	-	600	182,705	1,365,532
Other trading activities	3	157,863	-	-	157,863	274,018
Investments	4	49,291	-	-	49,291	69,033
Total		389,259	-	600	389,859	1,708,583
Expenditure on:						
Raising funds	5	156,656	-	-	156,656	186,092
Charitable activities	6	286,513	80,934	12,543	379,990	2,020,800
Total		443,169	80,934	12,543	536,646	2,206,892
Net expenditure before losses on investments		(53,910)	(80,934)	(11,943)	(146,787)	(498,309)
Net gains on investments	11	171,077	-	-	171,077	351,402
Net income/(expenditure)		117,167	(80,934)	(11,943)	24,290	(146,907)
Transfers between funds	16	(48,160)	48,160	-	-	-
Net movement in funds		69,007	(32,774)	(11,943)	24,290	(146,907)
Reconciliation of funds:						
Total funds brought forward		3,434,524	667,862	155,968	4,258,354	4,405,261
Total funds carried forward		£ 3,503,531	£ 635,088	£ 144,025	£ 4,282,644	£ 4,258,354

The notes on pages 23 to 33 form part of these financial statements.

YORK AGAINST CANCER
(Registration number: 06884476)

BALANCE SHEET
AS AT 31 DECEMBER 2020

	Note	Charity 2020 £	Consolidated 2020 £	Charity 2019 £	Consolidated 2019 £
FIXED ASSETS					
Tangible Fixed Assets	12	573,526	585,342	589,541	600,882
Investments	11	3,741,011	3,741,010	3,548,077	3,548,076
		4,314,537	4,326,352	4,137,618	4,148,958
CURRENT ASSETS					
Stock		-	55,295	-	57,259
Debtors	13	551,936	462,285	783,450	694,330
Cash at Bank and in Hand		827,681	898,835	1,168,245	1,237,711
		1,379,617	1,416,415	1,951,695	1,989,300
CREDITORS: amounts falling due within one year	14	487,559	499,107	615,171	627,626
NET CURRENT ASSETS		892,058	917,308	1,336,524	1,361,674
TOTAL ASSETS LESS CURRENT LIABILITIES		5,206,595	5,243,660	5,474,142	5,510,632
CREDITORS: amounts falling due after one year	15	961,016	961,016	1,252,278	1,252,278
NET ASSETS		<u>£ 4,245,579</u>	<u>£ 4,282,644</u>	<u>£ 4,221,864</u>	<u>£ 4,258,354</u>
THE FUNDS OF THE CHARITY					
Unrestricted					
Undesignated	18	3,478,282	3,503,531	3,409,375	3,434,524
Designated	16,18	623,272	635,088	656,521	667,862
Restricted	17,18	144,025	144,025	155,968	155,968
TOTAL CHARITY FUNDS		<u>£ 4,245,579</u>	<u>£ 4,282,644</u>	<u>£ 4,221,864</u>	<u>£ 4,258,354</u>

Approved by the Trustees on 14 September 2021 and signed on its behalf by:

S B Wearing
Director and Trustee

The notes on pages 23 to 33 form part of these financial statements.

**YORK AGAINST CANCER
CONSOLIDATED CASHFLOW STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2020**

	Note	2020 £	2019 £
Cash flows from operating activities:			
Net cash provided by/(used in) operating activities	21	(363,320)	6,206
Cash flows from investing activities:			
Dividends, interest and rents from investments		49,291	69,033
Purchase of property, plant and equipment		(2,990)	(9,926)
Proceeds from sales of investments		1,095,488	1,295,325
Purchase of investments		(1,117,345)	(825,288)
Net cash provided by/(used in) investing activities		<u>24,444</u>	<u>529,144</u>
Change in cash and cash equivalents in the reporting period		(338,876)	535,350
Cash and cash equivalents at the beginning of the reporting period		<u>1,237,711</u>	<u>702,361</u>
Cash and cash equivalents at the end of the reporting period		<u>£ 898,835</u>	<u>£ 1,237,711</u>

The notes on pages 23 to 33 form part of these financial statements.

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

1. ACCOUNTING POLICIES

Legal entity

York Against Cancer is regulated by the Charities Commission (1130835), limited by guarantee and is registered in England and Wales. The address of the registered office and principal place of business is 31 - 33 North Moor Road, Huntington, York, YO32 9QN.

Basis of preparation

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The consolidated accounts include the results of the Charitable Company and its subsidiary undertaking. The results of the subsidiary are consolidated on a line by line basis.

No separate SOFA has been presented for the Charitable Company alone as permitted by the SORP.

The Charitable Company constitutes a public benefit entity as defined by FRS 102.

The accounts are presented in UK Sterling pounds (£).

Going Concern

The Charitable Company has cash resources and has no requirement for external funding. The cash and investments held are sufficient to see the Charitable Company through the financial impact of COVID-19. The Directors and Trustees have a reasonable expectation that the Charitable Company has adequate resources to continue in operational existence for the foreseeable future. They continue to believe the going concern basis of accounting appropriate in preparing the annual financial statements.

Income

Donations and legacies

Credit is taken for donations and subscriptions when they are received. Credit is taken for legacies when received or if, before receipt, there is sufficient evidence to provide the necessary certainty that the legacy will be received and the value of the incoming resources can be measured with sufficient reliability.

Other trading activities

Fundraising income - represents gross income from events.

Subsidiary's non-charitable trading turnover - represents gross income from York Against Cancer Trading Company Limited, the Charitable Company's trading subsidiary.

Investments

Investment income has been accounted for on an accruals basis.

Expenditure

Raising funds

Fundraising costs - represents the total costs of fundraising events and activities held during the year.

Non charitable trading expenditure - comprises of the direct costs and administrative costs of the Charitable Company's trading subsidiary, York Against Cancer Trading Company Limited.

Charitable activities

Direct costs - comprises of expenditure on various projects the Charitable Company is supporting and is accounted for in full when the Charitable Company commits to provide the funding.

Support costs - comprises of the salaries and office expenses of the Charitable Company.

Governance costs - comprises the costs associated directly with the management by the Directors/Trustees of the Charitable Company's activities, including audit fees and costs of meetings.

All costs are apportioned on an actual cost basis.

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

1. ACCOUNTING POLICIES (continued)

Pension costs

The Charitable Company operates a defined contribution money purchase pension scheme for specific employees. The assets of the scheme are invested and managed independently of the finances of the Charitable Company. The charge for pension costs represents the contributions payable in the year.

Fixed Assets

Individual fixed assets costing £200 or more are capitalised and included in the accounts at cost.

Tangible fixed assets are depreciated over their expected useful lives at the following annual rates:

Freehold/Leasehold property	at straight line over 50 years
Equipment	
- Shop and office equipment	at straight line over 10 years
- Computer equipment	at straight line over 3 years
- Respite home equipment	at straight line over 4 years
Motor vehicles	at 25% reducing balance

Stock

Stock is valued at the lower of cost and net realisable value. Cost is computed on a first in first out basis. Net realisable value is based on estimated selling price less the estimated cost of disposal.

Funds Structure

Unrestricted Funds are funds which are available for use or retention at the discretion of the Directors/Trustees, in accordance with the Charity's objects. Designated Funds represent unrestricted funds earmarked by the Directors/Trustees for particular purposes. Restricted Funds are subjected to restrictions on their expenditure imposed by the donor or through the terms of an appeal. Details of Designated and Restricted Funds are contained in Notes 16 and 17, respectively.

Investments

The investment portfolios have been valued at market value at 31 December 2020. The SOFA includes the net gains and losses on investments arising on revaluation at the year end and on disposals throughout the year. Realised gains and losses on sales of investments are calculated as the difference between the sale proceeds and opening market value. Unrealised gains and losses represent the movement between market values.

Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

Cash at bank and in hand

Cash at bank and cash in hand includes cash and any short term deposit accounts with a maturity of three months or less from the date of opening.

Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

Financial instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

Operating Leases

Rentals paid under operating leases are charged in the SOFA on a straight line basis over the lease term.

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

2. DONATIONS AND LEGACIES	Unrestricted £	Restricted £	2020 £	2019 £
Donations	117,589	600	118,189	155,183
In Memoriam	24,957	-	24,957	32,312
Legacies	13,225	-	13,225	1,168,941
Government grant	21,334	-	21,334	-
Intangible income	5,000	-	5,000	9,096
	<u>£ 182,105</u>	<u>£ 600</u>	<u>£ 182,705</u>	<u>£ 1,365,532</u>

Intangible income comprises accounting services, a proportion of which is provided free of charge for the preparation of the Charitable Company and Subsidiary statutory accounts. A corresponding amount is included within governance costs.

3. OTHER TRADING ACTIVITIES	2020 £	2019 £
Fundraising income	72,639	150,469
Subsidiary's non-charitable trading turnover	85,224	123,483
Miscellaneous income	-	66
	<u>£ 157,863</u>	<u>£ 274,018</u>

4. INVESTMENTS	2020 £	2019 £
Interest received	2,696	3,463
Dividends received	46,595	65,570
	<u>£ 49,291</u>	<u>£ 69,033</u>

5. ANALYSIS OF RAISING FUNDS	Unrestricted £	Restricted £	2020 £	2019 £
Advertising	7,900	-	7,900	13,181
Fundraising costs	65,847	-	65,847	77,106
Non charitable trading expenditure	70,995	-	70,995	81,865
Investment fees	11,914	-	11,914	13,940
	<u>£ 156,656</u>	<u>£ -</u>	<u>£ 156,656</u>	<u>£ 186,092</u>

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020

6. ANALYSIS OF CHARITABLE ACTIVITIES

<i>Direct project costs:</i>	Unrestricted £	Restricted £	2020 £	2019 £
Research				
Jack Birch Unit	-	-	-	1,413,264
Clinical Trial Nurses	19,239	-	19,239	127,478
Support and Care				
Cancer Care Centre	26,330	-	26,330	47,803
Complementary therapy	29,541	-	29,541	44,003
Health Care Assistant	7,865	-	7,865	13,052
Respite property expenses	29,257	-	29,257	41,315
Minibus running costs	25,562	-	25,562	21,122
Mobile Chemotherapy Unit	-	321	321	-
Psychology services	5,680	-	5,680	-
Restricted grants	-	12,222	12,222	-
Family Support Worker	-	-	-	22,379
Health Welfare Advisor	-	-	-	95,000
Hospital equipment	-	-	-	35,473
Release of committed projects	-	-	-	(96,508)
Education				
Education expenses	7,170	-	7,170	26,353
	150,644	12,543	163,187	1,790,734
Support costs:				
Staff costs	157,081	-	157,081	156,400
Staff training and travel	1,702	-	1,702	3,597
Rent and rates	4,352	-	4,352	12,773
Heat and light	1,666	-	1,666	1,668
Repairs and maintenance	1,932	-	1,932	1,073
Insurances	2,963	-	2,963	3,374
Printing, stationery and postage	4,856	-	4,856	3,943
Computer expenses	7,867	-	7,867	8,425
Telephone	1,710	-	1,710	1,514
Sundry expenses	3,953	-	3,953	4,407
Depreciation	16,015	-	16,015	16,632
	204,097	-	204,097	213,806
Governance costs:				
Audit fees	3,480	-	3,480	3,480
Accountancy fees	7,663	-	7,663	11,596
Bank charges	1,563	-	1,563	1,184
	12,706	-	12,706	16,260
Total charitable activities	£ 367,447	£ 12,543	£ 379,990	£ 2,020,800

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

7. NET INCOMING RESOURCES FOR THE YEAR

	2020 £	2019 £
This is stated after charging:		
Depreciation	18,530	18,849
Auditor's remuneration for audit services	3,480	3,480

8. REMUNERATION AND EXPENSES OF TRUSTEES

None of the Trustees received any remuneration or benefits by virtue of being a trustee of the Charity and no Trustees were reimbursed any expenses incurred for services provided to the Charity.

9. STAFF COSTS

	2020 £	2019 £
Wages and salaries	155,368	137,566
Social security costs	8,710	8,181
Pension costs	7,104	6,143
Medical Insurance	4,432	4,510
	<u>£ 175,614</u>	<u>£ 156,400</u>

The average monthly head count was 8 staff (2019 8) and the average monthly number of full-time equivalent employees (including casual and part-time staff) during the year were as follows:

Management and administration of the Charitable Company	7	7
---	---	---

No employee received emoluments in excess of £60,000.

The key management personnel of the Charitable Company, comprise the directors and trustees and the General Manager. The total employee benefits of the key management personnel of the Charitable Company were £49,937 (2019 - £49,196).

10. SUBSIDIARY COMPANY

The Charitable Company owns the whole of the issued ordinary share capital of York Against Cancer Trading Company Limited. This company is registered in England and Wales (reg. no. 3405708) and its registered office is 31 North Moor Road, Huntington, York, YO32 9QN. The subsidiary is used for the raising of funds for the Charitable Company through the sale of bought in goods through the Charitable Company's shop and stalls. All activities have been consolidated on a line by line basis in the SOFA.

There is a loan account between the Charitable Company and the subsidiary. The balance on the loan account outstanding at the year end was £95,637 (2019 £93,645). Interest of £141 (2019 £1,355) was charged during the year in respect of this loan.

A summary of the results of the subsidiary is shown below:

	2020 £	2019 £
Turnover	85,224	123,483
Cost of sales	<u>(46,891)</u>	<u>(53,112)</u>
Gross profit	38,333	70,371
Administrative expenses	<u>(48,953)</u>	<u>(62,391)</u>
Operating profit	(10,620)	7,980
Other operating income	11,334	-
Interest payable	<u>(141)</u>	<u>(1,355)</u>
Profit on ordinary activities before taxation	573	6,625
Taxation	<u>-</u>	<u>-</u>
Profit on ordinary activities after taxation	573	6,625
Amount gifted to York Against Cancer	<u>-</u>	<u>-</u>
Retained within/(withdrawn from) Subsidiary	<u>£ 573</u>	<u>£ 6,625</u>
Net Assets	<u>£ 37,063</u>	<u>£ 36,490</u>

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

11. INVESTMENTS

Consolidated	2020	2019
	£	£
Market value at 1 January 2020	3,548,076	3,666,711
Additions at cost	1,117,345	825,288
Disposals	(1,095,488)	(1,295,325)
Revaluations	171,077	351,402
Market value at 31 December 2020	<u>£ 3,741,010</u>	<u>£ 3,548,076</u>
Analysis of investments by class:		
Listed investments	<u>£ 3,741,010</u>	<u>£ 3,548,076</u>
The historical cost of the above investments amounts to:	<u>£ 3,521,243</u>	<u>£ 3,521,243</u>

The following material investments are over 5% by value of the investments held

	2020	2019
	Market value	Market value
	£	£
HSBC FTSE All Share Index	302,095	278,825
Ruffer Charity Assets Trust Account	2,010,192	1,798,655
	<u>£ 2,312,287</u>	<u>£ 2,077,480</u>

The Charitable Company holds all of the issued shares of its subsidiary undertaking York Against Cancer Trading Company Limited, at cost of £1, in addition to the above investments.

12. TANGIBLE FIXED ASSETS

	Property	Motor	Equipment	Charity	Subsidiary -	Consolidated
	£	Vehicles	£	Total	Shop	Total
		£		£	Equipment	£
					£	
<i>Cost</i>						
At 1 January 2020	635,602	41,515	46,469	723,586	31,881	755,467
Additions in year	-	-	-	-	2,990	2,990
At 31 December 2020	<u>635,602</u>	<u>41,515</u>	<u>46,469</u>	<u>723,586</u>	<u>34,871</u>	<u>758,457</u>
<i>Depreciation</i>						
At 1 January 2020	60,015	34,096	39,934	134,045	20,540	154,585
Charge for year	12,712	1,855	1,448	16,015	2,515	18,530
At 31 December 2020	<u>72,727</u>	<u>35,951</u>	<u>41,382</u>	<u>150,060</u>	<u>23,055</u>	<u>173,115</u>
<i>Net book value</i>						
At 31 December 2020	<u>£ 562,875</u>	<u>£ 5,564</u>	<u>£ 5,087</u>	<u>£ 573,526</u>	<u>£ 11,816</u>	<u>£ 585,342</u>
At 31 December 2019	<u>£ 575,587</u>	<u>£ 7,419</u>	<u>£ 6,535</u>	<u>£ 589,541</u>	<u>£ 11,341</u>	<u>£ 600,882</u>

All fixed assets are held for direct charitable purposes in Designated Funds.

YORK AGAINST CANCER

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020**

13. DEBTORS

	Charity 2020 £	Consolidated 2020 £	Charity 2019 £	Consolidated 2019 £
Amounts owed by subsidiary	95,637	-	93,645	-
Prepayments	9,250	13,902	9,709	14,234
Accrued income	446,909	448,243	680,096	680,096
Other debtors	140	140	-	-
	£ 551,936	£ 462,285	£ 783,450	£ 694,330

14. CREDITORS: amounts falling due within one year

Trade creditors	30,378	33,524	31,117	36,685
Project creditors	444,038	444,038	561,184	561,184
Taxation and social security	3,128	8,730	3,495	7,582
Accruals	8,893	11,693	18,227	21,027
Other creditors	1,122	1,122	1,148	1,148
	£ 487,559	£ 499,107	£ 615,171	£ 627,626

15. CREDITORS: amounts falling due after one year

Project creditors	£ 961,016	£ 961,016	£ 1,252,278	£ 1,252,278
-------------------	-----------	-----------	-------------	-------------

16. DESIGNATED FUNDS (consolidated)

The Charitable Company transfers to designated funds sufficient resources to meet such commitments, as shown below.

Designated Funds - 2020	Balance 01/01/2020 £	Income £	Expenditure £	Transfers £	Balance 31/12/2020 £
Cancer Care Centre	31,500	-	(26,118)	-	5,382
Complementary Therapy	35,480	-	(29,116)	-	6,364
Education Project	-	-	(7,170)	7,170	-
Minibus	-	-	-	28,000	28,000
Patient Travel	-	-	-	10,000	10,000
Fixed Assets Fund	600,882	-	(18,530)	2,990	585,342
Total	£ 667,862	£ -	£ (80,934)	£ 48,160	£ 635,088

Designated Funds - 2019	Balance 01/01/2019 £	Income £	Expenditure £	Transfers £	Balance 31/12/2019 £
Cancer Care Centre	-	-	(18,900)	50,400	31,500
Complementary Therapy	-	-	(21,288)	56,768	35,480
Education Project	-	-	(26,353)	26,353	-
Fixed Assets	609,805	-	(18,849)	9,926	600,882
Total	£ 609,805	£ -	£ (85,390)	£ 143,447	£ 667,862

Cancer Care Centre

The Board is committed to a service level agreement with York Hospital to provide the funding for 3 administrator posts from 1 April 2019 to 31 March 2021.

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

16. DESIGNATED FUNDS (consolidated continued)

Complementary Therapy

The Board is committed to a service level agreement with York Hospital to provide the funding for a therapist post from 1 April 2019 to 31 March 2021.

Minibus

The trustees have set aside monies for the purchase of a new minibus which will be purchased next year.

Patient Travel

The trustees have set aside monies to fund Patient Travel and this will be reviewed next year once demand is known.

Fixed Asset Fund

This fund represents funds invested in tangible fixed assets.

Education Project

The Board agreed to fund the annual budgeted costs of the Education Project which is aimed at raising the awareness of cancer to the public.

17. RESTRICTED FUNDS (consolidated)

Restricted Funds - 2020	Balance 01/01/2020	Income	Expenditure	Transfers	Balance 31/12/2020
	£	£	£	£	£
Mobile Chemotherapy Unit	142,069	600	(321)	-	142,348
Prostate Cancer	12,222	-	(12,222)	-	-
Mouth Cancer	1,677	-	-	-	1,677
Total 2020	£ 155,968	£ 600	(£ 12,543)	£ -	£ 144,025

Restricted Funds - 2019	Balance 01/01/2019	Income	Expenditure	Transfers	Balance 31/12/2019
	£	£	£	£	£
Minibus Appeal	6,898	-	(6,898)	-	-
Mobile Chemotherapy Unit	139,046	3,023	-	-	142,069
Prostate Cancer	-	12,222	-	-	12,222
Mouth Cancer	-	1,677	-	-	1,677
Total 2019	£ 145,944	£ 16,922	(£ 6,898)	£ -	£ 155,968

Minibus Appeal

The Minibus Appeal relates to funds raised for the specific purpose of purchasing and running a minibus to transport cancer patients between York Hospital and Cookridge Hospital in North Leeds.

Mobile Chemotherapy Unit

The Mobile Chemotherapy Unit Appeal relates to funds raised for the specific purpose of running the service.

Prostate Cancer

50% of the R U taking the P monies raised where to be allocated to prostate cancer research.

Mouth Cancer

Monies raised for the Head and Neck cancer department.

YORK AGAINST CANCER

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020**

18. ANALYSIS OF GROUP NET ASSETS BETWEEN FUNDS

	General Funds £	Designated Funds £	Restricted Funds £	Total 2020 £
Fund balances at 31 December 2020 are represented by:				
Tangible fixed assets	-	585,342	-	585,342
Investments	3,741,010	-	-	3,741,010
Current assets	1,222,644	49,746	144,025	1,416,415
Current liabilities	(499,107)	-	-	(499,107)
Long term liabilities	(961,016)	-	-	(961,016)
	£ 3,503,531	£ 635,088	£ 144,025	£ 4,282,644
	General Funds £	Designated Funds £	Restricted Funds £	Total 2019 £
Fund balances at 31 December 2019 are represented by:				
Tangible fixed assets	-	600,882	-	600,882
Investments	3,548,076	-	-	3,548,076
Current assets	1,833,332	-	155,968	1,989,300
Current liabilities	(627,626)	-	-	(627,626)
Long term liabilities	(1,252,278)	-	-	(1,252,278)
	£ 3,501,504	£ 600,882	£ 155,968	£ 4,258,354

19. OPERATING LEASE COMMITMENTS

As at 31 December 2020 the charitable company had future minimum lease payments under non-cancellable operating leases as follows:

	At 31 December 2020		At 31 December 2019	
	Land and buildings £	Office equipment £	Land and buildings £	Office equipment £
Operating leases which expire:				
Within one year	15,000	-	15,000	-
Between two and five years	-	-	7,500	-

20. RELATED PARTIES

During the year the Charitable Company paid £2,620 (2019 £2,493) to HPH Chartered Accountants for accountancy services and software costs, a firm in which the Charitable Company's Treasurer, Sarah Wearing, is a partner. At the year end there was £nil (2019 £nil) owing to HPH Chartered Accountants.

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

21. RECONCILIATION OF NET MOVEMENT IN FUNDS TO NET CASH FLOW FROM OPERATING ACTIVITIES

	2020 £	2019 £
Net income/(expenditure) for the reporting period	24,290	(146,907)
Adjustments for:		
Depreciation charges	18,530	18,849
(Gains)/Losses on investments	(171,077)	(351,402)
Dividends, interest and rents from investments	(49,291)	(69,033)
Increase in stocks	1,964	(14,524)
Increase in debtors	232,045	(576,507)
(Increase)/Decrease in creditors	(419,781)	1,145,730
Net cash provided by/(used in) operating activities	£ (363,320)	£ 6,206

ANALYSIS OF CASH AND CASH EQUIVALENTS

Cash at bank and in hand	898,835	1,237,711
Total cash and cash equivalents	£ 898,835	£ 1,237,711

22. VOLUNTEERS

The Charity is fortunate to be supported by over 100 volunteers. Their activities include working in our shops, attending events, supporting the office, collections and baking. Without them the Charity could not achieve what it does; their support is a massive asset in both workforce and financial terms. Whilst going about their work they are also ambassadors for the Charity which encourages more people to volunteer and support.

With varied knowledge, skills and experience the volunteers make an invaluable group. Our thanks goes to them all – together we really do make a difference to cancer patients and their families.

YORK AGAINST CANCER
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020

24. COMPARATIVE INFORMATION

	Unrestricted General Fund £	Designated Funds £	Restricted Funds £	Year ended 31 Dec 2019 £
Income and endowments from:				
Donations and legacies	1,348,610	-	16,922	1,365,532
Other trading activities	274,018	-	-	274,018
Investments	69,033	-	-	69,033
Total	1,691,661	-	16,922	1,708,583
Expenditure on:				
Raising funds	186,092	-	-	186,092
Charitable activities	1,928,512	85,390	6,898	2,020,800
Total	2,114,604	85,390	6,898	2,206,892
Net income/(expenditure) before losses on investments	(422,943)	(85,390)	10,024	(498,309)
Net gains/(losses) on investments	351,402	-	-	351,402
Net income/(expenditure)	(71,541)	(85,390)	10,024	(146,907)
Transfers between funds	(143,447)	143,447	-	-
Net movement in funds	(214,988)	58,057	10,024	(146,907)
Reconciliation of funds:				
Total funds brought forward	3,649,512	609,805	145,944	4,405,261
Total funds carried forward	£ 3,434,524	£ 667,862	£ 155,968	£ 4,258,354